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ABSTRACT 
 
 
Wanting Liu 
 
AN INTEGRATED BIOINFORMATICS APPROACH FOR THE IDENTIFICATION 
OF MELANOMA-ASSOCIATED BIOMARKER GENES 
A ranking and stratification approach as a new meta-analysis methodology for 
the detection of robust gene biomarker signatures of cancers 
Keywords: 
Melanoma, Microarray, Meta-analysis, Biomarker, Integrated Analysis 
 
Genome-wide microarray technology has facilitated the systematic discovery of 
diagnostic biomarkers of cancers and other pathologies. However, meta-
analyses of published arrays using melanoma as a test cancer has uncovered 
significant inconsistences that hinder advances in clinical practice. In this study 
a computational model for the integrated analysis of microarray datasets is 
proposed in order to provide a robust ranking of genes in terms of their relative 
significance; both genome-wide relative significance (GWRS) and genome-wide 
global significance (GWGS).  
 
When applied to five melanoma microarray datasets published between 2000 
and 2011, a new 12-gene diagnostic biomarker signature for melanoma was 
defined (i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, TNC, CXCL13, COL11A1, 
CHP2, SHC4, PPP2R2C, and WNT4). Of these, CXCL13, COL11A1, PTPRF 
ii 
 
and SHC4 are components of the MAPK pathway and were validated by 
immunocyto- and immunohisto-chemistry. These proteins were found to be 
overexpressed in metastatic and primary melanoma cells in vitro and in 
melanoma tissue in situ compared to melanocytes cultured from healthy skin 
epidermis and normal healthy human skin.  
 
 
One challenge for the integrated analysis of microarray data is that the 
microarray data are produced using different platforms and bio-samples, e.g. 
including both cell line- and biopsy-based microarray datasets. In order to 
address these challenges, the computational model was further enhanced the 
stratification of datasets into either biopsy or cell line derived datasets, and via 
the weighting of microarray data based on quality criteria of data. The methods 
enhancement was applied to 14 microarray datasets of three cancers (breast, 
prostate, and melanoma) based on classification accuracy and on the capability 
to identify predictive biomarkers. Four novel measures for evaluating the 
capability to identify predictive biomarkers are proposed: (1) classifying 
independent testing data using wrapper feature selection with machine leaning, 
(2) assessing the number of common genes with the genes retrieved in 
independent testing data, (3) assessing the number of common genes with the 
genes retrieved in across multiple training datasets, (4) assessing the number 
of common genes with the genes validated in the literature. 
 
This enhancement of computational approach (i) achieved reliable classification 
performance across multiple datasets, (ii) recognized more significant genes 
into the top-ranked genes as compared to the genes detected by the 
independent test data, and (iii) detected more meaningful genes than were 
validated in previous melanoma studies in the literature.  
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1. INTRODUCTION 
This chapter provides background and review on the subject areas of this 
thesis. This study was focused on the development of an integrated 
bioinformatics approach for the discovery of diagnostic biomarkers of 
melanoma, based on microarray genome-wide expression data. In this chapter I 
will introduce the topic of melanoma, including its definition and characteristics, 
how it develops, its related staging, genetic organization and other relevant 
information. To evaluate the effectiveness of bioinformatics method, developed 
in this project an enhancement of this method also to other microarray datasets 
including breast cancer and prostate cancer was applied (Chapter 2), and so 
provide a brief review of breast and prostate cancer here too. At the end of this 
chapter, I discuss to topics of DNA microarray and meta-analysis. 
 
1.1. Skin and Melanoma 
 
1.1.1. Human skin structure and function  
Many people do not immediately think of skin as a functional organ like the 
heart or the liver, instead believing that skin simply protects them from different 
external stimuli, like excessive heat or cold (Poole & Guerry IV, 2005). 
 
Actually, human skin is considered to be the largest organ in the body (Tobin, 
2006) and plays a unique role in not only providing the main barrier between the  
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internal and external environment, but also maintains our internal homeostasis 
(Slominski & Wortsman, 2000) by exhibiting all the requirements of a classic 
endocrine organ. It is proposed to be an independent peripheral endocrine 
organ (Slominski & Mihm, 1996). The barrier effect of skin is not only evident by 
the physical function of its epidermis, but skin also has a chemical or 
biochemical role through its array of lipids, enzymes, defense-related cells and 
so on (Proksch et al, 2008). The structure of skin is shown in Figure 1 below.  
 
 
 
 
 
As shown in above figure, human skin includes two main layers; the epidermis 
(outer layer) and dermis (inner layer). The epidermis can be further divided to 
two layers: the outer „dead‟ but biochemically-active keratinized layer (stratum 
corneum) and the inner living layer „nucleated epidermis‟ (Proksch et al, 2008; 
Fig.1: Anatomy of human skin (Sherwood, 2007) 
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Sherwood, 2007). The keratinized layer is made from dead or peeling cells, and 
is the main barrier to prevent ingress by microbes, as well as chemical and 
mechanical stress (Madison, 2003). 
 
The living layer of the epidermis is further stratified and consists of four cell 
types; keratinocytes, melanocytes, Langerhans cells and Merkel cells 
(Sherwood, 2007). The function of nucleated epidermis is to contribute to 
forming the main barrier, which is present to prevent loss of water and invasion 
of noxious substances and materials (Honari, 2004). If trauma causes damage 
of the epidermis, the barrier function will be severely disturbed (Elias et al, 
1977). And repair of the barrier needs increased DNA synthesis (for cell 
proliferation) and lipid synthesis (Proksch et al, 1993). 
 
The dermis can also be separated into two parts: the upper papillary dermis and 
the lower reticular dermis (Poole & Guerry IV, 2005). The dermis contains hair 
follicles, exocrine glands like sweat glands and sebaceous glands (holocrine) 
and various cell types including adipocytes, monocytes, mast cells, and 
fibroblasts (Sherwood, 2007). The skin is both the source and target of various 
hormones, growth factors and binding proteins, steroid hormones and vitamin D 
etc. (Zouboulis, 2000).  
 
Most skin cancers originate in the epidermis (Poole &Guerry IV, 2005). For 
melanoma, the originating cell is the melanocyte or its precursor cell the 
melanoblast, which is located mainly in the epidermis layer (see below) and the 
upper hair follicle.  
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1.1.2. Melanocytes 
 
 
1.1.2.1. Melanocytes and Melanoblasts 
 
A significant component of a functional skin barrier is its complement of pigment 
(i.e., melanin)-producing cells (Lin & Fisher, 2007). The term „melanocyte‟ was 
first introduced by Meyerson in 1889 (Westerhof, 2006), and represents a 
dendritic cell which originates from the neural crest. They exist as a minor cell 
subpopulation in the basal layer of skin‟s epidermis, mucous membranes, 
striavascularis of ear, hair matrix, various locations in the eye, and central 
nervous system (Sulaimon & Kitchell, 2003). The distribution of melanocytes in 
skin epidermis is shown in Figure 2. 
 
 
 
 
 
Fig. 2: Melanocytes in the epidermis of human skin (Robins, 1991) 
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Melanoblasts are precursors of the melanocytes and may contain pre-melanin 
granules (Westerhof, 2006). After melanoblasts are formed, they proliferate, 
differentiate, migrate, and finally arrive in the correct destinations including hair 
follicles and the base of the epidermis (Lin & Fisher, 2007). 
 
Melanocytes exist in very close proximity to keratinocytes, so that they have 
ability to easily deliver their produced melanin to keratinocytes. The delivered 
melanin accomplishes a primary function of melanocytes, i.e., to provide skin 
pigmentation (Poole & Guerry IV, 2005; Sulaimon & Kitchell, 2003).  
 
While pigment cells of the retina originate in the optic cup of the forebrain, all 
other melanocytes are neuroectodermal in origin (LaBonne & Bronner-Fraser, 
1998). During human embryogenesis, melanocyte development begins when 
the melanoblasts migrate from the neural crest. The melanoblasts are induced 
to migrate by other neural crest cells and travel to various body sites, and finally 
form mature melanocytes (Sulaimon & Kitchell, 2003). Melanoblasts are 
generated at the second month of intra-uterine life in humans (Costin & 
Hearing, 2007). The earliest skin-homing melanoblasts are found in the dermis 
at the 10th to 12th week of gestation, and then about 2 weeks late, they leave the 
dermis to enter the epidermis. After approximately 50 days gestation, 
melanocytes can be detected in the epidermis (Westerhof, 2006; Costin & 
Hearing, 2007). When melanoblasts reach their terminal destinations, most will 
differentiate into melanocytes. The whole process is completed by month 6 of 
human intra-uterine life. In parallel there is a gradual decrease in the number of 
melanocytes in dermis, such that when the baby is born most melanoblasts / 
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melanocytes have disappeared from the dermis. The mature melanocyte 
locates in the basal layer of the epidermis and produce melanin (Costin & 
Hearing, 2007).  
 
1.1.2.2. Melanosomes and melanin 
 
Once the mature melanocyte is formed, it starts to produce its unique organelle, 
the melanosome. Melanosomes are generated from the endoplasmic reticulum 
of the melanocyte and are of lysosomal origin (Westerhof, 2006). Melanosome 
are the place where melanin is produced, and prepared for ultimate transfer into 
keratinocytes, where they play an important role in skin photo-protection 
(Meyskens et al, 2001). 
 
A wide range of colours in skin and hair is possible, and is due to tonal 
variations in the pigment melanin, which is synthesized as a high density, 
insoluble biopolymeric pigment produced via a complex tyrosine redox reaction 
pathway (Costin & Hearing, 2007). However, the visual effect of melanin is seen 
on the surface of skin or in the hair fiber. It is separated into two broad types 
called eumelanin and pheomelanin according to colour, shape, and size of 
granules and item subsequent packaging and processing in skin (Sulaimon & 
Kitchell, 2003; Lin & Fisher, 2007). Brown/black eumelanin is a high density, 
insoluble and dark pigment, and is contained in the eumelanosome and is the 
major source of pigmentation of skin. Pheomelanin is yellow or red in colour, is 
soluble in alkali. The synthesis of this latter type of pigment is influenced by the 
intercellular concentration of cysteine (Potterf et al, 1998). Eumelanin is more 
photoprotective than pheomelanin, due to the latter‟s greater photo-instability 
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associated with its chemical structure, and also relate to eumelanin‟s 
preferential binding of cations, anions, chemicals and so on (Costin & Hearing, 
2007). 
 
 
1.1.2.3. Melanogenesis 
 
Melanogenesis is a biochemical pathway that synthesizes melanin (either 
eumelanin or pheomelanin) in the melanosome. The balance of variable 
enzyme expression and other pigment genes can influence the ratio of these 
two melanin types. During melanogenesis, at least 3 kinds of enzymes are 
needed to synthesis different melanins. Tyrosinase is produced by ribosomes 
before being transported into maturing melanosomes (Westerhof, 2006) and is 
the rate-limiting enzyme in melanogenesis for eumelanin or pheomelanin (Lin & 
Fisher, 2007; Sulaimon & Kitchell, 2003). Melanocytes with lower levels of 
active tyrosinase produce (eu)melanin more slowly than do melanocytes with 
low tyrosinase activity (Lin & Fisher, 2007). 
 
Eumelanin synthesis also involves tyrosinase-related proteins-1 and -2 (TRP1 
and TRP2/DCT). These two enzymes have 40-45% homology with tyrosinase 
(Lin & Fisher, 2007; Sulaimon & Kitchell, 2003) and can contribute to tonal 
variations in brown vs black melanin production. Pheomelanin appears to be 
more photo- and chemically- unstable, for example to sources of radiation 
exposure and oxidative stress. The formation of pheomelanin requires a 
cysteine and/or glutathione supply (Lin & Fisher, 2007). 
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Human evolution only success has depended on the ability of melanocytes to 
transfer their melanin product efficiently to neighboring keratinocytes and so 
protect the skin from harmful ultraviolet radiation (UVR). In humans, one 
melanocyte can make intimate contact with 37 viable keratinocytes to form, so 
called „epidermal melanin unit‟ (Fitzpatrick & Breathnach, 1963; Eisenger & 
Marko, 1982).  The correlate in the hair follicle has been termed the „follicular 
melanin unit‟ (Tobin, 2008). The synergistic relationship of the melanocyte and 
keratinocyte helps protect skin from outside-in damage, e.g. UVR (Sulaimon & 
Kitchell, 2003). Melanin pigment transfer ensures melanin is distributed 
throughout the epidermis including its upper layers (Agar & Young, 2005), 
though the melanin granule itself is largely degraded in the keratinocyte during 
this upward movement differentiation of cells. While individual melanin granule 
can be seen in the stratum corneum of African skin, melanin is largely degraded 
in the upper layers of Caucasian skin (Sulaimon & Kitchell, 2003). Table 1 
outlines the melanocyte life history.  
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The process of melanin synthesis can itself result in the production of 
intermediates of hydrogen peroxide and quinine (Meyskens et al, 2001). Thus, 
deficient handling of melanin intermediates could cause epidermal melanocytes 
damage (Sulaimon & Kitchell, 2003). 
 
 
Step I Melanoblasts migrate from the neural crest 
Step II Melanoblast differentiates to melanocyte. Clonal population of skin by melanocytes 
Step III Melanosome organelle biogenesis and matrix formation 
Step IV Melanogenic genes for tyrosinase, tyrosinase-related proteins and melanosomal 
matrix components are induced 
Step IV Tyrosinase and related melanogenic proteins are synthesized 
Step V  Post-translational processing and glycosylation of tyrosinase 
Step VI Fusion of vesicles to form melanosomes and initiation of melanogenesis 
Step VII Control of tyrosinase activity 
Step VIII  Control of the activity of tyrosinase-related protein 
Step IX Post-tyrosinase modification of biosynthesis 
Step X Modification of melanin 
Step XI Melanosome transfer to keratinocytes 
Step XII Melanosome degradation 
Step XIII Melanin removal with loss of cornified cell (i.e., stratum corneum) 
Table 1: Steps in melanogenesis (Sulaimon & Kitchell, 2003). 
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1.1.2.4. Melanocyte response to UVR and melanogenesis 
 
In 1917, Bloch reported on role of 3, 4-dihydroxyphenylalanine (DOPA) in 
melanocytes, and indicated that DOPA was a special substrate for the DOPA-
oxidase activity of tyrosinase. Then, his co-worker Lutz found that the activity of 
DOPA-oxidase was increased in pigment cells by UVR, and concluded that 
increased melanin production would offer protection against UVR (Westerhof, 
2006). 
 
While pigmentation gene expression can decide the constitutive pigmentation of 
skin and hair; this level of pigment production can be increased further (i.e., 
facultative) by a range of stimuli including UVR exposure (i.e. tanning), 
hormones, and growth factors etc. (Sulaimon & Kitchell, 2003). However, 
exposure to UVR can cause both inflammation and pigmentation (Heenen et al, 
2001; Gledhill et al, 2010). Stimulated or facultative pigmentation exhibits both 
„immediate‟ and „delayed‟ subphases (Costin & Hearing, 2007; Sulaimon & 
Kitchell, 2003).  
 
Immediate „tanning‟ pigmentation develops within seconds and minutes of UVA 
exposure, inducing pre-existing melanosomes to darken and their movement 
from the perinuclear area to the dendritic area in melanocytes. However, the 
number of the melanosomes is not increased. Immediate tanning peaks 1-2 
hours after UVR (Costin & Hearing, 2007; Sulaimon & Kitchell, 2003).  
 
By contrast, delayed pigmentation begins 2 to 3 days after UVB exposure (and 
to a minor extent by UVA and visible light) (Costin & Hearing, 2007). Maximum 
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tanning is reached approximately three weeks later. Remarkably, delayed 
pigmentation can take up to ten months to return back to original pigmentation 
level. Delayed pigmentation depends on the changing of melanocytes in quality 
(i.e. more eumelanin, more melanosomes) and to a limisted extent in quantity 
(via some very limited cell proliferation) (Costin & Hearing, 2007; Sulaimon & 
Kitchell, 2003).  
 
Both immediate and delayed tanning can produce pigment that can protect the 
skin against further damage and also against skin cancer, as UVR exposure 
can induce DNA damage (Fitzpatrick, 1988; Ortonne & Prota, 1993). UVR 
exposure of normal skin can increase melanin levels 10 to 15 fold even in the 
darkest individuals. However, melanin levels can be increased to 500 to 1000 
fold in paler skin, including those as risk of skin cancer induction (Kaidbey et al, 
1979). 
 
1.1.3. Melanoma 
 
In 1996, the American Academy of Dermatology reported that one melanoma 
patient dies each hour in the United States (Poole & Guerry IV, 2005). In the 
USA, human malignant melanoma has the second highest mortality rate of all 
cancers, second only to lung cancer. Rates of malignant melanoma are also 
increasing rapidly in other countries, like the UK, Germany, Canada, and 
Australia (Sulaimon & Kitchell, 2003).  Indeed, since the middle of 1960s, the 
incidence of melanoma has increased by 3% to 8% per year in many countries 
(Lens, 2008). However, thankfully the survival rate has also increased from 11% 
to 39%. This increased survival ratio depends however on early detection and 
 
Chapter 1: Introduction 
 
12 
 
atypical nevi removal (Gremel et al, 2009). 
 
Melanoma appears to be produced in two ways. In one melanocytes are 
activated and subsequently transformed by UVR after unprotected sunlight 
exposure; the other way is via transformation of benign nevi when benign nevi 
including after unprotected sun exposure (Lejeune, 1997). 
 
1.1.3.1. Melanoma from a historical perspective 
 
Melanoma was mentioned as a „black pigmented human tumour‟ at the time of 
Hippocrates (460-370 B.C.E.) (Balch et al, 2003). John Hunter, an English 
physician, published the first report of melanoma in Western medical literature 
in 1787, describing it as “soft and black” and as a “cancerous fungous 
excrescence”. He removed a melanoma tumour from the lower jaw of a 35y old 
man and preserved it. In 1968, the specimen was confirmed as a melanoma 
(Balch et al, 2003). 
 
1.1.3.2. Definition of melanoma 
 
Melanoma is a cancer that arises from the genetic transformation and 
uncontrolled growth of the melanocyte or melanoblast (i.e., melanocyte stem 
cell) (Miller & Mihm, 2006). Melanoma may form in skin, mucosa, uvea of eye, 
and leptomeningitis (Eigentler & Garbe, 2006). The most common type is 
cutaneous melanoma, and once melanoma cells have reached the dermis they 
have the potential to enter blood and lymph vessels and then to spread to other 
areas of the body (Poole & Guerry IV, 2005). Even though melanoma only 
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accounts for less than 5% of all skin diseases, it induces nearly 80% of skin 
disease mortality. Only 14% of patients with metastatic melanoma can expect to 
gain 5 years survival. The cure rate depends on early detection and removal by 
surgery. Some reports showed more than a 90% cure rate if the tumour is 
removed when it is less than 1mm in depth (Bolognia et al, 2003). 
 
Cutaneous melanoma can be classified into four types: superficial spreading 
melanoma, nodular melanoma, lentigo maligna melanoma, and acral 
lentiginous melanoma (Porras & Cockerell, 1997). 
 
The most common melanoma subtype is the superficial spreading type, which 
occurs in 70-80% of the all melanoma (Poole & Guerry IV, 2005). It can appear 
anywhere on the body and is commonly found on the upper arms, thigh and 
back of body, even though this skin is somewhat paradoxically not routinely 
exposed to the sun. The melanoma may begin from an abnormal nevus with 
irregular contour and various colours (Brannon, 2004). An existing nevus 
usually is the starting point of the development of a superficial spreading 
melanoma. However, melanoma can also develop from apparently unblemished 
skin. The diameter of nevus is commonly more than half a centimeter, it is more 
likely to be at risk of becoming a melanoma (Poole & Guerry IV, 2005). 
 
About 15% to 20% of the all melanoma occur as the nodular form. This type can 
appear on any part of the body, and locates at the same body sites as seen with 
superficial spreading melanoma (Brannon, 2004). Like superficial spreading 
melanoma, nodular melanoma often arises from existing nevi. It is slightly more 
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common in men than in women, is commonly dome-shaped and sometimes it 
looks like a blood blister (Poole & Guerry IV, 2005).  
 
The least frequent type of melanoma is lentigo maligna melanoma, which 
accounts for only 5% of all melanoma. It develops from a small abnormal patch 
on sun exposed skin in older people, usually on the regions of head and neck 
(Brannon, 2004). This melanoma results from many years of intense 
unprotected sun exposure, and does not arise from pre-exisiting nevi. The 
melanoma first appears on the skin as a dark irregular stain (Poole & Guerry IV, 
2005).  
 
The above three types of melanoma appear most frequently in Caucasians. 
However, another type of melanoma called acral lentiginous melanoma has 
lower frequency for white people and is the most common subtype in people 
with darker skins, e.g., xanthoderm (Poole & Guerry IV, 2005). The acral 
lentiginous melanoma is less than 5% of all melanomas, and is often on the 
palmar-plantar surface of hands, feet and the fingers or toes and under the nails 
(Brannon, 2004). When under the nails, the melanoma will appear on the base 
of the nails as a streak then reaches out to the tip. It most often appears on 
thumbs and great toes. The frequency of acral lentiginous melanoma is also 
reported to be associated with extent of sun exposure (Poole & Guerry IV, 
2005). 
 
Mucosal melanoma has been found on the mucous membranes inside the 
mouth and on the anal-genital region. The carcinogen involved is unknown, as 
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this type of melanoma is unlikely to be related to sun exposure (Poole & Guerry 
IV, 2005). Rarely, melanoma can present without melanin pigment, are pink or 
red, and so these melanomas can be very difficult to detect. (Poole & Guerry IV, 
2005). 
 
1.1.3.3. Melanoma risk factors 
 
Sun-sensitive skin has greater risk of all skin cancers than darker skin types 
because the photosensitive skin usually produces lower levels of the protective 
pigment eumelanin (Lin & Fisher, 2007; Mille & Mihm, 2006). A suppressed skin 
immune response and excess UVR exposure are enhancer risk factors of 
melanoma (Mile & Mihm, 2006). It is thought that a single risk factor is not on its 
own sufficient to develop melanoma, but that multiple risk factors together in the 
same individuals can markedly increase the risk for melanoma (Poole & Guerry 
IV, 2005), e.g. certain MCIR variants (Healy et al, 2014). 
 
 
 Ultraviolet Radiation 
 
Three kinds of electromagnetic radiation from sunlight can influence us 
physiologically including visible, infrared and ultraviolet light/irradiation (UVR). 
The greatest potential comes from the invisible UVR. UVR can be divided into 
UV-A (320-400 nm), UV-B (290-320 nm) and UV-C (200-290 nm). Only UV-A 
and UV-B reach the surface of the earth. They are carcinogens and play a role 
as both promoters and enhancers of melanoma (Setlow et al, 1993). UV-B is 
described as the main carcinogenic factor at the formation stage of melanoma 
and other skin cancers. UV-A and UV-B both induce skin damage, e.g., sunburn 
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and skin aging. Melanin pigment plays an important protective role in absorbing 
UVR and via a detoxifying function (Mile & Mihm, 2006). Actually, the sunburn 
sensitivity of different skin phototypes is related to the packaging and 
distribution of the melanin in the skin cells. Melanin type is under genetic 
control, and is the major factor to determine type and colour of the skin (Poole & 
Guerry IV, 2005). 
 
White Caucasian skin is the most susceptible skin type for melanoma, except 
for acral lentiginous melanoma. Even a brief strong sun exposure episode on 
sensitive skin can cause it to become inflamed and red. Commonly, this kind of 
individual has red(-ish) hair, freckles and porcelain white skin (e.g., Celtic 
people) (Poole & Guerry IV, 2005), a phenotype associated with a small number 
of MCIR variants (Healy et al, 2014). 
 
Is all sun exposure bad? 
 
For most people, mild sun exposure is not deleterious. In fact, mild sun 
exposure can be beneficial e.g., for the production of vitamin D. It has also been 
reported some tanning (without burning) may actually aid melanoma prevention 
(Poole & Guerry IV, 2005; Zouboulis, 2000). While excessive exposure to UVR 
has been indicated as the main etiological factor in melanoma, except is rare 
hereditary cases (Sulaimon & Kitchell, 2003; Halaban, 1996), the precise 
relationship is complex. For example, primary melanoma commonly appears 
first on non-exposed body sites (Tronov et al, 2010). Still, many in vitro studies 
have demonstrated that UV radiation induces DNA damage, gene mutations, 
induction of reactive species oxygen, inhibition of the skin immune system and 
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increasing growth factor production (Halaban, 1996). All these changes can 
lower the resistance of skin to protect itself from the ill-effects of UVR (Tronov et 
al, 2010).  
 
Nevi (moles) 
 
The average number of nevi or moles on their body surface of a white 
Caucasian adult is about 25. Most children appear to be born without nevi. 
However, these children develop nevi by approximately 3 years old (Gallagher 
& Mclean, 1995). It has shown that sun exposure induces moles. Commonly, 
when a mole is produced on a child‟s skin, it is a flat dark brown and pinhead 
size dot. Then, the mole will slowly grow to a round or oval shape, flat or 
domed. Some moles are not influenced by sun exposure. For example, 1% of 
newborn babies have a dark brown, flat or shortly domed single moles, and 
some of these moles may be more that 1 centimetre diameter. Some doctors 
may advise to remove these moles to prevent melanoma. However, the chance 
of evolution to melanoma is rare (Pools & Guerry IV, 2005). Almost all people 
have some normal round and small moles. However, in 15% of white skinned 
persons these can show dysplastic features. Dysplastic moles are larger than 
normal mole (>5mm in diameter), and have domed centres. They appear more 
or less on sun-exposed parts of the body (Pools & Guerry IV, 2005).  
 
Both dysplastic moles and normal moles deserve attention, because people 
with large numbers of moles are at relatively higher risk of melanoma than 
those without. The presence of numerous on normal moles and a few dysplastic 
moles can also help to warn individuals that they may have 2-10 times greater 
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risk to develop melanoma during their lives than people who have few or no 
moles (Pools & Guerry IV, 2005). Still, the prevention of melanoma by removing 
all dysplastic moles and ordinary moles may be viewed as an extreme 
precaution. The key is to know the moles which are dysplastic and to watch out 
for changes to them (Pools & Guerry IV, 2005). For example, if a person has an 
isolated dysplastic mole and has already had melanoma, the mole should be 
removed. Similarly, if someone‟s mole is changing in phenotype, the mole 
should be removed.  
 
Melanoma genetics— Inherited and mutated genes 
 
Only approximate 10% of melanoma patients have familial disease with family 
members expressing relevant and associated gene mutations. From 1976, the 
National Cancer Institute and the University of Pennsylvania‟s Pigmented 
Lesion Clinic have detected gene mutation frequency in 23 suspicious families. 
Strikingly, their results show that 90% of close blood relatives did not express 
these genes. However, if two or more melanoma patients exist in the same 
family, doctors would hypothesize that these patients will have inherited similar 
melanoma-associated genes (Pools & Guerry IV, 2005). Though the number of 
these patients still constitutes only 10% of the total, a family history of 
melanoma is a strong risk factor of melanoma. The members of a family with 
atypical nevi or previous melanoma should also be assessed for possible 
positive melanoma family history, even though these changes have not yet 
developed to malignant melanoma (Miller & Mihm, 2006). 
 
The cell growth regulator p16 or CDKN2A have been identified as a relevant 
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mutant gene on chromosome 9. Multiple studies have determined that mutation 
of CDKN2A plays a key role for the development of melanoma (Miler & Mihm, 
2006). Experimental findings have shown that the loss of CDKN2A expression 
and function increases the chances of transformation of dysplastic nevi to 
melanoma, or increases the probability to develop melanoma (Miler & Mihm, 
2006). CDKN2A mutations were detected in the GenoMEL (Melanoma Genetics 
Consortium) and found that relatively low mutation detection rate of CDKN2A is 
not based on a failure to detect rather it implies other high penetrance 
melanoma genes exist (Harland et al., 2008). BRAF is a second dominant gene 
associated with melanoma that encodes for a protein called B-Raf that can 
activate MEK. BRAF mutations are the most common mutations found in 
melanoma to date. BRAF mutations induce the melanocyte population to 
become senescent by inhibiting proliferation; it also cooperates with p16 
mutations to induce high penetrance and short latency of melanoma (Delmas et 
al., 2007). 
 
1.1.4. From melanocyte to melanoma 
 
 
 Fig.3: The evolution of melanoma (Gremel et al, 2009). 
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 As shown in Figure 3, the melanocytes are located in the basal layer of the 
epidermis, where malignant transformation of an affected melanocyte starts to 
develop melanoma (Bittener et al., 2000). However, the melanoma is not only 
transformed from epidermis-associated melanocytes, it also can be from cells in 
the dermis. Studies have proposed that melanoma may also originate via the 
transformation of melanocyte stem cells in the epidermis (Grichnik et al., 2006) 
and dermis-derived stem cells (Zabierowski et al., 2011). 
 
The commonest methods used in clinical practice to classify melanoma for 
diagnosis rely on the histologic thickness of melanoma, the degree of invasion, 
and melanoma with or without ulcerations (Balch et al., 2001). These are 
discussed in the following section.  
 
1.1.4.1. The transition of melanocytes to melanoma: five phases 
 
 
The transition of melanocytes to melanoma could be separated into five steps 
(Shown as the above Figure 3). 
 
1. Melanocytes in normal skin or benign nevi (Gremel et al, 2009). 
 
2. Dysplastic and atypical nevi: These dysplastic and atypical nevi are formed 
from normal nevi, which may mean melanoma changes have begun (Gremel 
et al, 2009).  
 
 
Chapter 1: Introduction 
 
21 
 
3. Radial growth phase: Atypical cells emerge to form the radial growth phase 
(RGP), which is the initial stage of melanoma. The newly-formed melanoma 
does not spread to other organs of the body, until it moves to successive 
growth phases (Pool & Gerry IV, 2005). The radial growth phase melanoma 
invades the epidermis and metastasizes to the upper dermis. However, it 
may not be easy to detect using a diagnostic test at this stage (Gremel et al, 
2009). The radial growth phase consists of two steps: The first is where the 
melanoma cells are still in situ i.e., still in the epidermis. The second is 
where the melanoma cells have ability to invade to the dermis. However, the 
number of melanoma cells still remains low. From the second step, the 
melanoma cells break free of their epidermis in situ containment. During the 
radial growth phase, the melanoma cells cannot yet spread to other parts of 
the body. Moreover, if the melanoma cells are not detected and removed, 
they will proceed to the vertical growth phase (Poole & Gerry IV, 2005).  
 
 
4. Vertical growth phases: When the growing RGP melanoma invades into the 
dermis and subcutaneous fat layer, the stage is called vertical growth phase 
(VGP) (Gremel et al, 2009). It is also called the tumourigenic phase. The 
melanoma exists as a group of spreading abnormal melanocytes that move 
to the dermis where they start to form a tumour mass. In this phase, the 
melanoma has a chance to expand to other parts of body. Removing the 
melanoma at the radical growth stage i.e., before the beginning of the 
vertical growth phase, can stop the tumour from becoming potentially fatal 
(Poole & Gerry IV, 2005). 
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5. Metastatic melanoma: After the vertical growth phases of melanoma, the 
tumour cells metastasize to the blood vessels, lymph nodes, lung, liver, brain 
and others parts of the body. This stage is metastatic melanoma (Gremel et 
al, 2009).   
 
 
1.1.4.2. Other schemes for the classification of melanoma 
 
 
Other methods have been used to describe the stages of melanoma, like the 
„Clark‟ and „Breslow‟ staging. The Clark model describes the development 
process of melanoma from dysplastic nevus to metastatic melanoma (Clark et 
al, 1984). The details of the different measure methods are shown on the Table 
2. 
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Malignant melanoma: staging 
 
Clark staging (Clark et al, 1984) 
 Level I: all tumour cells are in the epidermis above basement 
membrane (i.e., in situ) 
 Level II: tumour extends to the upper papillary dermis 
 Level III: tumour extends to interface between the papillary and 
reticular dermis 
 Level IV: tumour extends between bundles of collagen in the reticular 
dermis 
 Level V: tumour invasion of subcutaneous tissue 
Breslow staging (Breslow, 1970) 
 Thin: < 0.75 mm depth of invasion 
 Intermediate: 0.76-3.99 mm depth of invasion 
 Thick: >4 mm depth of invasion 
 
 
Clark level I is melanoma in situ as classified by WHO (Leboit et al, 2006). At is 
first level, abnormal cells of dysplastic nevi appear with a reduced ability of DNA 
repair. However, the cells cannot produce colonies in agar (Tronov et al, 2010). 
Clark level II is microinvasive melanoma within the upper papillary dermis, 
which corresponds to the radial growth melanoma. Clark level III to level V and 
the Breslow staging are equivalent to histological features from the vertical 
Table 2: Staging of malignant melanoma http://chorus.rad.mcw.edu/doc/00955.html, (Kahn,   
2006) 
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growth phase of melanoma to metastasis melanoma (Leboit et al, 2006; Tronov 
et al, 2010). At these stages, the malignant melanocytes have the ability to grow 
in a relatively unrestrictive way, and can form colonies on agar (Tronov et al, 
2010). The histopathological appearance of the 5 steps of the Clark model is 
presented in Figure 4. 
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Figure 4: The 5 steps of melanoma development (Clark model) (taken from Miller & 
Mihm, 2006) 
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1.1.4.3. Melanoma tumour invasion and metastasis 
 
The extent of local invasion and metastasis of tumour cells directly influence the 
morbidity and mortality of melanoma, which mainly occur in the melanoma‟s 
vertical growth phase (Miller & Mihm, 2006). The tumour is said to be metastatic 
when it spreads and invades to blood vessels, lymph, and some surrounding 
stroma (Haass et al, 2005). Some studies have demonstrated that melanoma 
invasion is related to changes in cell adhesion (Miller & Mihm, 2006). Normally, 
cell adhesion controls cell migration, and also organizes tissue and 
organogenesis. Once cell adhesion is disturbed, the tumour cell can respond to 
stimulate different tumour-associated signaling pathways to establish new 
relationships between tumour and stroma that assists the tumour cells to invade 
(Miller & Mihm, 2006). 
 
 
1.1.5. Pathogenesis  
 
The role of genetics in melanoma development has been demonstrated by 
several epidemiology studies, like gene changes that are associated with a 
disturbed cell cycle mechanism and via other transcriptional mechanisms 
(Halachmi & Gilchrest, 2001). A major gene that is considered to be implicated 
in melanoma is CDKN2A, which locates on chromosome 9p21, and it also is 
known as INK4a. The exons 1α, 2, and 3 of CDKN2A are used for encoding the 
protein p16. The protein p14ARF is transcribed from exon 1β and the shared 
exons 2 and 3. Both gene products play an important role as negative 
regulators in cell cycle progression, and Daniel et al determined that the p14ARF 
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is more commonly inactivated than p16 by genetic and epigenetic analyses 
(Freedberg et al, 2008). A view of the CDKN2A locus is shown as Fig. 5. 
 
 
 
 
 
As shown in Figure 5 above, p16 protein competitively inhibits of CDK4 (cyclin-
dependent kinase 4). CDK4 and cyclin D can activate Rb (retinoblastoma 
protein) by phosphorylation, and the phosphorylated Rb can arrest cell cycle S 
phase, cell division and proliferation. A  CDKN2A mutation leads to loss of the 
p16 protein function, and the functional loss of the p16 influences the mutagenic 
DNA repair before cell division. The incidence of an abnormal p16 protein in 
melanoma is between 30-50% in familial melanoma and between 25-40% in 
sporadic melanoma (Nestle & Kerl, 2003).  
Figure 5: CDKN2A locus (Lin et al, 2008) 
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The p14ARF gene interacts with MDM2 to regulate melanocyte growth via the 
p53 pathway (Piepkorn, 2000). The activated p53 pathway inhibits the cell cycle 
and regulates the apoptosis. So loss of p14ARF function, due to the mutation of 
CDKN2A, can increase cell growth or survival (Nestle & Kerl, 2003).  
 
Many studies indicate advocate that melanoma development involves several 
additional genes located in chromosome regions 1p, 6q, 7p, 11q, 9p, 10q. 
These high mutation regions can be analyzed by new mutation analyses 
techniques, like cDNA and tissue microarrays (Pollock & Trent, 2000). 
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1.2. Breast cancer 
 
In the current study, microarray datasets for other cancers were used for the 
evaluation of the proposed bioinformatics approach and included Breast Cancer 
and Prostate Cancer. 
 
Breast cancer is generated in breast tissue, and commonly occurs in the 
associated ducts and lobules, called ductal carcinomas and lobular carcinomas 
respectively. The incidence of breast cancer is 100 times higher in females than 
males. (Sariego, 2010), Breast cancer occupies 22.9% of all female cancer 
(excludes non-melanoma skin cancers), and around 13.7% cancer deaths in 
women in 2008 (Buchholz, 2009). 
 
Risk factors of breast cancer include smoking, high levels of estrogen hormone, 
diet and obesity. Negative risk factors include young age and breastfeeding. 
However, whether breastfeeding has a relationship with breast cancer is still an 
open question, some studies found the positive associations between them, but 
others did not (Yang & Jacobsen, 2008). Smoking increases the risk of breast 
cancer especially for heavy smokers who started smoking at a young age, or for 
those with a long term smoking habit (Johnson et al., 2011). Higher hormone 
levels have been associated with breast cancer e.g. estrogen-related drugs 
increased the risk of breast cancer (Johansen et al., 2010) as do high fat diets 
and obesity (Blackburn & Wang, 2007). 
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Mutations in BRCA1 and BRCA2 are significant biomarkers for breast cancer. 
Mutations in these two gene mutations have been found in up to 90% of breast 
cancers with a demonstrated genetic influence. Other significant gene 
associations with breast cancer include p53, PTEN, STK11, CHEK2, ATM, 
BRIP1 and PAL2 (Gage et al, 2012).  
 
Staging of breast cancer is based on the Tumour, Node, Metastases (TNM) 
system, i.e. the size of the tumour, whether the tumour spreads to the lymph 
nodes in the armpits, and whether the tumour starts to metastasize. The stage 
has been classified from 0 to 4, viz. stage 0 is carcinoma in situ (including 
ductal or lobular carcinoma); stage 1 – 3 represent a tumour that is still within 
the breast or within the regional lymph nodes; and stage 4 exhibits tumour 
metastases outside the breast (Johansen et al., 2010). 
 
Survival rates for breast cancer depend on several factors: type, stage, 
treatment and location of the patient. The major treatment methods are surgery 
(the physical removal of the tumour, surrounding tissue and sentinel lymph 
node), medications including hormonal therapy (drugs have been used for 
blocking the estrogen receptors or production of estrogen), chemotherapy 
(causing DNA damage to proliferating cancer cells), radiotherapy (usually given 
after surgery to reduce the risk of recurrence) and immunotherapy (Florescu et 
al., 2010).   
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1.3. Prostate cancer 
 
 
This tumour originates in the prostate, a gland of the male reproductive system, 
and grows as a classical adenocarcinoma and glandular cancer. Although it 
develops relatively slowly, some prostate cancers can come aggressive. 
Metastatic prostate cancer spreads to other parts of body, especially to the 
lymph nodes and bones (Lister, 2009). This cancer most commonly affect men 
over fifty years old (Siegel, 2011), and ranks sixth in cancer deaths in men 
(Baade et al., 2009). 
 
As with breast cancer, the stages of prostate cancer are also measured by the 
four stages TNM system, viz. based on tumour size, nodal involvement and 
metastases. Stage I and II of prostate cancer means the tumour is limited to the 
prostate. When the cancer cells spread to lymph nodes and other organs the 
cancer is graded stage III and IV (Makarov et al., 2012). Mortality of prostate 
cancer has not decreased over the last 10 years, due largely to unawareness of 
disease, even though prostate-specific antigen (PSA) testing has increased 
cancer detection (Djulbegovic et al., 2010). Like breast cancer, treatment of 
prostate cancer includes surgery, radiation therapy, hormonal therapy and 
chemotherapy (Dimitropoulou et al., 2009). 
 
Obesity, age and family history are the main risk factors of prostate cancer. 
Whether diet is associated with prostate cancer is still unclear; with some 
studies reporting that meat intake has little relationship with higher risk of 
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prostate cancer (Alexander et al., 2010), and that fruit or vegetable also have 
little positive effect (Key, 2011). An elevated testosterone level in blood may 
increase prostate cancer risk (Gann et al., 1996). Age is a well-reported risk 
factor, and the cancer is very unusual in men who are younger than forty five. 
The average age of diagnosis is seventy (Hankey et al., 1999). Family history 
also is a key, as first-degree relatives of prostate cancer patient have twice the 
background risk. If two or more prostate cancer patients exist in one family, 
other first-degree relatives have a five-fold risk than men with family history 
(Steinberg et al, 1990). Some other factors influence prostate cancer risk. 
Statins (cholesterol lowering drug) decrease the risk of prostate cancer 
(Shannon et al., 2005), while infection or inflammation in prostate may increase 
risk (Dennis et al., 2002).  
 
At the gene mutation level, BRCA1 and BRCA2 are biomarkers (like in breast 
cancer) for prostate cancer (Struewing et al., 1997). Hereditary prostate cancer 
gene 1 (HPC1), the androgen receptor and vitamin D receptor have also been 
reported as genes linked to prostate cancer (Gallagher & Fleshner, 1998). 
Mutations in P53, PTEN and KAI1 based on loss of the corresponding 
suppressor genes also play a role in prostate cancer (Beuzeboc et al., 2009). 
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1.4. DNA MICROARRAY AND ANALYSIS 
 
1.4.1. Introduction to DNA microarray 
 
 
While the Human Genome Project has reported the location of all known human 
genes (Wren, 2009), the function of each gene has not yet been determined. 
While the functions of some of genes are frequently reported in the literature, 
still 37% of human genes have no published functional information (Wren, 
2009). Conversely, protein domain analysis could help us to speculate on the 
corresponding functions of some genes. For example, a DNA binding function 
can be inferred when the gene‟s encoded protein contains zinc finger domains, 
and a protein-protein interaction can be inferred when the protein contains 
coiled-coil domains (Cahan et al., 2007). Similarly, the cellular location of an 
unknown, cytosolic or membranous protein can be inferred if the protein 
contains trans-membrane domains. This „guesstimating‟ should however be 
done in a biological context, because most gene expression is highly regulated 
by context and circumstance (Wren, 2009).  
 
To deal with these challenges, the microarray technique has gained popularity 
in many biomedical areas, such as cancer, inflammation, cardiovascular 
disease, alcohol consumption, and stem cell differentiation and so on (Cahan et 
al, 2007). 
 
DNA microarray is a high throughout technique, which has application in 
detecting and quantifying mRNA (gene) expression (Gremel et al., 2009). 
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Although the microarray technique was first devised in 1975 (Mlakar & Glavac, 
2007), the mature Microarray was built only in the early 1990‟s, and has rapidly 
developed since then. The technique was first used for measurement of DNA 
fragments, so it is named as DNA microarray (Kunz, 2008). The technique 
involves small pieces of discrete single strand DNA fragments with inherent 
properties as probes, which are used for binding their complementary and 
unique gene sequences (Gremel et al., 2009). So the quantified amount of the 
detected gene sequences should be measureable with high accuracy due to 
complementary binding (Kunz, 2008). 
 
 
Microarray technology has been used as an advanced high-throughput strategy 
for the discovery of diagnostic gene signatures of human diseases on a 
genome-wide scale. The genome-wide discovery of signatures enables one to 
gain important insights into the underlying biological mechanisms driving 
tumourigenesis. A significant amount of microarray data has been deposited in 
publically-available data repositories over the past decade, e.g., the Gene 
Expression Omnibus (GEO) (Barrett et al., 2011), the ArrayExpress Archive 
(Parkinson et al., 2011), CIBEX (Kodama et al., 2010), and SMD (Hubble et al., 
2009). These repositories enable scientists to advance the discovery of 
diagnostic and prognostic gene signatures by means of data integration and 
integrated bioinformatics analysis. For example, one group constructed a global 
map of human gene expression by integrating microarray data from 5,372 human 
samples representing 369 different cell and tissue types, disease states and cell 
lines (Lukk et al., 2010).  
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Although the microarray experiments are performed on different platforms, all 
platforms include a step of hybridization. Hybridization is used for binding the 
DNA probe to the solid support and then binding the probe to the fluorescent 
dyed target nucleotides of the samples (Mlakar & Glavac, 2007). The basic 
steps of microarray are shown on Fig. 6. 
 
 
 
 
 
 
 
 
 
Figure 6: Basic steps of microarray analysis (Mlakar & Glavac, 2007) 
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1.4.2. DNA microarray experiments 
 
 
There exist currently two main techniques for DNA microarray:  Oligonucleotide 
DNA microarray and cDNA microarray (Gremel et al, 2009). An oligonucleotide 
DNA microarray can detect 25 to 70 base length short DNA or RNA sequences. 
cDNA microarray is used to detect 200 to 2000 base length sequences. 
Normally, standard PCR is used for the amplification step (Mlakar & Glavac, 
2007). 
 
Total RNA is extracted from tissue samples or cell lines. Usually, the target 
mRNA sequences are amplified by PCR. The total RNA are reverse transcribed 
into cDNA and stained with a fluorescent dye, and then hybridized to probes of 
microarray (Kunz et al., 2004; Yang et al., 2002).  
 
DNA microarrays have been used to detect the gene expression of different 
disease phases, e.g., from normal skin or normal cells to metastatic tumour 
(Smith et al., 2005). Researchers have noticed that the analysis of disease 
phase diversity can offer insights into how these genes are associated with 
enhanced melanoma cell survival (Smith et al., 2005; Jaeger et al., 2007).  
 
 
1.4.3.  Microarray databases 
 
There are four of main repositories for microarray data including; GEO (Gene 
Expression Omnibus), ArrayExpress, and CIBEX (Center for Information 
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Biology gene EXpression database) and SMD (Stanford Microarray database). 
The first three have been recommended by the Microarray Gene Expression 
Data (MGED) Society for storing public available microarray datasets 
(Parkinson et al, 2005). 
 
1.4.3.1. GEO (http://www.ncbi.nlm.nih.gov/geo/) 
 
The Gene Expression Omnibus (GEO) of the National Center for Biotechnology 
Information (NCBI) was built in 2000, which provides free access to the 
published gene expression data sources. The GEO project provides the 
simplest procedure and free-download mechanisms of high-throughput gene 
expression data (Barrett et al., 2008). At Sept 2013 the database contained 
microarray datasets of over 300,000 samples of over 10,000 experiments from 
around the world. 
 
The GEO includes three types of submission entity; „platform‟ (a record for a 
summary of array-based platform, e.g., Agilent, Affymetrix), „series‟ (a record for 
linking a group of related samples), and „sample‟ (a record for conditions of 
each individual sample). The „platform‟ is the parent platform which should be 
defined first (Edgar et al., 2002). The „platform‟ set contains a microarray data 
table and a brief introduction of these data to present the main features of the 
array e.g. cDNA microarray, oligonucleotides microarray and so on. Every 
platform begins with „GPL (GEO Platform)‟ followed by a unique GEO accession 
number (Barrett et al., 2008). A „sample‟ record contains a data table with the 
experimental material and method protocols. Each „sample‟ matches one 
 
Chapter 1: Introduction 
 
38 
 
„platform‟; however, the sample should be contained in multiple „series‟ (Barrett 
et al., 2008). Every sample record begins with „GSM (GEO Soft format Sample 
file)‟ followed by a unique GEO accession number (Barrett et al., 2008). A 
„series‟ record is a group of related „samples‟; it may include one or more tables. 
Every „series‟ begins with „GSE (GEO Series format file)‟, followed by a unique 
GEO accession number (Barrett et al., 2008).  
 
The GEO deposit options and formats were shown on below table. 
 
 
Option Formation Key features 
Web deposit Web forms Deposit of individual records. 
Simple step-by-step interactive web forms. 
GEO archive Spreadsheets  
(e.g. Excel) 
Batch deposit. 
Good choice for most users who have many 
samples to submit. 
SOFT (Simple Omnibus Format 
in Text) 
Plain text 
 
Batch deposit. 
A simple, line-based, tab-delimited format 
that can be readily generated, particularly if 
the data are already in a database. 
MINiML (MIAME notation in 
Markup Language) 
XML Batch deposit. 
Basically an XML rendering of SOFT format, 
and similarly suitable if data are already in a 
database. The XML schema definition is 
available at the GEO website. 
 
Table 3: GEO deposit options and formats (Barrett et al., 2008) 
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1.4.3.2. ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) 
 
The ArrayExpress database is available as an international microarray data 
repository of the European Bioinformatics Institute (EBI) since 2002 (Brazma et 
al, 2003). The ArrayExpress database contains gene names, gene function and 
other information related to the gene (Parkinson et al, 2005). The data comes 
from two sources: one is users‟ submission, the other one is mapping from the 
NCBI Gene Expression Omnibus. GXA (Gene Expression Atlas) is a separate 
database available from the ArrayExpress interface (Parkinson et al, 2011). The 
ArrayExpress and GEO have an agreement for data exchange that is 
ArrayExpress connects to GEO to import all GDS and GES data. Therefore all 
of the submitted high-throughput and HTP sequencing data in GEO will appear 
in ArrayExpress (Parkinson et al., 2011). 
 
1.4.3.3. CIBEX (Center for Information Biology gene EXpression 
database) (http://cibex.nig.ac.jp/) 
 
CIBEX is a public microarray expression database constructed for organizing 
MIAME (Minimum Information about Microarray Experiment), and began storing 
microarray data in 2004. The CIBEX is one of the primary databases run by the 
Center for Information Biology and DNA Data Bank of Japan (CIB-DDBJ) and 
this database is now organized by the Microarray Gene Expression Data 
Society (MGED) (Kodama et al., 2010). Most of submitted data comes from 
Japan, and is automatically presented in the related tables (Ikeo et al., 2003). 
The submitted data contains its own CIBEX accession number, started with 
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“CBX”. CIBEX has links to other databases, like PubMed (Ikeo et al., 2003). 
From 2009, the CIB-DDBJ exchanges GEO and ArrayExpress data to join the 
International Database Plan (Kodama et al., 2010). 
 
1.4.3.4. SMD: Stanford microarray database (http://smd.stanford.edu) 
 
The SMD provides a platform for biological researchers to analyze, share, view 
and annotate microarray data of more than 60 organisms. Over 70,000 
microarrays have been stored in the SMD by Sept 2013. There are about 9,000 
sets of Homo sapiens-specific data and have been used in over 400 published 
research articles. The SMD stores microarray data generated by multiple 
platforms, like spotted cDNA microarray, oligonucleotide microarrays, Affymetrix, 
Agilent (Hubble et al., 2009). SMD provides a biological annotation of genes 
and sequences in each organism, and also has some annotation tools for users 
dealing with their own data. For example, MAGE-ML files writing tools 
(Parkinson et al., 2007), directly with the ArrayExpress and Gene Expression 
Omnibus (Wheeler et al., 2007). Registration is required to use of these tools for 
selected, downloaded, analyzed data etc. (Hubble et al., 2009). 
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1.4.4. Microarray data analysis 
 
1.4.4.1.  Data pre-processing 
 
Two kinds of microarray techniques have been used widely for comparative 
studies in order to detect changes in gene expression, including the spotted 
complementary DNA (cDNA) and the oligonucleotide microarray. Each single 
microarray experiment can detect the expression level of thousands of genes. 
There exist experimental noise and systematic errors in the raw data, which can 
greatly influence understanding of the true biological information (Bilban et al, 
2002). Pre-processing and normalization is thus always necessary in microarray 
data analysis. 
 
Data pre-processing of microarrays is done by the following steps: gene 
mapping, gene filtering, and data normalization. For gene mapping, the 
relationship between probe-sets (unique and identifiable set of individual 
probes) and genes is arranged. When multiple probe-sets map to one gene in 
the dataset, the expression value of that gene should be extracted from the 
associated probe-sets. Otherwise, when one probe-set is mapped to multiple 
genes, these genes will be assigned with the same expression value. Details 
are shown in section 2.2. 
 
Gene filtering focuses on the genes that have significant expression changes 
across samples and on the availability of gene controlling DNA sequences (Yue 
et al, 2001). Several factors are frequently used for gene filtering, including 
standard deviation (SD) and p-value. Genes with associated large SD indicate 
that their expression difference between, for example, normal and disease 
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condition is significant, whereas genes with a relatively smaller SD will be 
filtered out. Furthermore, there often exists missing values in experiments. If 
this involves missing values in considerably large number of samples, it will be 
excluded in the analysis. The ratio of missing value for a gene determines the 
gene filter using a predefined threshold value (Hackstadt & Hess, 2009). For a 
gene with a small number of missing values, a non-parametric method called 
“KNN” (k-nearest neighbors algorithm), which is a type of instance-based 
learning approach, is applied to fill the missing values of genes (Altman, 1992). 
The „knn‟ „R package‟ was used in this study. K is a user-defined parameter for 
counting the numbers of neighbors to be applied to estimate the expression of 
the missing one, i.e. the values of k nearer neighbors are used to estimate the 
missing value, by weighting the associated neighbors as 1/d, where d is the 
distance of the neighbor (Altman, 1992).  
 
Normalization of microarray data is done by fitting (filtering or smoothing) the 
raw data in order to enable the microarray data is comparable. The classical 
approaches for normalizing of expression data include linear regression 
analysis (Chatterjee & Price, 1991), rank invariant methods (Tseng et al, 2001), 
log centering and so on. But, none of these can deal adequately with the 
possible systematic bias caused by microarray noise. To address this, some 
studies suggested that the log2 (ratio) values should be applied to microarray 
analysis, which a dependence relationship with intensity value in microarray. 
LOWESS (Locally Weighted Scatterplot Smoothening) analysis was proposed 
and applied to remove the effect of intensity dependence in a binary logarithm 
ratio (Yang et al., 2002). Non-linear normalization is adopted for high-density-
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oligonucleotides (Affymetrix) and cDNA microarrays. Normalization factors (like 
median value or mean value) are used to process the expression value of 
genes (Welsh et al., 2001).  
 
Comparative analysis of microarray data 
 
1. Fold change: 
 
The comparison of expression levels of genes across samples is one of the 
main steps in microarray studies. It is intended to determine differences in 
expression between genes in various biological samples. For example, fold 
change, widely used in microarray analysis, is defined by: 
 
𝑇𝑖 =
𝑅𝑖
𝐺𝑖
 
 
where Ti is the ratio of ith gene, and Ri and Gi represent the expression levels of 
the associated gene.  
 
The formula is not limited to any microarray platform, the measurement of R 
and G can be taken from either one array or two arrays (Quackenbush, 2002). 
 
 
2. Statistical tests:   
 
Microarray studies can identify differentially-expressed genes across different 
samples to reveal biomarker genes. To make project with this aim, statistical 
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tests are widely used, including three main statistical tests as described below. 
 
 
2.1. t-test 
 
The t-statistic measures the distance between the two samples in units of 
standard deviation, based on comparing the between- or within-group 
differences (Cui & Churchill, 2003). The calculation shows the significant 
difference of a gene from the mean expression level of group A and group B:  
 
𝑡 =
𝑋𝐴̅̅ ̅ − 𝑋𝐵̅̅̅̅
𝑆
 
 
      where  𝑥𝐴̅̅ ̅ =
∑ 𝑥𝑘
𝑛𝐴
𝑘=1
𝑛𝐴
  ;              𝑥𝐵̅̅ ̅ =
∑ 𝑥𝑘
𝑛𝐴+ 𝑛𝐵
𝑘=𝑛𝐴+1
𝑛𝐵
;                𝑆 = √
𝑆𝐴
2
𝑛𝐴
+
𝑆𝐵
2
𝑛𝐵
; 
 𝑆𝐴 =  √
∑ (𝑋𝑘−?̅?𝐴)2
𝑛𝐴
𝑘=1
𝑛𝐴−1
;                     𝑆𝐵 = √
∑ (𝑋𝑘−?̅?𝐵)2
𝑛𝐴+𝑛𝐵
𝑘=𝑛𝐴+1
𝑛𝐵−1
   
𝑥𝑘, k=1~nA+nB, is the kth expression value of a gene in the independent study. 
 
 
2.2. Analysis of Variance (ANOVA) 
 
ANOVA is used for microarray analysis of variance where multiple groups 
(e.g. normal group, disease group…) are involved. The significant genes 
retrieved by ANOVA (F-statistics) between two groups should be the same 
as genes retrieved by t-statistics, because two group-ANOVA is formally 
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equivalent to the t-test.  The ANOVA test is based on calculating the Sum of 
squared residuals within (SSw) or between (SSB) groups and should be 
calculated separately (Hinkelmann & Kempthorne, 2008). 
 
𝑆𝑆𝑤 = ∑ ∑ (𝑋𝑖𝑗 − ?̅?𝑗)
2𝑛𝑗
𝑖=1
𝑚
𝑗=1         (1) 
𝑆𝑆𝐵 = ∑ 𝑛𝑗(?̅?𝑗 − ?̅?)
2𝑚
𝑗=1              (2)      
F𝑚−1,𝑁−𝑚 =
𝑀𝑒𝑎𝑛 𝑠𝑞𝑢𝑎𝑟𝑒𝑑 𝑏𝑒𝑡𝑤𝑒𝑒𝑛
𝑀𝑒𝑎𝑛 𝑠𝑞𝑢𝑎𝑟𝑒𝑑 𝑤𝑖𝑡ℎ𝑖𝑛
=
𝑆𝑆𝑤/(𝑚 − 1)
𝑆𝑆𝐵/(𝑁 −𝑚)
   (3) 
 
where 𝑋𝑖𝑗, i=1~n, is the jth independent study. m is the number of groups; N 
is     the total number of cases. ?̅?: Ground mean=sum of all values/N.m-1or 
N-m: the degrees of freedom. 
 
2.3. Significance analysis of microarrays (SAM) 
 
The SAM is a statistical technique for microarray data analysis for 
measuring the changes in gene expression as statistic d (Tusher et al, 
2001). The SAM analysis is defined by the difference between two groups 
and the standard deviation adjusted by an exchangeability factor s0 which is 
as denominator of test statistic, default is automatic choice (Tusher et al, 
2001). 
𝒅 =  
𝒓
𝒔 + 𝒔𝒐
 
where, 𝑠 = √(
1
𝑛𝐴
+
1
𝑛𝐵
)
∑ (𝑋𝑘−?̅?𝐴)2
𝑛𝐴
𝑘=1 +∑ (𝑋𝑘−?̅?𝐵)
2𝑛𝐴+𝑛𝐵
𝑘=𝑛𝐴+1
𝑛𝐴+𝑛𝐵−2
;   𝑟 = ?̅?𝐴 − ?̅?𝐵 ;                      
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𝑥𝑘, k=1~nA+nB, is the kth expression value of a gene in an independent study, s0 
is the exchangeability factor, and can be any percentile of the s value. When 
s0=0, the d-statistic is equal to t-statistic. 
 
1.5. Meta-analysis of Microarray Data 
 
 
1.5.1. Introduction of meta-analysis 
 
The definition of meta-analysis was first given by Glass in 1976 as “the 
statistical analysis of a large collection of analysis results for the purpose of 
integrating the findings” (Glass, 1976). Meta-analysis is a systematic approach 
and combines results of multiple studies using a set of statistical techniques, in 
order to increase the reliability of results (Ramasamy et al., 2008; Hong & 
Breitling, 2008). It has been demonstrated that meta-analysis has the ability to 
increase the effect of statistics by amending the false negative rate of an 
individual study (Choi et al, 2003). Meta-analysis is a useful tool not only for 
individual primary studies the may contain inconsistent results, but also for 
extracting valuable information from individual primary studies with inadequate 
sample sizes (Cochran, 2007). Meta-analysis to analyse microarray data 
involves 7 steps, shown in below Table 4 (Ramasamy et al., 2008).  
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Steps Meta-analysis 
1 Identify suitable microarray studies 
2 Extract the data  
3 Prepare individual datasets 
4 Annotate individual datasets 
5 Resolve the many-to-many relationship between probes and genes (like one gene 
contains multiple probe-sets, or one probe-set represents more than one gene)  
6 Combine the study-specific estimates 
7 Analyze, present and interpret results 
 
 
 
 
1.5.2. A review on meta-analysis of microarray data 
 
Published microarray studies have been produced for the same biological topic, 
e.g., they focus on the same disease or biological phase. Integrated analysis 
across multiple microarray datasets was hoped to yield more robust research 
interpretations than would individual studies. To integrate multiple microarray 
datasets and enhance the reproducibility of research findings, two approaches 
have been applied:  
1. Merging multiple studies: through the combination of raw data of primary 
studies. The merits and complications of such primary datasets are reviewed, 
here, different meta-analysis methods in different disease datasets have been 
reported (Larsson et al, 2006).  
Table 4: The seven steps of meta-analysis (Ramasamy et al, 2008) 
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2. Comparing and analysing the results of different published studies.   
Microarray data may contain some level of „noise‟ („unreal‟ data produced in 
experimental process, e.g., the background noise) (Cahan et al, 2007). The 
quality of meta-analysis depends on the quality of each individual microarray 
dataset. It is known that not all of microarray raw data deposited in public 
databases have equally quality thus contain unequally meaningful information 
(Larsson & Sandberg, 2006).  The accuracy and reproducibility of microarray 
data have therefore, presented a big challenge (Severgnini et al, 2006), not 
least when different microarray datasets are produced by different platforms, 
backgrounds, and with different samples types (e.g., cell lines vs. biopsy). 
 
While special care is needed when processing raw microarray data, 
researchers have successfully gained much valuable information from 
microarray studies. For example, a cross-species comparable analysis of yeast 
and human has determined a common transcriptional profile in aging (McCarroll 
et al., 2004), and a common host transcriptional response to pathogens (Janner 
& Young, 2005). Wennmalm et al found the similarity between the expression 
pattern of aging and cellular senescence in mice (Wennmalm et al., 2005). An 
aging database was built for collecting data of microarray studies (Pan et al., 
2007). A smaller robust gene signature for acute myeloid leukemia diagnoses 
has been revealed by comparing potential diagnostic genes reported in multiple 
studies (Cahan et al, 2005). 
 
As alluded to above, enhanced insights can be gained by merging data from 
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multiple studies. In 1999, researchers realized that discoveries could be made 
through the synthesis of related but individual experiment microarray studies 
(Khan et al., 1999; Normand, 1999). It is hard to compare directly microarray 
datasets obtained in different array experiments (Kuo et al., 2002). However, 
using this approach, Rhodes and his colleagues identified differentially-
expressed genes between benign and localized prostate cancer tissue by meta-
analysis of four prostate cancer datasets (Rhode et al., 2002). As discussed in 
Choi et al study, meta-analysis is able to reduce false negatives of individual 
analysis and thus increased the effectiveness of the statistical analysis of 
microarray data (Choi et al., 2003). When comparing results of meta-analysis 
with that of independent studies, the reproducibility was significantly improved in 
meta-analysis studies (Hong et al., 2006). Similarly, Park and Stegall 
investigated gene expression level of cytokines through the combination of data 
from open source and their own microarray datasets (Park & Stegall, 2007).  
 
However, two contradictory results were showed on two recent meta-analyses 
of melanoma microarray studies (Tímár et al. 2010, Schramm et al. 2011). The 
first compared gene signatures derived from 4 microarray datasets of human 
melanoma tissues, and found very little overlap between these signatures 
(Tímár et al. 2010). They considered this lack of congruence, (which is also 
discussed in this study, see 1.5.4 section) may be induced by sample 
heterogeneity (like different platforms, different types of samples etc.). By 
adding 5 additional studies, another team demonstrated some significantly over-
represented functions among the melanoma-associated gene signatures 
(Schramm et al. 2011). For example, most of the genes signatures were related 
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to the immune response. Moreover, a „leave-one-out‟ cross validation of the 
data showed that a low average error rate (28%) was achieved across all 
validation expression data of the gene signature (Mann et al. 2010). A gene 
signature proposed by Jönsson et al. (2010) reported an error rate of 45%. 
 
To deal with the heterogeneity of datasets (including various types biological 
sample, platforms, and quality of datasets), a new methodology is needed. In 
this study, a new method is proposed which takes into considerations of two 
factors („stratification‟ and „weighting‟) (see section 2.2). 
 
 
1.5.3. Methods used for microarray meta-analysis 
 
 
Typically, three typical methodologies have been applied in the meta-analysis of 
integrated analysis of multiple studies, including t-test, ranking and Fisher‟s 
inverse Chi-square approaches. The t-test based approach was adopted in 
Choi et al, 2003, and is implemented in the GeneMeta package of Bioconductor 
(R package).  The ranking based approach (a non-parametric statistic method), 
first applied for the analysis a single dataset (Breitling et al., 2004) was then 
applied to measure each gene in combined multiple studies as implemented in 
the Rank Prod Bioconductor package (Hong et al., 2006). Finally, Fisher‟s 
inverse method is based on an improved Fisher‟s inverse X2 test to combine the 
individual studies (Zaykin et al., 2002) based on their p-values. The p-values 
can be calculated by the t-test or ranking-based approaches (Hong & Breitling, 
2008).  
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The three approaches above were compared using two datasets, and evaluated 
for their advantages and disadvantages (Hong & Breitiling, 2006). As Fisher‟s 
product is based on p-values, which can be obtained from both t-test-based and 
ranking-based approaches, the authors excluded it and instead focused on 
comparing the t-test-based approach and the Ranking-based approach. The t-
test based approach, which was improved from Student‟s t-test, directly 
compares the magnitude of gene expression under different biological 
conditions. The ranking based approach provides the relative importance of a 
gene compared to other genes. When studies have a small sample size (large 
sample size in biological experiments is uncommon), the ranking based 
approach has its important advantage compared to the t-test based approach.  
The latter can suffer unreliable error estimates when sample sizes are small 
(Hong & Breitling, 2008).  
 
1.5.4. The challenges of meta-analysis on microarray datasets 
 
One of the main issues affecting individual microarray studies is that the testing 
power is often weakened by a large number of hypotheses being applied to a 
small sample size database. Thus, when the false positive rate is 0.05, in 
24,000 transcripts of a microarray study, there are 1,200 genes (i.e., 0.05 × 
24,000) that could be random fluctuations i.e., false positive genes. Meta-
analysis has the potential of reducing these false positives, such that the truly 
significant genes will be determined by combining different studies. Similarly, 
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meta-analysis also can reduce the influence of different experimental conditions 
(Cahan et al., 2007). 
 
Another important issue related to microarray study is the poor congruence 
between gene signatures identified by different individual microarray-based 
studies, e.g., non-overlapping melanoma signatures (John et al., 2008; Bittner 
et al., 2000; Tímár et al., 2010). Microarray technology has also been applied to 
the comparative analyses of different melanoma stages and has identified 
various gene signatures (Hoek, 2007). However, microarray-based melanoma 
gene markers have thus far had less than optimal translation to the clinical 
situation, and the diagnosis of melanoma is still largely based on the clinical and 
histopathological features of the tumour (Schramm et al., 2011). 
 
In order to explore this poor congruence issue, the current project conducted a 
comparison on 16 independent microarray-based signatures of metastatic 
melanoma published from 2000 to 2011. These 16 studies of melanoma only 
reported a metastatic melanoma gene signature in all melanoma published 
microarray studies. The start year is 2000, which was the earliest melanoma 
microarray study in the literature. These gene signatures involved various 
numbers of genes ranged from 5 to 589 genes. Remarkably pair-wise 
comparison showed that the microarray-based gene signatures shared very few 
common genes (Table 5). For example, only 84 genes were common to two of 
the signatures (Scatolini et al., 2010, Jaeger et al., 2007), 14 to three studies 
(Scatolini et al., 2010, Jaeger et al., 2007 and Riker et al., 2008), and strikingly 
only 2 common genes (KRT15, RORA) appeared in four of the 16 studies 
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(Scatolini et al., 2007, Jaeger et al., 2007, Riker et al., 2008 and Smith et al., 
2005). Remarkably no gene was found to be common in five or more of the 
independent studies (Table 6). This finding suggests that some fundamental 
issues exist, for either the individual microarray studies designed, or the 
suitability of direct comparison meta-analyses. 
 
 
 
 
  
Table 5: The 16 individual studies from 2000 to 2011 used in this study 
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The aims of the study: 
The aim of this study is to develop a robust model for meta-analysis of multiple 
microarray data, including: 
1. Develop a bioinformatics approach to identify robust gene biomarker 
signature from multiple microarray data. 
2. Identify a gene signature for melanoma, and validate them by 
computational and laboratory-based studies. 
 
In this study, I propose a new model that measures the genome-wide relative 
significance (GWRS) and genome-wide global significance (GWGS) of gene 
expression. As will be described in this thesis, this new model provides an 
important advantage for the integrative analysis of microarray datasets 
produced by different platforms and protocols. Using this method, 200 top 
genes of melanoma were identified based on the integrated analysis of five 
melanoma data. Based on the relationship of those 200 genes with melanoma 
driver genes, 12 genes were defined as a metastatic melanoma biomarker. 4 
genes were validated by wet-lab experiments, showing clearly differential 
expression in melanoma cells than normal cells. 
 
To enhance the computational model further, and to make the method suitable 
to the datasets of other diseases, I later take into account the concept of 
„Stratification‟ (classify microarray datasets by different features, e.g., types of 
platforms, types of samples etc.) and Dataset quality (ω) to deal with the 
datasets in the integrated analysis, and call it the „Stratification with weighting‟ 
method. Extensive evaluations on this new integrated analysis approach were 
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performed.  
 
Computational experimental results, on melanoma, breast cancer and prostate 
cancer, demonstrated the enhanced of performance of this method which could 
generate more robustly associated genes. As shown in the evaluation against of 
180 known metastatic melanoma biomarkers, the ranking positions of robust 
genes were higher than the genes identified by previous method. This indicates 
that the enhanced method could identify more „stable‟ and „reliable‟ gene 
associations (i.e., the genes may be considered as biomarker).   
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2. MATERIAL AND METHODS 
2.1. Microarray data 
 
 
Fourteen datasets were used for this project across in three kinds of cancers 
(i.e. melanoma, breast and prostate) for research on gene association.  
 
Five melanoma microarray datasets were selected (see table 7, melanoma part) 
to investigate a robust biomarker of genes using GWRS (Genome-wide relative 
significance) which investigates the signature within individual microarray 
dataset, and GWGS (Genome-wide global significance) which investigates the 
signature across multiple microarray datasets. These five datasets were 
selected as they containing gene expression values of normal skin and/or 
benign nevi, and metastatic melanoma. Four of them were contained in the 16 
metastatic melanoma studies published between 2000 and 2011 (see table 5) 
and included open access databases as shown on table 8. The microarray data 
were extracted from the GEO database (GEO access number: GSE7553, 
GSE4587, GSE4579, and GSE12391). An additional GSE22301 dataset was 
extracted from Rose et al. (2011). Rose et al. did not provide the gene signature 
of metastatic melanoma in the paper, thus it was not included in the meta-
analysis of 16 studies. However, it does include 14 samples of metastatic 
melanoma data and so the microarray data was included in our integrative 
analysis. As a result a total of five microarray datasets of normal and/or benign 
nevi and metastatic melanoma were used in this study (Table 7 - the melanoma 
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datasets).  
 
A further aim was to enhance the computational method beyond melanoma for 
generalized use by including two groups of datasets (i.e., breast and prostate 
cancer) to evaluate the effectiveness of the methods overall. Details of the three 
groups of datasets are shown on table 7 and described in the following 
sections. 
 
 
 
 
 
 
 
 
 
Data number 
in our study
Study
Microarray 
data access 
number
Platform
Sample size 
of control
Sample size of 
disease
Data1 Mecham et al , 2004 GSE1299 Affymetrix Human Genome U133A Array 2 4
Data2 Richardson et al , 2006 GSE3744 Affymetrix Human Genome U133 Plus 2.0 Array 7 40
Data3 Casey et al , 2009 GSE10797 Affymetrix Human Genome U133A 2.0 Array 10 56
Data4 Turashvili et al,  2007 GSE5764 Affymetrix Human Genome U133 Plus 2.0 Array 20 10
Data5 Liu et al , 2007 GSE6883 Affymetrix Human Genome U133A Array 3 9
Data1 Tomlins et al , 2007 GSE6099 Chinnaiyan Human 20K Hs6 34 52
Data2 Chandran et al , 2007 GSE6919 Affymetrix Human Genome U95B Array 17 91
Data3 Nanni et al , 2006 GSE3868 Affymetrix Human Genome U133A Array 4 20
Data4 Varambally et al , 2005 GSE3325 Affymetrix Human Genome U133 Plus 2.0 Array 6 14
Data1 Hoek et al , 2004 GSE4570 Affymetrix Human Genome U133A Array 2 5
Data2 Smith et al , 2005 GSE4587 Affymetrix Human Genome U133 Plus 2.0 Array 2 5
Data3 Riker et al , 2008 GSE7553 Affymetrix Human Genome U133 Plus 2.0 Array 5 40
Data4 Scatolini et al , 2010 GSE12391 Agilent-012391 Whole Human Genome Oligo Microarray G4112A 18 5
Data5 Rose et al,  2011 GSE22301 Affymetrix Human Genome U133A 2.0 Array 2 14
Breast Cancer
Prostate Cancer
Melanoma
Table 7: Details of the 3 groups of datasets used in the project 
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Table 8: Publically available microarray datasets of metastatic melanoma 2000-
2011 used in this study 
 
 
 
 
2.1.1. Melanoma microarray datasets used in this project 
 
2.1.1.1. Hoek Data (GSE4570, 2004) 
 
Hoek Data (GSE4570) 
Number of 
samples 
Normal 
melanocyte 
Primary 
melanoma 
Metastatic 
melanoma 
8 2 1 5 
 
 
The Hoek dataset was obtained using Affymetrix U133A. It contains 8 samples: 
2 from normal melanocyte, a primary melanoma and 5 metastatic melanoma. In 
the original study of Hoek et al (2004), 589 genes were identified to be 
significantly differentially-expressed between normal melanocytes and 
melanoma (>2.5 fold change). Of these genes, 315 were up-regulated and 274 
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were down-regulated. They reported some novel pathways in melanoma cells, 
including NOTCH activation, as well as an altered expression in embryonic 
development and epidermal transcriptional regulators, activation of cancer 
antigens, and down-regulation of growth suppressors (e.g. NECDIN).  
 
2.1.1.2. Smith data (GSE4587, 2005) 
 
Smith data (GSE4587) 
Number of 
samples 
Normal benign nevus 
atypical 
nevus 
primary 
melanoma 
metastatic 
melanoma 
18 4 2 2 4 6 
 
 
The Smith dataset (GSE4587) is a mixed sample type dataset and was derived 
from 15 frozen tissues and 3 cell lines, RNA was extracted from 2 normal 
biopsies, 2 benign nevi, 2 atypical nevi, 2 melanoma in situ, 2 vertical growth 
phased melanoma, 2 metastatic growth phase melanoma, 3 lymph node 
metastasis melanoma tissues, 2 normal epidermal cell lines, and 1 metastatic 
melanoma cell line. These authors conducted a comprehensive study on the 
different stages of malignant melanoma development, based on whole genome 
expression profiles, and investigated the top 50 up-regulated and 50 down-
regulated genes in advanced-stage melanoma compared to early-stage 
melanoma.  
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2.1.1.3. Riker data (GSE7553, 2008) 
 
 
 
 
 
The Riker dataset (GSE7553) contains 87 samples. In addition to 15 basal cell 
carcinoma samples and 11 squamous cell carcinoma samples, the sample set 
also included 56 melanoma samples, 2 samples of melanoma in situ, 14 
primary melanoma, 40 metastatic melanoma samples, and 4 normal skin and 
one from melanocytes. The authors compared 40 metastatic melanoma (MM) 
samples to 16 primary melanoma samples (14 primary melanoma samples plus 
2 melanoma in situ samples). They identified that the expression of SPRR/A/B, 
KRT16/17, CD24, LOR, GATA3, MUC15, and TMPRSS4 were dramatically 
higher in primary basal cell carcinomas, squamous cell carcinomas and thin 
melanomas compared to metastatic melanoma. Conversely, expression of 
MAGE, GPR19, BCL2A1, MMP14, SOX5, BUB1, and RGS20 was higher in 
metastatic melanoma than in the other sample types. They also identified 65 
differentially-expressed genes by comparing normal human epidermal 
melanocytes to thin primary cutaneous and metastatic melanoma samples. 
 
2.1.1.4. Scatolini data (GSE12391, 2010) 
 
Scatolini data (GSE12391) 
Number of 
samples 
benign 
nevus 
atypical nevus 
primary 
melanoma 
metastatic 
melanoma 
57 18 11 23 5 
 
 
Number of 
samples
Normal melanocytes
melanoma in 
situ
primary 
melanoma
metastatic 
melanoma
basal cell 
carcinoma
squamous cell 
carcinoma
87 4 1 2 14 40 15 11
Riker Data (GSE7553)
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The Scatolini data (GSE12391) used RNA isolated from a total of 57 freshly-
harvested patient tissues from 5 stages of progression from normal to 
metastatic melanoma were involved. Agilent oligonucleotide glass arrays were 
used for hybridization, and the data were presented by 10 base logarithms after 
processing and normalization using the Agilent Human Whole Genome 
platform-specific error model. The log ratio value of gene expression was 
treated using the LIMMA package, involving different functions of LIMMA incl. 
“backgroundcorrect”, “normalizeWithinArrays” and “normalizeBetwwenArrays”. 
The authors determined the 5 different stages from normal to melanoma by pair 
comparisons. They found 36 annotated transcripts were differently expressed 
between benign nevi and primary radial growth phase melanomas, including 
GDF15, AMICA1, and GLA.  
 
2.1.1.5. Rose data (GSE22301, 2011) 
 
Rose data (GSE22301) 
Number of 
samples 
melanocytes primary melanoma 
metastatic 
melanoma 
22 4 4 14 
 
 
 
Here, there are 22 samples separated into three types. Four samples represent 
normal melanocyte controls, 4 primary melanoma and 14 metastatic melanoma 
cell lines. By investigating the differences between superficial spreading 
melanoma and nodular melanoma, Rose et al identified 8 significant genes (i.e., 
DIS3, FGFR1OP, G3BP2, GALNT7, MTAP, SED23IP, USO1 and ZNF668) that 
were differentially expressed. 
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2.1.2. Breast cancer microarray datasets using in this project 
 
2.1.2.1. Mecham data (GSE1299, 2004) 
 
Mecham data (GSE1299) 
Number of samples normal breast epithelium breast cancer cells 
6 2 4 
 
 
This microarray dataset was derived from 6 samples including 4 human breast 
tumour cell lines and 2 human mammary epithelial cells cell lines (HMEC). The 
authors assessed gene expression in these samples across 4 platforms (i.e. 
Affymetrix U133A, U133B, U95 Version 2 Arrays, and Agilent Human 1 cDNA 
microarray [G4100A] array). They introduced RNA aliquots to a cross-platform 
analysis, and found they could significantly improve the consistency of 
platforms. They concluded that their cross-platform analysis strategy yielded 
more efficient results from different cDNA microarray and Affymetrix gene-chip 
platforms than single platform of one.  
 
2.1.2.2. Richardson data (GSE3744, 2006) 
 
Richardson data (GSE3744) 
Number of 
samples 
Normal  Non-BLC BLC 
BTCA1 associated 
cancer  
47 7 20 18 2 
 
This dataset contains 47 samples, including 7 normal breast samples, 20 non-
basal like cancer samples (non-BLC), 2 BRCA1-associated cancer samples, 
and 18 basal-like cancer (BLC) samples. Analysis of the microarray data 
revealed that the active X chromosome had been duplicated and the inactive X 
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chromosome had been lost in almost half of BLC samples. While the 
abnormalities of the X chromosome did not change the global X chromosome 
transcription, it was associated with overexpression of a small group genes 
located on this chromosome. Because the association between abnormal X 
chromosome and gene changes did not show in the non-BLC samples, these 
results suggest that the X chromosome abnormalities may have been 
contributed in BLC. 
 
2.1.2.3. Casey data (GSE10797, 2009) 
 
Casey data (GSE10797) 
Number of samples normal invasive breast cancer tissues 
33 5 28 
 
 
Here, gene expression was assessed using total RNA of epithelial and stromal 
cells from 5 normal breast specimens and 28 invasive breast cancer tissues by 
Affymetrix U133A 2.0 GeneChips. According to comparisons of gene expression 
of different cell types (epithelial or stromal) and diagnosis (normal or cancer), 
the researchers determined that the transcriptome of epithelial cancer was 
enriched for proliferative, motility and ECM gene ontologies when compared 
with normal epithelial tissue. The transcriptomes also showed that genes were 
overexpressed in ECM and proteolytic ontologies in invasive breast cancer 
compared to epithelial and stromal cancer tissues. 
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2.1.2.4. Turashvili data (GSE5764, 2007) 
 
 
Turashvili data (GSE5764) 
Number of 
samples 
normal 
ductal cells 
normal 
lobular cells 
invasive 
ductal 
carcinomas 
invasive 
lobular 
carcinomas 
30 10 10 5 5 
 
 
 
In this database, Turashvili et al. focused on invasive ductal and lobular 
carcinomas; the two most common histological types of breast cancers. They 
examined 30 samples including 10 normal ductal cells, 10 normal lobular cells, 
5 invasive ductal carcinomas (IDC) cells and 5 invasive lobular carcinomas 
(ILC) cells. When comparing the different samples via algorithm and rank 
products, they identified 84 significantly differentially-expressed genes between 
ILC and normal cells, 74 significant genes between IDC and normal cells, 78 
significant genes between normal ductal and lobular cells, and 28 differentially 
expressed genes between IDC and ILC. When these changes were combined, 
the authors extracted seven differentially-expressed genes (i.e., CDH1, EMP1, 
DDR1, DVL1, KRT5, KRT6, and KRT17) as novel biomarkers of breast cancer, 
and validated these by PCR and immunohistochemistry on tissue microarrays. 
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2.1.2.5. Liu data (GSE6883, 2007) 
 
 
Liu data (GSE6883) 
Number of 
samples 
normal 
breast 
epithelium 
non-
tumourigenic 
breast cancer 
tumourigenic 
breast cancer 
12 3 3 6 
 
 
 
This microarray dataset was compiled from samples of tumourigenic breast 
cancer cells and normal breast epithelium cells. The samples set included 3 
normal breast epithelium cells, 3 non-tumourigenic breast cancer cells and 6 
tumourigenic breast cancer cells. The authors compared gene expressions in 
the 12 samples, and generated 186 genes as a signature for invasiveness. 
They found that these 186 genes were significantly associated with overall 
survival and metastasis-free survival in breast cancer patients. When they 
compared the 186 genes with the prognostic criteria of the National Institutes of 
Health, the invasiveness gene signature could be used to separate high-risk 
from early breast cancer, and also for prognosis in medulloblastoma, lung 
cancer, and prostate cancer.  
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2.1.3. Prostate cancer microarray datasets using in this project 
 
2.1.3.1. Tomlins data (GSE6099, 2007) 
 
Tomlins data (GSE6099) 
Number of 
samples 
benign 
epithelia 
atrophic 
lesions 
localized 
prostate cancer 
prostatic 
intraepithelial 
neoplasia 
metastatic prostate 
cancer 
101 34 5 32 13 17 
 
 
Total RNA was isolated from 101 specific cell populations of 44 individuals to 
examine genes associated with the progression of prostate cancer. These 
included 34 benign epithelia, 5 atrophic lesions, 32 localized prostate cancers, 
13 prostatic intraepithelial neoplasia, and 17 metastatic prostate cancers. 
Through analyzing the gene signatures of over 14,000 resultant probe-sets, the 
authors generated a model of prostate cancer progression that included protein 
biosynthesis, E26 transformation-specific family transcriptional targets, 
androgen signaling, and cell proliferation. From the model, the signature of 
androgen signaling was found to be similar in high-grade prostate cancer and 
metastatic prostate cancer relative to the low-grad prostate cancer. This may 
explain the clinical grade of the tumour with its prognosis. In this study, the 
researchers emphasized that the integrative analysis of gene expression 
signatures is a useful tool to understand cancer biology. 
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2.1.3.2. Chandran data (GSE6919, 2007) 
 
Chandran data (GSE6919) 
Number of 
samples 
normal 
normal 
adjacent to 
tumour 
primary 
prostate tumour 
metastatic 
prostate tumour 
152 23 41 64 24 
 
 
 
This database included 152 human samples of normal prostate tissue, normal 
prostate tissue adjacent to tumour, and primary and metastatic prostate cancer 
tissues. Gene expression profiles of 24 androgen ablation-resistant metastatic 
samples (4 patients) and 64 primary prostate tumour samples were analyzed to 
investigate differences between primary and metastatic prostate tumours. The 
authors found at least a 2 fold over-expression change in 415 genes, 364 of 
which were down-regulated in metastasis samples. These genes were 
associated with some androgen ablation pathways and other networks (e.g. cell 
adhesion, bone remodeling and cell cycle), including transcription factor 
Forkhead Box M1 (FOXM1) and cell adhesion molecule Osteopontin (SPP1). 
 
2.1.3.3. Nanni data (GSE3868, 2006) 
 
Nanni data (GSE3868) 
Number of 
samples 
normal benign basaloid tissue 
primary 
tumour 
metastatic tumour 
30 2 2 3 22 1 
 
This in vitro-based dataset includes 30 samples representing cell lines 
established from 2 normal tissue, 2 benign hyperplasia tissues, 3 basaloid 
tissues, and 1 metastatic tumour sample, and from 22 primary prostate tumour 
samples and 1 metastatic prostate tumour sample. The goal of this study was to 
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generate a model with signatures of tumours based on gene expression 
profiling. The authors examined the model and suggest that it can be used for 
studying primary prostate cancer biology and also could characterize tumours 
for prognostic and predictive purposes. 
 
2.1.3.4. Varambally data (GSE3325, 2005) 
 
Varambally data (GSE3325) 
Number of 
samples 
benign 
primary 
tumour 
metastatic 
tumour 
19 6 7 6 
 
 
 
This dataset includes 19 samples representing 6 benign prostate, 7 primary and 
6 metastatic prostate cancers. During the analysis of cancer progression, which 
included comparing different stages of disease via high-throughput immuno-
blotting, and also integrated analysis with transcriptomic data (i.e., gene 
microarray), the authors identified 64 proteins that were altered relative to 
benign prostate, and 156 proteins which were altered relative to metastatic 
prostate cancer. These differential alterations of protein expression were 
considered by the authors as possible predictors of clinical outcome in prostate 
cancer.  
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2.2. Data preparation 
 
One important pre-processing step for microarray data is to extract the 
expression value for each individual gene from the associated probe-sets using 
a gene mapping approach. When a probe-set is mapped to multiple genes, all 
the genes are assigned with the same expression value.  For example, 
„209994_s_at‟ associated to two genes „ABCB1 / ABCB4‟ in GSE4570, both 
genes are given the expression value of the „209994_s_at‟ probe-set. However, 
in many cases, a gene is associated with multiple probe-sets. In this case the 
expression value achieving the highest significance in differentially expression 
sample classes (e.g., normal vs. disease) is assigned to this gene. For 
example, for a gene associated with probe-sets 1, 2, 3, if the probe-set 1 has 
achieved the highest p-value in a statistical test in the comparative study then 
the expression value of probe-set 1 is assigned as the expression value of the 
gene in this study. The impact of selecting the expression value of a probe-set 
that has the mean-, or median-value in statistical testing was also tested in this 
study. I found that using the highest differentially-expressed probe-set (maxim-
based method), it was possible to retrieve the most significant probe-set of a 
gene. Thus, the aim of this study to extract the most differentially-expressed 
genes across multiple studies was attempted.  
 
As a result of the above approach, a list of genes (G) from each datasets was 
retrieved. The number of datasets was denoted by n. For n datasets, the total 
genes across n datasets were retrieved by taking all the gene sets together (G). 
Thus, the number of genes of these n datasets is denoted by m, i.e. m=|G|. The 
value „NA‟ was applied in cases where a gene is absent from an individual 
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study. A gene is also removed from G where NA is greater than a pre-defined 
value δ (δ=2 in this study, i.e., keeping the genes which were included in more 
or equal to 3 of 5 datasets). This means a gene was removed for further 
analysis if it is absent for more than two of five datasets. This resulted in a total 
of m=24,097 genes and n=5 of datasets for this study. 
 
2.3. Melanoma biomarker detection 
 
 
2.3.1. The application of melanoma datasets 
 
This study focused on investigating the differential gene expression between 
normal skin and/or benign nevi and metastatic melanoma. The melanoma 
datasets was described in section 2.1 and table 7. Figure 7 shows the 
experimental protocol for melanoma biomarker detection and validation.   
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Figure 7: Experimental protocol for Melanoma Biomarker Detection and 
Validation 
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2.3.2. Genome-wide relative significance (GWRS) and Genome-wide 
global significance (GWGS) for integrated analysis of cross-
laboratory (between independent studies) microarray data 
 
A relatively simple method of integrative meta-analysis was proposed by 
Rhodes et al in 2002. This method recognizes the significance of each 
individual gene, based on the p-value of the corresponding gene, in each 
individual microarray data: 
 
where pi, i=1~n, is the p-value of a gene in the i-th independent study. This 
method has at least two significant limitations in its application to microarray 
data: (1) many microarray studies contain a small number of samples, for which 
the p-value can therefore be problematic, and (2) the p-values of a gene across 
different studies may have large variation. Thus, the smallest p-value may 
determine the outcome of Sp (effective significance of p-value). 
 
A new approach is proposed here to overcome these limitations based on 
measuring the genome-wide relative significance (GWRS) and genome-wide 
global significance (GWGS) of genes (Liu et al. 2013). The GWRS measures 
the significance of a gene based on its ranking position on a genome-wide scale 
(r value) (Jurman et al, 2008). The ranking position of genes can be determined 
based on a differential expression measure, such as fold change, t-test p-value, 
SAM (Significance Analysis of Microarray data) p-value etc. Most meta-analysis 
methods in the literature focus on the top-k (k is the number of genes) genes 
(e.g. Jurman et al, 2008).  In contrast to these, the method proposed here 
instead counts the ranking at the genome-wide scale. Compared to the model 



n
i
ip ps
1
)log(2
 
Chapter 2: Material and Methods 
 
74 
 
of Rhodes et al this new approach has two important enhancements: (1) it can 
apply multiple different methods for measuring the degree of differential 
expression of a gene (e.g. fold change, t-test, Anova or SAM p-values) and (2) it 
uses a ranking r value instead of the test statistic (i.e., fold change, or p-value) 
to avoid the influence of a high variation of test statistics. The details are shown 
in the following 2.3.3 section.   
 
2.3.3. Measuring the GWRS of genes in each single microarray database 
 
For each gene in the gene list (G), the degree of differential expression can be 
measured by the commonly used methods such as fold-change, t-test (p-value), 
ANOVA, SAM or other statistical test. These four methods were used for this 
study to test the suitability of method to be used in the GWRS. However, the 
numbers of samples in individual datasets of this study are quite different: some 
datasets contained very small number of samples, for which the p-value based 
method may not suitable. For this reason, the fold-change is chosen and used 
in this study. The computational evaluation indicated that the use of fold-change 
produced more reliable results, likely due to the limited number of samples in 
some of the datasets. Each gene in the gene list G is assigned a rank number 
(in descending order starting from 1 to m) according to their corresponding 
degree of differential expression. Thus, a gene with a high degree of differential 
expression is ranked more highly and so on with a smaller ranking number. An 
m*n matrix (R) was created for m genes across n datasets, in which rij is the 
ranking number of the i-th gene in the j-th dataset. Thus, the GWRS of the i-th 
gene in the j-th dataset is measured by: 
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where rij, i=1~m, j=1~n, is the rank number of the i-th gene in the j-th study. The 
range of GWRS value (sij ) is between 0 and -2log(1/m). For a gene with „NA‟ 
value the sij is set to be „NA‟. 
 
As an example, GSE3189 and GSE12391 were applied to these two different 
methodologies. The gene association with a small p value is considered as 
being an expressed gene. The r values of a gene in different studies are 
relevant to the p values. The smallest p value leads to the smallest r value, and 
the biggest sr value. Thus, genes with large sr values are considered to be 
significant genes in meta-analysis. The top 50 genes sorted by decreasing sr 
value have been displayed below. 
 
Table 9: The Sr values of combined two microarray datasets 
Sort Gene r(GSE3189) r(GSE12391) sr 
1 AHNAK 0.003596491 0.001008772 25.05364 
2 ABLIM1 8.77E-05 0.043640351 24.94628 
3 HLF 0.000614035 0.008508772 24.32423 
4 ALDH2 0.000701754 0.012807018 23.23938 
5 GLA 0.224298246 8.77E-05 21.67229 
6 RPL30 0.079780702 0.000307018 21.23416 
7 CYP4F12 0.002982456 0.009912281 20.85798 
8 TMEM30B 0.003903509 0.008070175 20.73092 
9 NFIB 0.000789474 0.040350877 20.70857 
10 KIAA1305 0.000526316 0.063070175 20.62623 
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11 KRT15 0.000877193 0.041315789 20.45059 
12 PHACTR1 0.029342105 0.001710526 19.79937 
13 RPL10A 0.004342105 0.011842105 19.75098 
14 MAOA 0.000175439 0.301578947 19.69389 
15 PHYHIP 0.001403509 0.046578947 19.27077 
16 ARF1 0.017763158 0.003903509 19.15302 
17 RPL34 0.073070175 0.001008772 19.03071 
18 PTPRF 0.004561404 0.01622807 19.02228 
19 CHST6 0.020263158 0.004254386 18.71751 
20 CTSB 0.001754386 0.049210526 18.71457 
21 NACA 0.000394737 0.222105263 18.68379 
22 LCP2 0.091929825 0.001008772 18.5715 
23 GSTO1 0.02627193 0.003684211 18.48591 
24 PGRMC2 0.002192982 0.044649123 18.46283 
25 CYP4B1 0.046403509 0.002192982 18.38575 
26 DNAJC15 0.101754386 0.001008772 18.36843 
27 ARMC9 0.102807018 0.001008772 18.34785 
28 LRRC1 0.002587719 0.043245614 18.19568 
29 NUDT11 0.112982456 0.001008772 18.15909 
30 CHST11 0.041798246 0.002894737 18.03952 
31 TIMP2 0.018026316 0.007149123 17.91338 
32 IFITM2 0.739649123 0.000175439 17.8996 
33 ITM2B 0.055657895 0.002412281 17.83143 
34 EPHX2 0.00122807 0.109473684 17.82876 
35 GDF15 0.081973684 0.001710526 17.74462 
36 PDZD2 0.021666667 0.006491228 17.73857 
37 RBM35B 0.036929825 0.003903509 17.68923 
38 HYOU1 0.002587719 0.059736842 17.54957 
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39 GATM 0.156491228 0.001008772 17.50755 
40 IL11RA 0.000394737 0.403421053 17.49013 
41 ACADL 0.004342105 0.036710526 17.48818 
42 LDOC1 0.000263158 0.61745614 17.44981 
43 NEBL 0.002017544 0.082982456 17.39 
44 CTDSPL 0.009561404 0.017850877 17.35145 
45 IFITM3 0.595526316 0.000307018 17.21383 
46 MICAL1 0.092719298 0.002017544 17.16811 
47 RPS6 0.002982456 0.066447368 17.05271 
48 AP3D1 0.00754386 0.026666667 17.02272 
49 MRCL3 0.212017544 0.001008772 16.90022 
50 KLK1 0.001140351 0.191140351 16.86233 
 
 
The sp value formula is referred to the meta-analysis method proposed by 
Rhodes et al (Rhoders et al, 2002), which applies the p-values to calculate sp 
value. The top 50 genes were selected by sp value and are shown on below 
table. 
 
Table 10: The Sp values of combined two microarray datasets 
Sort Gene P (GSE3189) P (GSE12391) sp 
1 ABLIM1 1.35E-25 0.040286149 120.9525406 
2 MAOA 4.73E-19 0.260988884 87.07693805 
3 HLF 2.18E-17 0.010400721 85.8610037 
4 LDOC1 6.36E-19 0.573431223 84.91041133 
5 ALDH2 4.32E-17 0.016320781 83.59201451 
6 KIAA1305 1.77E-17 0.057930257 82.84296498 
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7 NFIB 5.06E-17 0.038033905 81.58371476 
8 NACA 1.02E-17 0.194366519 81.52430717 
9 KRT15 5.77E-17 0.039293992 81.25591629 
10 IL11RA 1.02E-17 0.355474641 80.31689064 
11 PHYHIP 1.44E-16 0.043497529 79.22353904 
12 EPHX2 1.11E-16 0.094551745 78.191219 
13 CTSB 2.74E-16 0.046175334 77.81742617 
14 KLK1 9.63E-17 0.166285548 77.34622431 
15 AHNAK 4.67E-15 0.003824143 77.12807642 
16 CYP4F12 2.63E-15 0.012688143 75.87775978 
17 EMP2 1.90E-16 0.190351823 75.71677764 
18 PGRMC2 9.65E-16 0.04141238 75.51715796 
19 NET1 7.94E-17 0.621639439 75.09485668 
20 TMEM30B 5.20E-15 0.010151958 74.96041291 
21 NEBL 8.41E-16 0.073364552 74.64850883 
22 PLOD3 7.99E-17 0.896441924 74.35015518 
23 LRRC1 2.25E-15 0.040206057 73.8831676 
24 PALMD 1.20E-16 0.754188741 73.88230511 
25 EFS 9.43E-16 0.097825304 73.84407479 
26 KLHDC2 1.57E-16 0.615120104 73.75244722 
27 RPL10A 7.30E-15 0.015301682 73.46138914 
28 HYOU1 2.25E-15 0.055514925 73.23789911 
29 NDRG2 6.78E-16 0.188237382 73.19487166 
30 AZGP1 1.57E-16 0.834299864 73.14289652 
31 PTPRF 7.71E-15 0.017745281 73.05578773 
32 IL22RA1 1.69E-15 0.093503497 72.76760862 
33 RPS6 2.63E-15 0.060770378 72.74489072 
34 ACADL 7.30E-15 0.034017829 71.86354511 
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35 TMEM16A 2.87E-15 0.09115912 71.75922619 
36 ACOT7 5.41E-15 0.051465837 71.63472871 
37 GLRX2 3.76E-15 0.076989495 71.55688747 
38 SATB1 2.63E-15 0.122586759 71.34145762 
39 RNF43 6.78E-16 0.523433661 71.14945873 
40 MAPKBP1 5.20E-15 0.10459419 70.29557009 
41 EPS8L2 2.25E-15 0.242105326 70.29245719 
42 ATP5C1 2.25E-15 0.247238885 70.25049289 
43 CNIH3 1.16E-14 0.058623632 69.84877737 
44 PSD3 2.35E-15 0.307256738 69.72886534 
45 KRT1 1.10E-15 0.884100805 69.13330081 
46 KCNK7 4.67E-15 0.23615853 68.88173857 
47 PKM2 1.67E-14 0.081697968 68.45618765 
48 ABCA5 1.84E-14 0.077299144 68.37299625 
49 RP6-213H19.1 2.20E-14 0.067266132 68.2936647 
50 GATA3 4.16E-15 0.40217291 68.04826896 
 
The reason for using the sr value, instead of the sp value, is because the sr 
value is relevant to the p-value but not dominated by the smaller p-value. The 
sp values, unlike sr values, always incline to the smallest one of p-value groups. 
As shown in above sp value table (Table 10), the order of sp values is largely 
controlled by the p-values of GSE3189, because the p-values of GSE3189 are 
much lower than the p-values of GSE12391. For example, for gene no.19 
(NETI), the p-value in GSE12391 is 0.621639439. This is many fold greater 
than the p-values of its above or below genes (gene no.18 and gene no.20) in 
GSE12391. Comparing the p-value (7.94E-17) of NETI in GSE3189 with its 
above and below genes (sr value table), there are not much difference. This 
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imbalance is caused by the huge gap of the order of magnitudes existing in the 
two datasets. The use of the sr value, however, is able to copy with this issue. 
As shown in the sr value table (Table 9), no such difference exists in the sr 
value formula by rank number of p-values. 
 
 
2.3.4. Measuring the GWGS of a gene across multiple microarray datasets  
 
We estimated the GWGS (genome-wide global significance ) of a gene 
based on its GWRS (genome-wide relative significance) across n datasets, by 
 
where represents the relative importance/weight of the j-th dataset, and
. The value of weight ( ) can normally be assigned based on the 
data quality of the j-th datasets. However, it is important to note that the value of 
 can also be used to reflect the differential importance of biopsy-derived 
versus cell line-derived samples, which biological scientists may wish to take 
into account. In this study, all the datasets are treated as equally important, thus 
the weight of each datasets is set equally to be 1/n for j=1~n. The top 200 
genes were selected from the full gene list G for further analysis (i.e. selected 
genes with the greatest sr value). To determinate the number of top genes, an 
empirical evaluation of the classification performance (accuracy ratio) was 
performed. This was performed using the „wrapper-feature selection‟ after 
multiple rounds of gene addition to the classification performance model 
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(ranging from 20 genes up to 500 genes). This was done in order to achieve the 
maximum accuracy in distinguishing melanoma from normal skin/benign nevus. 
Using more than 200 genes did not improve further this classification. Thus, 200 
genes have been considered as the optimal gene set i.e., the smallest number 
of genes that can achieve the highest level of classification performance. 
 
 
2.3.5. Pathway analysis: functional relevance of 200 gene set  
 
A pathway analysis was performed to assess the functional relevance of the 
new 200 gene signature based on the DAVID database (Hosack et al. 2003). 
DAVID provides a useful tool to analyze large gene lists, including via gene 
ontology and pathway analysis. The top 200 genes were applied to the DAVID 
database in order to detect potentially over-represented KEGG pathways. 
Before inputting into the DAVID database, the corresponding probe-sets of the 
200 genes were extracted from each corresponding dataset. In order to 
compare the 200 genes to the original gene signatures of 16 studies, the probe-
sets of these original gene signatures were also extracted. Thirty-one KEGG 
pathways were retrieved. Twelve genes (i.e., EGFR, FGFR2, FGFR3, IL8, 
PTPRF, TNC, CXCL13, COL11A1, CHP2, SHC4, PPP2R2C, and WNT4) from 
this 200-gene signature were identified and were found to closely interact with 4 
melanoma driver genes (see Results section).  
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2.3.6. Immunocytochemistry (ICC) 
 
A primary epidermal melanocyte (EM) culture (donor-Female 44y), moderately 
pigmented human melanoma cells (FM55), and highly pigmented human 
melanoma cells (FM94) (melanoma cells were a gift of Dr Janis Ancans, 
University of Latvia) were cultured as previously described (Gledhill, 2010). The 
cells were fixed in ice-cold methanol (Sigma, Poole, Dorset, UK) for 10 min 
before air drying and rehydration in PBS. The cells were blocked with 10% 
donkey serum (DS) for 1 h, washed with PBS before incubation with their 
respective primary antibodies to four test antigens taken from this 12-gene 
signature. These antibodies included: COL11A1 (Abcam, ab64883), CXCL13 
(R&D Systems, AF801), PTPRF (NeuroMab, 75-193), SHC4 (Proteintech, 
12641-1-AP), and were incubated overnight at 4 oC followed by secondary 
antibody (1:300) for 1h (donkey anti-goat (Invitrogen, A11055), donkey anti-
mouse (Invitrogen, A21202), donkey anti-rabbit (Invitrogen, A21206), Alexa 
green). The optimal dilutions of antibodies were selected after titration (i.e.  
dilution tests). Following manufacturers‟ data sheets, the highest and lowest 
dilutions of these antibodies were tested respectively. According the results (i.e. 
most specific signal with least background) the optimal dilutions were applied. 
 
The slides were cover-slipped by VECTASHIELD mounting medium with DAPI 
and viewed using a Nikon Eclipse 80i fluorescence microscope and 
photographed with a Nikon Digital Sight DS-U1 camera. A full assessment of all 
12 proteins in our melanoma signature was beyond the scope of the current 
study, but will be assessed in detail in a follow-up studies. 
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2.3.7. Double immunohistochemistry (IHC) 
 
Paraffin-embedded primary melanoma in situ (nose) and metastatic melanoma 
(lower leg), obtained from the Bradford university ethical tissue bank (ethical 
tissue.org), deparaffinized and boiled 10 mins in sodium citrate buffer (10 mM, 
0.05% Tween 20, pH 6.0) for antigen retrieval. Acetone-fixed cryosections of 
normal human facial skin (donar-Female 52yrs) were used as control samples. 
All tissues were blocked with 10% donkey serum (DS) for 1h, washed with PBS 
before 2h incubation with NKi/beteb antibody raised against the melanocyte 
lineage-specific marker gp100 as a positive pigment cell control (Monosan; 
Mon7006-1) (1:15) which were used for many laboratory (including ours) and 
were validated that it is effective for gp100 antigen, followed by analysis by 
each of the 4 test antibodies as previously described (Gledhill, 2010). 
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2.4. A ‘Stratification-based’ Enhanced Method for Microarray 
Data Integration   
 
 
Two important factors, „stratification‟ and „weighting‟, were considered in order to 
improve the previous method using in this study. „Stratification‟ is the process to 
stratify individual datasets based on defined conditions (like platform, sample 
type, number of genes…), and then processed by GWGS and GWRS. 
„Weighting‟ is used to measure the quality of each individual dataset (see 
section 2.4.2). In the previously described method each microarray data was 
treated equally. This may not always reflect the need of analysis. For example, it 
may be useful to take into account differences in microarray datasets (e.g. 
different platforms, different types of samples). This diversity of dataset should 
be analysed by using appropriate values of ω in the GWGS model.  
 
 
2.4.1. The enhanced integrated analysis approach for microarray datasets 
 
The enhanced analysis method developed in this study is shown in Figure 8, 
and involves 4 different methods (i.e. non-stratification, non-stratification with 
weighting, stratification, and stratification with weighting).  
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Microarray datasets of one disease 
(D1…Dn)
Training datasets e.g. 
D1…Dn-1
Datasets are grouped by
 ‘leave-one-out’ method
 Evaluations:
 3.The number of common genes across different variation of 
training datasets
 4.The number of common genes with 180 known metastatic     
melanoma markers
Testing 
dataset e.g. Dn
Stratification
Non-
stratification 
with ω
Stratification 
with ω
Non-
stratification
Group 1 Group 2
GWRS &GWGS
GWGS
Gene list
Sub-group datasets based on 
features (like differences of 
sample type, platform etc.)
 1.classification performance of selected genes with SVM  ( Support 
vector machine)
2.The number of common genes training datasets against the        
testing dataset
GWRS &GWGS
 
 
 
 
The entire process (figure 8) can be described as follows: 
 
Assume there are n microarray datasets concerning one specific disease, and 
the datasets are named D1…Dn. For each dataset the ranking value of each 
Figure 8: Procedures of stratification /non-stratification analysis 
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gene in one dataset is calculated by GWRS, and the data quality is measured 
based on Hoeffding‟s D-statistic (ω) (Kauffmann et al, 2009). The top ranked 
genes for D1…Dn are denoted by L1…Ln. 
 
Step 1: Apply „Leave-one-out‟ to divide the data into two groups: n-1 datasets 
for „training‟ and the remaining one as „testing‟ data. For example D1…Dn-1 for 
training while Dn for testing. 
 
Step 2: Apply the four different methods on the training dataset (D1…Dn-1) („non-
stratification‟, „non-stratification with ω‟, „stratification‟, and „stratification with ω‟) 
to calculate the significance of expression of a gene across multiple microarray 
studies respectively. 
 
Step 3: For the two „stratification‟ methods, the datasets are sub-grouped based 
on the features of datasets (e.g. different platforms, different type of samples 
etc.). In this study, the different sample types are cell line and biopsy. 
 
Step 4: Apply GWRS and GWGS to calculate the significance of expression of 
genes across multiple microarray studies. 
 
Step 5: Evaluate the methods on testing data (Dn), across the multiple studies 
and the 180 metastatic melanoma biomarkers (table s3 in appendix) were 
picked up from PubMed (based on conditions as follows: metastatic, melanoma, 
biomarkers) published to March of 2013.   
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2.4.2. Determination of the weights (  ) of microarray datasets  
 
The quality of microarray data can be directly influenced by the experimental 
set-up of obtaining microarray, which brings inherent quality instability to the 
next level of analysis of the experimental procedure. The assessment of 
microarray dataset quality becomes a very important factor in the analysis of 
microarray datasets and particularly for the combination of multiple microarray 
datasets (Schuchhardt et al, 2000). In this study, an R software package called 
„arrayQualityMetrics‟ was applied to assess the quality of microarray data for all 
arrays and platforms (Kauffmann et al, 2009).  The assessment is based on the 
MA plot [present an M (log rations) and A (mean) average scale for visual 
representation of two channel DNA microarray gene expressions] with 
Hoeffding‟s D-statistic. The formula for Hoeffding‟s D is: 
 = 3 
(𝑛 −  )(𝑛 − 3) 1 +  2 −  (𝑛 −  ) 3
𝑛(𝑛 − 1)(𝑛 −  )(𝑛 − 3)(𝑛 −  )
 
 1 =∑ ( 𝑖
𝑖
− 1)( 𝑖 −  ) 
 2 =∑ (𝑅𝑖 − 1)(𝑅𝑖 −  )(𝑆𝑖 − 1)(𝑆𝑖 −  )
𝑖
 
 3 =∑ (𝑅𝑖 −  )(𝑆𝑖 −  )( 𝑖 − 1)
𝑖
 
where Ri and Si are the rank of X and Y, which are the two sets of values.  𝑖 is 
the bivariate rank as 1 plus the number of points with all arrays less than the ith 
point (SAS institute, 2012). The D values of arrays in every individual dataset 
were assessed. The mean D values is used for describing the quality of each 
dataset. Based on the mean D values of a dataset, in this improved method 
step, the ω of GWGS formula (section 2.3.4) was instead by the ratio of D 
j
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values which is calculated as relative weighting. The sum of relative weighting 
(ω) is 1 as the above formula. For example, there are n datasets, thus for 
dataset 1 the corresponding D value is D1 and the ratio of dataset 1 is D1 / (D1 + 
D2 + D3…Dn). 
 
2.4.3. Validation and selection of top genes by ‘wrapper feature selection’ 
method and machine learning for classification  
 
Machine learning and data-mining techniques have been successfully applied in 
various biomedical domains. In this study, the „wrapper-based feature selection 
method‟ was used (Peng et al. 2010), which applies SVM (Support vector 
machine) and selects significant genes that achieve the best classification 
performance (Figure 9). SVM is a machine learning approach based on Kernel 
techniques for classification or regression (Ivanciuc, 2007). The advantage of 
SVM is its capability to deal with high-dimensionality (larger than classical 
multivariate) of „training‟ data (Peng, 2006), and so has been widely applied in 
microarray classification. It can produce the largest separation between the 
decision function values for instances that are located at the borderline between 
classes. The advantage of wrapper approaches with SVM is that they provide a 
high probability of identifying the feature subset (situation), and so producing 
better classification performances as they take into account the feature 
dependencies and their collective contribution to model generation (Peng, 2006).  
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In this study, the R package for SVM “e1071” was employed. Extract from the 
ranked gene lists produced by the Stratification or Non-Stratification procedure 
is the „feature‟ for training SVM. The SVM was then applied on the testing 
dataset for the feature selection using the wrapper function, which determines 
which genes achieve the best predictive power in classifying the condition of the 
samples. 
 
 
 
 
Genes of dataset (g) corresponding with x 
values 
gk = rank(x) , K=|gk| 
SVM classification 
(gk) 
 
 
Output:  g|best|= gk 
 
Reach the stable 
Accuracy ratio 
 
K=k+1, search for 
g* No 
gk = g* 
 
Figure 9: The wrapper feature selection method based on SVM that was used for robust 
signature attainment between control and disease states 
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2.5. Access to the associated microarray data 
 
The microarray data used in the study were retrieved from Gene Expression 
Omnibus (GEO) with the access numbers shown on table 6. The 16 gene 
signatures of melanoma reported in the literature between 2000 and 2011 were 
extracted from the associated publications and are presented in SI – Table s, 
data as excel file stored in attached CD). 
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3. RESULTS 
3.1. The discovery of new biomarkers of melanoma 
 
 
3.1.1. A new melanoma gene signature revealed by an integrated analysis 
of cross-laboratory microarray datasets  
 
A new approach has been applied here for the integrated analysis of five 
independent microarray studies (Hoek et al., 2004, Smith et al., 2005, Riker et 
al., 2008, Scatolini et al., 2010, Rose et al., 2011) (see Methods) in order to 
determine gene associations in melanoma, rather than to look for associated 
gene mutations. The genome-wide „global significance‟ of a gene (i.e., across 
multiple datasets) was measured by the GWGS (sr) function (see Methods). A 
gene with a large sr value is considered to be significant across multiple 
independent studies (i.e., globally significant). The 200 genes with the largest sr 
values were selected as the starting point for the new proposed gene signature 
of melanoma, as listed in Table 11 and Table s2 of appendix. This set of 200 
signature genes was empirically determined, based on classification accuracy 
ratios after various rounds of gene additions (using the „wrapper feature 
selection‟ approach) in order to distinguish melanoma from normal skin cells 
and/or benign nevus. The classification accuracy ratio was improved very little 
by adding more than 200 genes, and so 200 genes achieved, computationally, 
the highest classification accuracy with the smallest number of genes. 
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Table 11: The 200 genes with largest sr values selected as the proposed starting point 
for a gene signature of melanoma 
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3.1.2. Validation of a new 200-gene signature based on experimental 
studies reported in the literature 
 
 
The 200 genes found to have genome-wide global significance (GWGS) in this 
study were compared with the gene signatures identified in previously-published 
reports (see appendix – Table s2).  
 
The new 200-gene signature was first validated by (i) comparing it with 16 
signatures in the referred set of microarray studies (Table 6), and (ii) by 
checking if any existing experimental validation for the gene associations in 
question has been published in the literature (PubMed, last access: 16 April 
2013). This analysis revealed that (a) 85 genes in our 200-gene signature were 
reported in at least one of the 16 microarray studies, and (b) 21 genes of the 
200-gene signature were reported in both microarray studies and biological 
experimental-based studies (Table 12, labeled yellow background). While 38 
genes of this 200-gene signature were not reported in any of the 16 reference 
studies, they had in fact been previously validated in independent wet-lab 
studies (Table 12 and discussion section). These 38 genes, including EGFR 
and MIA, can be considered as “validated novel genes” as they were not 
identified in the previous microarray studies but validated by biological 
experiments. 
 
On the other hand, the new gene signature reported an additional 77 genes that 
were not previously reported anywhere in the literature in association with 
melanoma (Figure 13). The ranking positions of these 77 genes show that 39% 
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of these appear in the top 100 and 34% in bottom 50 of the 200 gene set (table 
11). These genes may represent „novel genes‟ as they were not previously 
identified in any previous microarray studies.  
 
We further investigated the characteristics of the 85 genes reported in at least 1 
of the 16 reference microarray studies (see Appendix - Table s2). Forty-four 
were reported in ≥2 studies, while 17 genes have been reported in ≥3 of the 16 
studies (Appendix - Table s2). KRT15, MAGEA6, RORA and SULF1 were most 
frequently reported, appearing in 4 of the 16 studies. It is noted that, using the 
method proposed in this study, we identified 4 of the 7 most frequently reported 
genes in the 16 studies. This suggests that the methodology used to select the 
top 200 genes provides a more powerful signature than these previously 
reported 16 published signatures (Table 6). 
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Table 12: Novel genes identified by the proposed method were validated by 
independent wet-lab experimental studies 
 
 
gene symbol
ALDH1A3
Luo et al. 2012. Stem Cellls
30:2100-2113
COL1A1
Lin et al. 2005. Arch Pathol Lab
Med 129:884-92
COL17A1
Krenacs et al. 2012. Histochem
cell Biol . 138:653-667
CSAG2
Feller et al. 2000. Anticancer Res
20:4147-4151
Janjic et al. 2006. J Immunol
177:2717-2727
CTAG2
Lethe et al. 1998. Int J Cancer
76:903-908
Usener et al. 2003. Br J
Dermatol 149:282-288
Svobodova et al. 2011. Eur
J Cancer 47:460-469
CYP3A5
Zhang et al. 2006. J Pathol
209:213-219
DCD
Rieg et al. 2004. Br J Dermatol
151:534-539
Huang et al. 1996. Anticancer Res
16:3557-3563
Scholes et al. 2001. Arch
Ophthalmol 119:373-377
Mallikarjuna et al. 2007.
Curr Eye Res 32:281-290
Ueno et al. 2008. Int J Cancer
123:340-347
Boone & Brochez. 2009.Verh K
Acad Geneeskd Belg 71:251-
294
Diaz et al. 2009. Front
Biosci 14:159-166
Topcu-Yilmaz. 2010. Melanoma
Res 20:126-132
Boone et al. 2011. J Cutan
Pathol. 38:492-502
EPHA3
Balakrishnan et al. 2007. Cancer
Res  67:3545-3550
Mosch et al. 2012. Cell Adh
Migr 6:113-125
Lisabethe et al. 2012.
Biochemistry  51:1464-1475
FCRLA
Inozume et al. 2007. J Invest
Dermatol  127: 2818-2822
FGFR2
Gartside et al. 2009. Mol Cancer
Res 7:41-54
FGFR3
Cheng et al. 2006. Bio Pharm Bull
29:655-669
Yadav et al. 2012. J Biol Chem
287:28087-98
GAGE family
Bazhin et al. 2007. Cancer Lett
251:258-267
GBP5
Fellenberg et al. 2004. J Invest
Dermatol 122:1510-1517
HLA-DQB1
Lee et al. 1994. Int J Cancer
59:510-513
Lee et al. 1996. Cancer
78:758-763
Kageshita et al. 1997.
Tissue Antigens 49:466-470
Bateman et al. 1998. Tissue
Antigens  52:67-73
HMGA2
Murakami et al. 2010. Mol Biol
Rep 37:1279-86.
IGF2/INS-IGF2
Soares et al. 2010. Growth Horm
IGF Res  20 :295-297
IL8
Zhang et al. 2011. Int J Mol Sci
12:1505-1518
LEP
Brandon et al. 2009. Cancer Biol
Ther 8:1871-1879
Ellerhorst et al. 2010. Oncol
Rep  23:901-907
Amjadi et al. 2011. J Exp
Clin Cancer Res  30:21.
Lawrence et al. 2012. Neurol Res
Int  2012:870807: Epub 2012 Jan 4
LUM
Vuillermoz et al. 2004. Exp Cell
Res  296:294-306
Sifaki et al. 2006. IUBMB Life
58:606-610
Radwanska et al. 2008. Life
Sci 83:651-660.
Brezillon et al. 2009. J Physiol
Pharmacol 60:15-22
MAGEA1
Brasseur et al. 1995. Int J Cancer
63:375-380
Mulcahy et al. 1996. Int J
Cancer 66:738-742
Chen et al. 1997.  J
Immunother 20:265-275
Luyten et al. 1998. Melanoma
Res 8:11-16
Caballero et al. 2010. PLoS One
5:e12773
Errington et al. 2012. Br
J Ophthalmol 96:451-
458
MAGEA2
Brasseur et al. 1995. Int J Cancer
63:375-380
Chen et al. 1997. J
Immunother  20:265-275
Luyten et al. 1998.
Melanoma Res  8:11-16
Caballero et al. 2010. Cancer
Immun  8:2
MAGEA3
Brasseur et al. 1995. Int J Cancer
63:375-380
Chen et al. 1997. J
Immunother  20:265-275
Luyten et al. 1998.
Melanoma Res  8:11-16
Vourc'h-Jourdain et al. 2009.
Arch Dermatol Res 301:673-679
Errington et al. 2012. Br J
Ophthalmol 96:451-458
MAGEA6
Gibbs et al. 2000. Melanoma Res
10:259-264
Errington et al. 2012. Br J
Ophthalmol 96:451-458
MAGEA12
Gibbs et al. 2000. Melanoma Res
10:259-264
Bosserhoff et al. 1997. Cancer
Res 57:3149-3153
Bosserhoff et al. 1998.
Hautarzt 49:762-769
Bosserhoff et al. 1999.
Anticancer Res  19:2691-
2693
Perez et al. 2000. Hum Pathol
31:1381-1388
Guba et al. 2000. Br J Cancer
83:1216-1222
Schmitz et al. 2000.
Anticancer Res 20:5059-
5063
Stahlecker et al. 2000. Anticancer
Res 60:5041-5044
Bosserhoff et al. 2001.
Recent Results Cancer
Res 158:158-168
Bosserhoff et al. 2001.
Melanoma Res 11:417-421.
Meral et al. 2001. Melanoma Res
11:627-632
Juergensen et al. 2001.
Tumour Biol 22:54-58
Hochberg et al. 2002. Br
J Dermatol 146:244-249.
Schaller et al. 2002. Melanoma
Res 12:593-599
Garbe et al. 2003. Cancer
97:1737-1745
Faries et al. 2004. Ann Surg
Oncol 11:85-93
Tas et al. 2004. Am J Clin Oncol
27:225-228
Reiniger et al. 2005. Graefes
Arch Clin Exp Ophthalmol
243:1161-1166
Cao et al. 2007.
Anticancer Res 27:595-
599
Lugovic et al. 2007. Coll Antropol
31 Suppl 1:7-11
Barak et al. 2007. Anticancer
Res  27:1897-1900
Faries et al. 2007. Cancer
Invest 25:285-293
Vucetic et al. 2008. Melanoma
Res  18:201-207
Dumitrascu et al. 2009. Roum
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The correlations between melanoma and the genes shown in table 12 are 
provided below: 
ALDH1A3 
Luo et al 2012 detected the relationship between ALDH1A3 and melanoma 
cells by Aldefluor Assay and FACS, mRNA copy number analysis and 
microarray analysis, and found that ALDH1A3 isozyme is a key molecule to 
regulate the function of melanoma cells. 
COL1A1 
Lin et al 2005 determined that COL1A1 was significantly increased in 
expression in melanoma compared with poorly invasive non-pattern–forming 
cells though real time PCR, and suggested COL1A1 may be synthesized by 
melanoma cells. 
COL17A1 
Krenacs et al 2012 tested expression of COL17A1 in benign and malignant 
melanoma by endodomain- and ectodomain-selective antibodies, and found it 
may be a potential biomarker or target for melanoma. 
CSAG2 
The expression of CSAG2 was compared in several melanoma cell lines by real 
time PCR in Feller et al study in 2000, and also in Janjic et al. study of 2006.  
Both of these two studies suggest CSAG2 as a novel antigen with application 
for melanoma vaccines. 
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CTAG2 
The CTAG2 protein was determined to be significantly expressed in melanoma 
by three studies, Lethe et al 1998 suggested the expression may be induced by 
demethylation, Usener et al 2003 evaluated CTAG2 and suggested it could be a 
new antigen in immunogenic response, and Svobodova et al 2011 investigated 
the expression by IHC and showed that it could be as potential therapeutic 
target of melanoma. 
CYP3A5 
CYP3A5 protein is as metabolism enzyme expressed in melanoma tissues and 
was determined by tissue microarray to indicate which drug pathway is 
dependent in melanoma, and then selected f or its potential in cancer therapy 
(Zhang et al, 2006). 
DCD 
The mRNA expression of DCD was detected in melanoma cells, but not in other 
kinds of epidermal cells (like keratinocytes, fibroblasts, and melanocytes). Thus, 
Rieg et al 2004 suggested that DCD may play an important role in preventing 
local and systemic pathogens invasion. 
EGFR 
Some studies reported EGFR expression in melanoma at DNA, RNA and 
protein levels in melanoma.  Huang et al. 1996 detected overexpression of 
EFGR in a melanoma cell line. Scholes et al. 2001 found that 23% of melanoma 
samples contained EGFR immunoreactivity, and ta imilar result was reported by 
Mallikarjuna et al. 2007, who found that EGFR was expressed in 30% of 60 
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uveal melanomas. Boone and Brochez 2009 found that the immunoreactivity of 
EFGR was more frequently present in melanoma patients with a positive 
sentinel lymph node. Next, EGFR gene and protein expression were 
established by Fluorescence in situ hybridizaiton (FISH) and 
immunohistochemistry (IHC) by Boone et al 2011 in a further study with positive 
sentinel lymph node patients. Targeting EFGR is as a therapeutic option in 
melanoma. Diaz et al 2009 suggested that the immune system in melanoma 
patients could downregulate the increased expression level of EFGR. Ueno et 
al 2008 inhibited the tyrosine kinase activity of EGFR using PD153035 to show 
the promoter role of EGFR in tumour growth and metastasis melanoma. Topcu-
Yilmaz et al. detected the expression of EGFR and suggested that it plays a 
role in uveal melanoma development and progression. 
EPHA3 
EPHA3 is highly mutated in melanoma as reported by Balakrishnan et al 2007, 
and Lisabeth et al 2012. Both studies suggested that the tyrosine kinase 
EPHA3 is a tumor suppressor gene and that the mutation of this gene could be 
caused by somatic cancer predisposition. The up-regulated of EPHA3 in X-ray 
irradiation-induced metastatic property of melanoma was detected by Mosch et 
al 2012. 
FCRLA 
FCRLA was reported by Inozume et al 2007as an antigen that was specifically 
expressed in melanoma cells, and also was recognized by IgG antibodies from 
melanoma. 
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FGFR2 
FGFR2 gene was reported to be mutated in 10% melanoma tumours and cell 
lines with loss of function in the receptor.  Gartside et al 2009 suggested that 
FGFR2 may play context-dependent opposing roles in melanoma. 
FGFR3 
FGFR3 was detected to be down-regulated by DNA microarray analysis by 
Cheng et al 2006, to suppress the biological processes of cell cycle in 
melanoma. The opposite result was detected by Yadav et al 2012, they found 
that FGFR3 was up-regulated by microarray, and this enhanced activation 
corresponding to Ras and MAPK activation. 
GAGE family 
GAGE family proteins were up-regulated in melanoma tissues by 
immunohistochemical analysis, and Bazhin et al 2007 first demonstrated that 
GAGE family proteins might be immunotherapy targets of melanoma. 
GBP5 
The expression of GBP5 protein was detected by western blotting in melanoma 
cell lines, and Fellenberg et al. suggested that GBP5 plays an important role in 
proliferation and differentiation which may relate to caner functions. 
HLA-DQB1 
Bateman et al 1998 reported that HLA-DQB1 expression is significantly 
increased in malignant melanoma in the UK population, when compared to 
control samples by PCR, and suggested HLA-DQB1 plays an important role in 
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the risk of development and prognosis of malignant melanoma in UK population. 
The similar results were detected by three other studies: the increased HLA-
DQB1 was detected by PCR-RFLP when comparing with control samples in 
Kageshita et al study 1997, Lee et al 1994 and Lee et al 1996 determined HLA-
DQB1 was highly expressed in melanoma samples, and found this gene may 
influence the progression or incidence of melanoma.  
HMGA2 
HMGA2 was reported to be related to TGF-beta/activin, and it also was down-
regulated E-cadherin by up-regulated zinc-finger transcription factors and which 
showed HMGA2 may be susceptible to metastasis melanoma by Murakami et al 
2010. 
IGF2 
Soares et al 2010 investigated IGF2 in a 100 healthy individuals and in 21 
patients with hereditary melanoma by Chi-square, Fisher‟s exact tests and 
RegRNA software, and found IGF2 was associated with progression of 
melanoma. 
IL8 
IL8 level was significantly increased by immunological tests with a special buffer 
which can eliminate the interference of serum, Zhang et al 2011 suggested IL8 
is as a prognosis serum marker for melanoma mortality. 
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LEP 
High protein expression of LEP was detected in melanoma blood samples by 
Brandon et al 2009 and Amjadi et al 2011, and they suggested that melanoma 
tumour growth rate is increased by LEP. A similar increased expression level of 
LEP also was determined by Ellerhorst et al 2010 and Lawrence et al 2012, by 
western blotting, indirect immunofluorescence and real time PCR. They 
concluded LEP is a growth factor to contribute uncontrolled melanoma cells 
proliferation. 
LUM 
The mRNA and protein levels of LUM were investigated by many ways  (e.g. 
Immunocytochemistry, confocal microscopy, western immunoblotting, Real-time 
Reverse Transcription-PCR) in four studies (Sifaki et al 2006, Vuillermoz et al 
2004, Radwanska et al 2008, and Brezillon et al 2009.) They detected that the 
mRNA level of LUM was overexpressed in melanoma cells, and that the LUM 
protein was expressed in melanoma cell lines but not be expressed in normal 
melanocytes. They suggested that LUM may induce apoptosis of melanoma 
cells to control of melanoma growth and invasion. 
MAGEA-1/ -2/ -3/ -6/ -12 
The expression of MAGEA1, MAGEA2 and MAGEA3 were analysed by RT-
PCR in three types of melanomas. Brasseur et al 1995 reported that the 
expression of these three genes was greater in thick  cutaneous melanoma, 
Chen et al 1997 examined these increased expressions in cultured ocular 
melanoma cells, and Luyten et al 1998 evaluated these expression in uveal 
melanoma cell lines. Three studies all found that the expression of MAGEA-1,-2 
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and -3 were significantly increased. Other studies also reported  similar results 
of gene expressions, which were detected by RT-PCR: The expression of 
MAGEA1 in metastatic uveal melanoma was determined in Mulcahy et al study 
1996, Vourc‟h-Jourdain et al 2009 determined that MAGEA3 was significantly 
expressed in melanoma, and Gibbs et al 2000 detected the significant 
expressions of MAGEA6 and MAGEA12 in 47 melanoma biopsies and 11 
melanoma cell lines. Except these mRNA level expressions, Errington et al 
2012 assessed that protein expressions of MAGEA-1, -3, and -6 by CT antigens 
in ocular melanoma cells. The mutations of MAGEA1 and MAGEA2 genes were 
determined in 111 fresh melanoma samples by Caballero et al 2010. 
MIA  
The mRNA level of MIA was indicated by RT-PCR in four studies: Bosserhoff et 
al 2001, Guba et al 2000 and Garbe et al 2003 these three studies determined 
the higher expression levels in melanoma stage III and IV (metastatic 
melanoma) than control samples or stage I and II melanoma, and suggested 
that MIA plays an important role in metastatic melanoma. Hochberg et al 2002 
ompared mRNA expressions of MIA between sentinel lymph nodes of 
melanoma and control nodes, and found that higher level is in sentinel lymph 
nodes melanoma, so they suggested MIA could help detect metastatic 
melanoma cells in sentinel lymph nodes to survival patients. 
The serum levels of MIA protein were quantitated by ELISA in quite a few 
studies: Bosserhoff and his colleagues published four studies about MIA serum 
level in 1997, 1998, 1999, and 2001, they detected the higher MIA serum levels 
were existed in stage I or II of melanoma in 32 patients and 350 patients, and 
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stage II to IV of melanoma in 84 patients, they suggested MIA is a novel serum 
marker for malignant melanoma and used to detect metastatic melanoma 
disease. Then they analysed the relationship between enhanced MIA 
expression and progression of melanoma, suggested that MIA play a role in 
promoting melanoma metastasis. Similar results and suggestions were 
generated by Schmitz et al 2000, Juergensen et al 2001, Tas et al 2004, 
Lugovic et al 2007, and Stahlecker et al 2000, they detected the MIA serum 
levels in 87, 50, 48, 50 and 326 melanoma patients respectively, and found that 
the increased MIA serum levels in stage III/IV melanoma comparing to stage I/II 
melanoma, and suggested MIA is specificity and sensitivity to detect 
progression of metastatic melanoma. Three studies of uveal melanoma were 
reported by Schaller et al 2002, Barak et al 2007, and Reiniger et al 2005, they 
applied the similar experiments to detect 139, 18 and 285 patients‟ serum 
samples of uveal melanoma, and found the significantly higher level of MIA in 
metastatic uveal melanoma, and suggested MIA is as a serum marker for 
monitoring uveal melanoma for metastasis. The MIA serum levels were 
detected in melanoma with positive and negative sentinel lymph nodes  by 
Vucetic et al 2008 and Hofmann et al 2011, Both teams found that there are 
much higher mean MIA values in positive lymph nodes melanoma than other 
groups with negative lymph nodes. Thus, they suggested that MIA serum level 
can be helpful in screening the tumour spread to sentinel lymph nodes. The MIA 
serum levels before or after therapy (e.g., surgical excision, radiotherapy, 
immunotherapy or chemotherapy) also are analysed by three studies (Meral et 
al 2001, Faries et al 2004, and Cao et al 2007), they all investigated that MIA 
levels significantly increased when melanoma progressed, and the MIA levels 
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significantly decreased when patients responded to systemic treatment. Thus, 
MIA levels play an important role in prognosis marker for survival. Comparisons 
between MIA and S100B these two serum markers have been done by Faries 
et al 2007, Diaz-Lagares et al 2011, Dumitrascu et al 2009, and Essler et al 
2011 in 75, 110, 123, and 125 patients and health samples, they found that MIA 
and S100B both significantly increased in progressions, and suggested 
combined MIA and S100B serum levels together showed a better prognostic 
value to indicate the evolution of melanoma.  
The protein levels of MIA in plasma were detected by ELISA in Kluger et al 
2011 study, they compared the MIA levels of 108 metastatic melanoma patients 
with 108 patients with melanoma stage I or II, and found the MIA levels are 
much higher in metastatic melanoma samples. They suggested the levels of 
MIA in plasma can be applied for monitoring disease recurrence. 
Except applied RT-PCR and ELISA respectively, some other techniques were 
applied to detect MIA. Receiver operating characteristic (ROC) analysis with 
ELISA was applied for analysis of MIA serum levels, and showed that MIA 
levels significantly higher in metastatic melanoma patients than other stages of 
melanoma patients by Klingenstein et al 2011. RT-PCR and 
immunohistochemistry were used to assay 23 melanoma and 25 nonmelanoma 
specimens by Perez et al 2000, MIA was over-expressed in most melanoma 
specimens. Schmidt et al discovered that the relationship between dimerization 
of MIA and functional activity, and also suggested that dodecapeptide AR71 as 
a MIA inhibitor to prevent MIA dimerization in melanoma therapy. 
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PRAME 
Significant expression of PRAME protein was detected in melanoma samples 
by immunohistochemistry in Westekemper et al 2010 study, they applied 
receiver operating characteristics (ROC) analysis to assess the value of 
PRAME as diagnostic markers, and suggested that PRAME is marker to 
discriminate cutaneous melanoma and conjunctival nevi. Asimilar result also 
was detected by Soikkeli et al 2007, they combined immunohistochemistry and 
RT-PCR to test PRAME in 160 melanoma patients, and determined that 
PRAME was a melanoma marker to distinguish melanoma from benign nevi in 
the sentinel lymph nodes. 
SERPINA3 
SERPINA3 was determined to be significantly down-regulated in malignant 
melanoma by ELISA, Dimberg et al 2011 suggested that SERPINA3 could be a 
potential biomarker and the concentration of SERPINA3 was related to systemic 
inflammation. 
SHC4 
The expression of SHC4 was revealed at  high protein in primary and metastatic 
melanomas, however, low levels of the protein were detected in normal 
melanocytes and benign nevi. Thus, Fagiani et al 2007 and Pasini et al 2009 
indicated SHC4 is a specific biomarker for metastatic melanoma, and could be 
a potential drugable target for melanoma therapeutic strategies. 
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TF 
The TF protein was investigated in blood samples of human melanoma patients 
by electron paramagnetic resonance (EPR) by Krzyminiewski et al 2011, and 
found that the TF saturation is correlated to the total iron ion complexes 
concentration.  
TFR12 
The increased hypermethylation of TFR12 in a melanoma cell line and in 
melanoma frozen samples was determined by quantitative methylation-specific 
PCR in Liu et al 2008, and Tanemura et al 2009 studies. Both suggested 
TFR12 might play an important role in malignant melanoma progression. 
TNC 
The protein level of TNC was strongly up-regulated in melanoma cells growth 
by detecting 3D spheres in Fukunaga-Kalabis et al 2010 study. They suggested 
that TNC may mediate protective signals in melanoma progression. Then, 
Grahovac and his colleagues 2012 found that up-regulated TNC is associated 
with EGFL domains of THC (TNCEGFL), which is expressed in melanoma cells. 
The authors suggested TNCEGFL may play a role in melanoma invasion 
through modulating ROCK signalling and cell migration. 
XAGE1 
XAGE1 is reported to overexpressed in metastatic melanoma by RT-PCR in 
Zendman et al 2002 study. The expressed protein level of XAGE1 was detected 
by cancer testis (CT) antigen in Egland et al 2002 study, they suggested that 
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XAGE1 may play a role as a potential target for melanoma and other cancers 
immunotherapies. 
 
 
 
 
Figure 10: Validation of the proposed 200-gene signature.  
 
The 200 signature gene set taken from the full list of genes associated with melanoma 
was selected for further analysis based on their classification accuracy ratio (i.e. genes 
with the greatest sr value). 
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Table 13: The Sr values and ranking position of the 77 „new‟ genes not previously 
reported in the association with melanoma 
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3.1.3. Pathway analysis of the new melanoma gene signature 
 
 
To validate whether the new melanoma gene signature provides a more robust 
association with melanoma biology, the difference in pathways associated with 
the new signature compared to pathways of previously-published signatures 
was investigated using the KEGG pathway database (Kanehisa et al. 2012). 
The proposed new melanoma gene signature was found to be focused largely 
on four clusters of pathways: (i) steroid hormone biosynthesis (Table 14, 
yellow), (ii) diabetes, asthma and cytochrome P450 (Table 14, blue), (iii) 
immune, allograft and graft versus host (Table 14, red), and (iv) cell adhesion 
(Table 14, amber). However, compared to the pathways of the new proposed 
melanoma gene signature, previously-reported gene signatures were distributed 
in a remarkably large number of pathways and were not significantly over-
presented in any pathways of Table 14. This suggests that the new signature 
reveal more biological meaningful functions than previously-published 
signatures. 
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Table 14:  KEGG pathways associated with the proposed new melanoma gene 
signature 
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Recently published studies have confirmed these functional associations with 
melanoma. For example, Morrison et al. (Morrison et al., 2011) and Norval 
(Norval, 2011) reported that type I diabetes mellitus, cytochrome P450 and 
asthma have all been related to vitamin D status, which is thought to play an 
important role in melanoma. Carretero et al. reported that immune rejection 
mediated the regression of metastatic melanoma (Carretero et al., 2011). A 
recent study by Miyamoto et al. reported that steroid hormone biosynthesis is 
associated with the emergence of nevi, they also showed that the increased 
steroid levels will increase the rate of indoor tanning, which is a risk for 
melanoma (Miyamoto et al., 2012). Koh and his colleagues (Koh et al., 2012) 
have reported recently that some genes differentially expressed in sentinel 
lymph node metastases are involved in cell adhesion, though melanoma may 
not mention specifically in this study. 
 
 
3.1.4. Interaction of a new 200-gene signature with melanoma ‘driver’ 
genes informs a new signaling network in melanoma 
 
The interactions between genes within this 200-gene signature and the four 
known melanoma „driver‟ genes (i.e., NRAS, BRAF, MITF and cKIT) in the 
corresponding pathways were investigated. Of these driver genes, NRAS is 
mutated in up to 25% of melanoma cases (Goel et al., 2006; Schubbert et al., 
2007), while BRAF (located downstream of NRAS) is mutated in up to 45% of 
malignant melanomas (Hocker & Tsao, 2007; Flaherty & McArthur, 2010). MITF, 
a master transcription factor in melanocyte function, cooperates when mutated 
with BRAF in melanomagenesis (Garraway et al. 2005; Taylor et al. 2011), and 
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recent studies show that mutant cKIT can activate the Ras/Raf/Mek/Erk 
pathway as well as MITF (Monsel et al., 2009; Phung et al., 2011). While these 
four well-known melanoma driver genes do not appear on the 200 gene list as 
identified in microarray studies, this is most likely because these four driver 
genes are associated with melanoma at the gene mutation level, rather than at 
the gene expression level.   
 
It is interesting to note, however, that 12 of the 200 genes closely interact with 
the above 4 melanoma driver genes. These 12 genes are engaged in 31 
pathways retrieved from the KEGG database that connect with the MAPK, Ca2+ 
and WNT signaling pathways (Table 15), and included EGFR, FGFR2, FGFR3, 
IL8, PTPRF, TNC, CXCL13, COL11A1, CHP2, SHC4, PPP2R2C, and WNT4. 
The differential expression (i.e., fold change) of these 12 genes in each of the 
five original studies is shown Figure 11.  
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Table 15: KEGG Pathways where the 12 genes closely interact with melanoma driver 
genes (BRAF, NRAS, c-KIT and MITF) 
 
 
 
Chapter 3: Results 
 
114 
 
 
 
 
Figure 11: Differential expression (y-Axis) of genes in corresponding microarray data. 
The numbers in the bracket show how many wet-lab studies report on the 
association of these 12 genes with melanoma.  
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Based on the complex interactions of the 12 signature genes (labeled in red) 
and the 4 melanoma driver genes (BRAF, cKit, NRAS, MITF) in 3 signaling 
pathways (MAPK, Ca2+ and WNT), a new signaling network for melanoma is 
proposed, which may provide insight into melanoma development and 
progression (Figure 12). This new signaling network is created based on the 
relationship between the signature genes retrieved from the 31 KEGG pathways 
(shown in table 15). Most genes of the network are known and have been 
validated by wet-lab studies, only four genes in the network (see speculative 
gene pathway location with light purple hexagon background) were not reported 
by any previous studies. The speculated location of these four genes in the 
pathway below is based on where other members of their gene families are 
reported to be located. That being said, the 4 genes have appeared in previous 
pathways (e.g., WNT family was shown in WNT pathway of KEGG database, 
but WNT4 in particular was). Thus, the involvement of these genes in this 
pathway needs formal investigation.  
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Figure 12：A proposed new signaling network for melanoma.  
The signaling network is based on the complex interactions of the 12 signature genes 
(labeled in red) and the 4 melanoma driver genes (BRAF, cKit, NRAS, MITF) 
represented in 3 major signaling pathways (MAPK, Ca2+ and WNT). Nine of these 12 
genes (i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, CXCL13, TNC, COL11A1, and SHC4) 
closely interact with three melanoma driver genes (i.e., NRAS, BRAF, and MITF) in the 
MAPK signaling pathway: The remaining 3 genes include WNT4, PPP2R2C and 
CHP2, which also play important roles in WNT and Ca2+ signaling pathways. 
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It is interesting to note that nine of these 12 genes (i.e., EGFR, FGFR2, FGFR3, 
IL8, PTPRF, CXCL13, TNC, COL11A1, and SHC4) closely interact with three 
driver genes (NRAS, BRAF, and MITF) in the MAPK signaling pathway as 
follows:  
 
 EGFR/FGFR2/FGFR3 Epidermal growth factor receptor and Fibroblast 
growth receptor: These cell surface receptors are activated by multiple 
ligands with multiple signaling trajectories.  
 PTPRF: Protein tyrosine phosphatase receptor type F membrane receptor 
can regulate cell growth, differentiation, mitotic cycle, and oncogenic 
transformation. It can inhibit FAK (Focal adhesion kinase) by tyrosine-
phosphorylation to process MAPK signaling (Medley et al, 2003), and can 
interact with β-catenin in melanoma (Bonvini et al. 2001).  
 CXCL13: A „novel‟ melanoma-associated gene detected in this study - is a 
small cytokine belonging to the CXC chemokine family and is selectively 
chemotactic for B cells of both B-1 and B-2 subsets. 
 IL8: A „novel‟ melanoma-associated gene detected in this study - also 
known as interferon-γ inducing factor- is a proinflammatory cytokine.  
 COL11A1: This gene encodes one of the two α chains of type XI collagen, a 
minor fibrillar collagen.  
 TNC: Encodes for Tenascin C, an extracellular matrix glycoprotein with anti-
adhesive properties by binding to fibronectin and so blocking fibronectin's 
interactions with specific syndecans. The expression of tenascin-C in the 
stroma of certain tumours is associated with a poor prognosis. Tenascin-C 
is highly expressed in melanoma and promotes tumour progression 
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(Fukunaga-Kalabis et al. 2010).  
 SHC4: A novel melanoma-associated gene detected in this study - forms a 
hub to connect EGFR/FGFR2/FGFR3, PTPRF, CXCL13, COLL1A, and 
TNC directly or indirectly, to work with NRAS, BRAF, MITF driver genes in 
the MAPK pathway.  
 
The remaining 3 of these 12 genes in this proposed new melanoma signature 
included WNT4, PPP2R2C and CHP2, which also play important roles in WNT 
and Ca2+ signaling pathway as follows: 
 
 WNT4 binds to Frizzled receptor on the cell surface to promote the WNT 
signaling pathway. 
 WNT4 and PPP2R2C interact with MITF in the WNT signaling pathway. The 
deregulation or activation of the WNT pathway may lead to melanoma 
formation (Larue and Delmas 2006).  
 A complex is formed by β-catenin with PPP2R2c and APC (adenomatosis 
polyposis coli protein) to inhibit the degradation of β-catenin.  
 CHP2 is activated by calcium ions in a Ca2+ signaling pathway and has a 
role in the immune response.  
 
Seven genes of our 200 signature including EGFR, FGFR2, IL8, IGF2, 
TACSTD2, PPP1R14C (KEPI) and LEP are reported to be associated with 
PTEN (Phosphatase and Tensin Homolog). PTEN is a tumour suppressor gene 
that is mutated in many cancers including in many cases of melanoma (Guntur 
et al., 2011). The loss of PTEN protein function was found in melanoma cell 
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spreading, migration as well as in growth factor-stimulated MAPK signaling. 
PTEN loss has been reported as a late event in melanoma (Guntur et al., 2011). 
Indeed, this has been confirmed for 3 of these 7 genes (IL8, IGF2, LEP) in 
independent melanoma studies.  The other four genes (EGFR, FGFR2, 
TACSTD2, PPP1R14C) have not been previously reported to be associated to 
PTEN in melanoma. 
 
3.1.5. Experimental validation of a MAPK pathway-associated subset in 
our 12-gene melanoma signature 
 
Based on the expression values of the 12 genes (figure 11), it was clearly seen 
that the expression of TNC, PRPTF, SHC4, COL11A1, IL8, EGFR, CXCL13 
were up-regulated to a high ratio between nevi and melanoma in 5 melanoma 
datasets. However, PTPRF, COL11A1 and CXCL13 have not yet been reported 
to be associated with melanoma (Figure 11). SHC4 plays an important role as a 
hub in the MAPK pathway (Figure 12). As COL11A1, CXCL13, PTPRF and 
SHC4 appear in the MAPK signaling pathway (KEGG pathway), I further 
attempted to validate their expression via wet-lab analysis, including in human 
melanoma cell lines and melanoma tissues.  Using this approach, COL11A1, 
CXCL13, PTPRF, and SHC4 were found to be over-expressed in two human 
melanoma cell lines (i.e., FM55 and FM94) compared to normal human 
epidermal melanocytes in vitro (Figure 13). A significant degree of heterogeneity 
in the expression pattern for these markers was observed. For example, 
COL11A1, a secreted collagen protein, was observed at low levels in the 
cytoplasm of normal melanocytes, but much more intensely in the perikayon of 
moderately-pigmented FM55 melanoma cells, and unexpectedly exhibited a 
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nuclear/nuclear membrane association in the pigmented FM94 melanoma cells. 
Similarly, a weak cytoplasmic localization of CXCL13 in normal melanocytes 
appeared to shift towards the perikayon and nucleus of FM55 and FM94 
melanoma cells respectively, as evidenced by co-localization with DAPI 
staining. Low level PTPRF expression in normal epidermal melanocytes 
contrasted with higher expression (both cytoplasmic and nuclear) in melanoma 
cells. Finally, SHC4 expression was membranous in normal melanocytes, 
contrasting with some punctuate nuclear membrane expression in melanoma 
cells (Figure 13).  
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Figure 13: Immunocytochemical analysis of human epidermal melanocytes and 
melanoma cells in vitro.  
 
The expression of COL11A1, CXCL13, PTPRF and SHC4 proteins was upregulated 
(green fluorescence) in melanoma cells. Inserts show higher power views of 
expression, including when associated with the perinuclear region of the cell.  
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The expression of these proteins encoded for by these four genes in the 
proposed 12-gene signature for melanoma was also assessed in normal human 
healthy skin and in melanoma patient tissue (both primary and metastatic 
melanoma). Using double immunofluorescence with a melanocyte lineage 
marker gp100, is expression profile of these four test proteins in melanocytes or 
melanoma cells within these tumour biopsy tissues was assessed. We included 
primary melanoma in addition to metastatic melanoma in a 
immunohistochemistry-based validation study because the expression levels for 
the 12 genes in the gene signature exhibited a several fold change between 
primary melanoma and normal skin/benign nevi across five microarray datasets 
(Table 16). 
 
Table 16: Fold change in the expression of 12 genes between normal skin/benign nevi 
and primary melanoma in five microarray datasets 
 
 
 
This experiment showed that COL11A1, CXCL13 and PTPRF were not 
expressed in normal human epidermal melanocytes in situ (Figure 14a), while 
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some low level expression of SHC4 was detected in normal pigment cells. By 
contrast, COL11A1 was expressed intensely by melanoma cells located in the 
dermis of both primary and metastatic melanoma (Figure 14b and 14c). 
CXCL13 was strongly expressed in a minor subpopulation of tumour cells in 
primary melanoma, while a greater fraction of cells in metastatic melanoma 
tissue expressed this protein. By contrast, PTPRF was intensely expressed in 
the majority of tumour cells of both primary and metastatic melanoma cells. 
Finally, SHC4 was found to be expressed in only a minor fraction of gp100-
positive primary melanoma, but in most gp100-positive metastatic melanoma 
cells. 
 
Figure 14:  
(a) Immunohistochemical analaysis of COL11A1, CXCL13, PTPRF and SHC4 in 
normal human skin epidermis (frozen donor-Female 52yrs sections). 
 
Melanocytes were detected using an antibody (NKi/beteb) raised against the 
melanocyte-specific marker gp100 (red, arrows). COL11A1, CXCL13, PTPRF (green) 
were not detected in normal epidermal melanocytes. SHC4 was expressed sronglty in 
proliferating keratinocytes in the basal layer on the epidermis, but only very weakly in 
melanocytes (i.e. double positive cells in orange-yellow).  
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Figure 14: 
(b) Immunohistochemical analaysis of COL11A1, CXCL13, PTPRF and SHC4 in primary 
melanoma. Double staining of test protein (shown in green) and pigment cell lineage-
specific marker gp100 (in red, arrows). Both immunoreactivites were merged with 
yellow/orange fluorescence indicating co-localization of these protiens in melanoma 
cells. 
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Figure 14: 
(c) Immunohistochemical analaysis of COL11A1, CXCL13, PTPRF and SHC4 in 
metastatic melanoma. Double staining of test protein (shown in green) and pigment 
cell lineage-specific marker gp100 (in red, arrows). Both immunoreactivites were 
merged with yellow/orange fluorescence indicating co-localization of these protiens in 
melanoma cells. 
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3.1.6. Computational evaluation of the robustness of a proposed 12-gene 
biomarker signature to distinguish melanoma from normal skin and/or 
benign nevi 
 
 
A computational evaluation of the robustness of the proposed 12-gene 
signature was performed with the aim of distinguishing melanoma from normal 
skin and/or benign nevi using cross-laboratory published microarray data. This 
data evaluation to assess the robustness of a new biomarker may yield 
information that may have potential diagnostic application and/or possible 
therapeutic development. The Support Vector Machine classification model 
(known as the SVM model) (Brown et al. 2000) and the „leave-one-out method‟ 
were used to classify the microarray datasets in this project (Hoek et al. 2004, 
Smith et al. 2005, Riker et al. 2008, Scatolini et al. 2010, and Rose et al. 2011). 
Results showed that these 12 genes achieved excellent classification accuracy 
ratios across all five datasets (i.e., averaging at 99.1%, Table 17). It is noted 
that the new 12-gene biomarker signature achieved a much better performance, 
on average, than the signatures of Smith et al. 2005, Riker et al. 2008, and 
Scatolini et al. 2010, and only very slightly less (0.44% less) classification 
accuracy than the signature of Hoek et al. 2004. It should be noted that the 
signature of Hoek et al. (2004) consisted of 589 genes, while this project‟s 
biomarker signature is very much shorter at just 12 genes. Thus, the 12-gene 
biomarker achieved the best classification accuracy, compared to the original 
signature of the individual studies, with a much smaller number of genes. 
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Table 17：Classification accuracy of four original signatures and our proposed 
12-gene signature using across-laboratory data 
 
 
 
 
3.2. Improvement of the computational method 
 
One of the potential weaknesses of the above method of generating the 12-
gene signature was the inclusion of data from both melanoma cell line and skin 
biopsy material. It was considered therefore move appropriated to attempt to 
„stratify‟ these data to analyse separately by sample type. Thus, the method for 
integrated analysis of microarray data was further improved to consider the 
gene differences on each individual dataset by platform, sample types etc. to 
make the method more biological meaningful. The improved method was called 
the “stratification based method”. 
 
In order to evaluate the performance of the “Stratification based method” on the 
integrated analysis of multiple microarray datasets, the method was applied on 
a broader set of 14 datasets (table 6) covering three distinct diseases (i.e., 
Breast cancer, prostate cancer, as well as melanoma).  
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For each disease, the microarray datasets were prepared for the „leave-one-out‟ 
validation. This involved separating the microarray datasets into two groups: 
one group was for „training‟ to generate the ranked gene list, while the other 
group was for „independent testing‟ (see methods). In order to understand how 
two main factors may lead to performance enhancement (i.e., influencing 
dataset quality, and the sub-grouping of datasets), results obtained by using 
four different methods (see Figure 8 and methods) were compared. These 4 
methods included: (1) datasets treated equally (non-stratification); (2) 
datasets treated with appropriate weighting (non-stratification with weighting). 
(3) datasets first sub-grouped and then treated equally (stratification), (4)  
datasets sub-grouped, but then each dataset treated with corresponding 
weighting (stratification with weighting). To evaluate the performance of the 
above four methods, the associated classification accuracy ratios were 
compared. The data emerging from these gene ranking analyses above were 
further evaluated to determine whether this stratification procedure, for 
detecting significantly-ranked and disease-associated genes, was more robust 
than those previously published. In brief, I checked whether there were good 
classification accuracy ratios across different test data, or whether more 
common genes occurred between the „training‟ studies and the „independent 
testing‟ dataset in the following ways:  
a) Classification accuracy of genes using „Wrapper feature selection’ and 
Machine Learning (SVM method): This is a computational measurement 
performed by both the „support vector machine classification‟ model and the 
„leave-one-out‟ method with Wrapper feature (e.g., Peng et al., 2010) and 
previously described earlier in this thesis (see Section 2.2.5; Liu et al., 2013). 
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The validation method was applied to detect the classification accuracy ratio 
between these top-gene ranking lists derived after combining multiple „training‟ 
datasets and the „individual testing‟ dataset. 
b) Evaluation of the number of common genes between the training 
datasets and the independent test study: This was an analysis of the genes 
common between the top-gene lists by combining „training‟ datasets and the top 
gene lists from the corresponding „individual testing‟ study. 
c) Evaluation of the number of common genes across different gene 
ranking lists of combined ‘training’ studies: This was an analysis of the 
common genes between these gene ranking lists that were derived from 
different „training‟ datasets combinations.  
d) Evaluation of the number of common genes between the combined 
melanoma studies and 180 known metastatic melanoma biomarkers: This 
was an analysis of the common genes between the gene lists were derived 
from different melanoma „training‟ datasets combinations and the 180 known 
metastatic melanoma biomarkers (the 180 biomarkers were picked up from 
PubMed based on conditions as follows: metastatic, melanoma, biomarkers 
published to March of 2013, Appendix-table s3).   
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3.2.1. Classification performance validated by wrapper feature selection 
and machine learning 
 
 
A top 500 gene list was generated using each of the above methods (i.e., 1-4) 
for each disease. These lists were further analysed with the „Wrapper feature 
selection‟ method by a one-gene incremental addition approach (figure 15). 
 
  
Figure 15a: Performance curve of the four methods when applied to Breast cancer 
data. 
 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: Accuracy ratio 
in % of SVM. The different line colors indicate the four different methods as indicated 
in the embedded key. The data number (e.g., Data4) shows which dataset was applied 
as the test data in the ‘leave one out’ study. (See table 7 datasets for the 
corresponding disease datasets). 
Note: Data 1, cell line-type data only and so was not used for testing data.  
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Figure 15b: Performance curve of the four methods when applied to Prostate cancer 
data. 
 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: Accuracy ratio 
in % of SVM. The different line colors indicate the four different methods as indicated 
in the embedded key. The data number (e.g., Data4) shows which dataset was applied 
as the test data in the ‘leave one out’ study (See table 7 datasets for the corresponding 
disease datasets). 
Note: Data 1, cell line-type data only and so was not used for testing data.  
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Figure 15c: Performance curve of the four methods when applied to Melanoma data. 
 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: Accuracy ratio 
in % of SVM. The different line colors indicate the four different methods as indicated 
in the embedded key. The data number (e.g., Data4) shows which dataset was applied 
as the test data in the ‘leave one out’ study (See table 7 datasets for the corresponding 
disease datasets). 
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In Breast Cancer, the accuracy ratios of „stratification with weighting‟ method 
(purple lines) were highest in data2 and data5 independent test studies, and 
second highest in data3 and data4 independent test studies. The next best 
accuracy ratios for breast cancer data was generated using the „non-
stratification with weighting‟ method (red lines), the ratios showed the second 
highest position in data3 and data5 independent test studies. The other two 
methods did not generate good ratios in this disease (figure 15a). 
 
In Prostate Cancer, the highest ratios were produced by „non-stratification with 
weighting‟ method (red lines) in data2 independent test studies, followed by 
„stratification with weighting‟, „non-stratification‟, and „stratification‟ for this 
dataset. In data3 and data4 independent test studies, the „stratification with 
weighting‟ method produced the highest ratios (purple lines), but the accuracy 
ratio of „non-stratification with weighting‟ was not good in data3 (red lines). The 
other two methods always produced middle level ratios; however, that said the 
ratios of „stratification‟ method (green lines) were always higher than the ratios 
of „non-stratification‟ method (blue lines) (Figure 15b). 
 
In Melanoma, the ratios are good for 3 of 5 total independent test studies. In 
data1, the accuracy ratios of „non-stratification‟ with or without „weighting‟ 
methods (purple lines) were higher than the ratios of two „stratification‟ with or 
without „weighting‟ methods (orange lines). However, the two highest ratios in 
data5 were generated by „stratification with weighting‟ method (green lines) and 
„stratification‟ method (blue lines) (Figure 15c). 
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When the accuracy ratios of all three diseases were combined, the best 
accuracy ratios were obtained with the „stratification with weighting‟ method 
(purple lines mostly; green lines in melanoma data5). This method yielded good 
results regardless of whether the other 3 methods did or did not individually, e.g. 
ratios in testing data2 of breast cancer or ratios in testing data1 of melanoma. 
The next best method was the „non stratification with weighting‟ method. Thus, 
these two methods showed that the „weighting‟ plays an important role, 
reflecting the benefit of measurement of each dataset, with qualities adjusted by 
D values calculated by the arrayQualityMetrics‟ R package (see section 2.4.2). 
Comparison of the method with or without „stratification‟ showed that the 
separation of data derived from „biopsy‟ or „cell line‟ produced more robust data, 
compared to applying the non-stratified combined cell line plus biopsy datasets. 
Thus, the two factors „stratification‟ and „weighting‟ were valuable method 
enhancements. 
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3.2.2. Evaluation of the number of common genes between the combined 
training studies and the independent test study 
 
 
In this study, the numbers of common genes between the combined „training‟ 
studies and the „independent test‟ study were detected 50 times (or 50 rounds), 
starting from applying 10 genes of top-gene lists up to the maximum 500 genes 
(using a 10 gene incremental addition approach). As gene numbers were 
increased, the numbers of common genes would be expected to increase 
(Figure 16). Figure 15 and figure 16 include results in breast cancer, prostate 
cancer and melanoma respectively. 
 
Clearly, the stronger will be to enhance that those common genes are truly 
associated with the disease state. Thus, under one method, if the top genes are 
retrieved regardless of the datasets used, the more robust that gene selection is 
likely to be (Figure 16). 
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Figure 16a: Common genes between combined studies and individual test study for 
breast cancer 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: the number of 
common genes. The different color symbols indicate the four different methods. The 
data number (e.g., Data4) shows which dataset was applied as the test data in the 
‘leave one out’ study. The datasets are showed on table 7 for the corresponding 
disease. 
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Figure 16b: Common genes between combined studies and individual test study for 
prostate cancer. 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: the number of 
common genes. The different color symbols indicate the four different methods. The 
data number (e.g., Data4) shows which dataset was applied as the test data in the 
‘leave one out’ study. The datasets are showed on table 7 for the corresponding 
disease. 
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Figure 16c: Common genes between combined studies and individual test study for 
melanoma. 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: the number of 
common genes. The different color symbols indicate the four different methods. The 
data number (e.g., Data4) shows which dataset was applied as the test data in the ‘leave 
one out’ study. The datasets are showed on table 7 for the corresponding disease. 
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For Breast Cancer, the best two methods were „stratification‟ and „stratification 
with weighting‟ methods, even though they did not generate a good number of 
common genes for data2 and data3 respectively; these methods yield good 
results for the other individual datasets, i.e., „stratification‟ method in data4 and 
data5, and „stratification with weighting‟ method in data2 and data4. Thereafter, 
„non-stratification with weighting‟ generated the best results in data2 and date 3, 
but also produced the poorest results for data4 and data5. The worst method 
was „non-stratification‟, which yielded a middle range for common genes (figure 
16a). 
 
For Prostate Cancer, more common genes were obtained by the „stratification 
with weighting‟ method, although this method was poor for data2. The next best 
method was „non-stratification with weighting‟, with more common genes 
generated using this method for data2 and data3 (Figure 16b). 
 
For Melanoma, the best method was „stratification with weighting‟ method, 
which generated the highest number of common genes in 4 of 5 individual 
studies. The next best was the „non stratification with weighting‟ method, 
followed by „stratification‟ method and then the „non-stratification‟ method 
(Figure 16c). 
 
When combined the three disease results together, the „stratification with 
weighting‟ method yielded the highest number of common genes for all three 
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diseases (shown as purple cross). Only in data3 of melanoma was there a large 
difference between the number of common genes of „stratification with 
weighting‟ method and common genes of the other three methods. The reason 
is the large difference may be induced by the weighting (ω) (i.e., the quality of 
datasets). The „non-Stratification with weighting‟ method also gave good results 
on most of datasets (green triangle), but the linear trend of numbers of common 
genes in this method was quite different from the trends of other three methods. 
And the numbers of common genes of this method also were not stable when 
applied it to different „training studies‟, e.g. especially in breast cancer and 
prostate cancer (Figure 16).  
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3.2.3. Evaluation of the number of common genes across different gene 
ranking lists of the combined training studies 
 
 
 
In order to identify the stability of each method, method stability is defined as 
the ability to retrieve similar significant genes regardless of changes in different 
combined datasets in each test time. Thus, the number of common genes 
detected across different gene ranking lists of combined studies was a 
measurement standard. The higher number of common genes means the more 
stable method. Like the above evaluation approach, the numbers of common 
genes were detected via 50 rounds, staring by applying the top 10 genes to the 
maximum top 500 genes, with 10 genes incrementally added approach each 
time. The best method should generate the highest number of common genes, 
and the linear trend of common genes in the figure 17 should reflect increasing 
stability of the method.  
 
The results obtained by the „non-Stratification‟ method (blue diamond) indicated 
that this method performed least well compared to the others, followed by 
„Stratification‟ method (green triangle). The trends in results of „non-Stratification 
with weighting‟ (red square) and „stratification with weighting‟ (purple cross) 
methods were similar, the former one was lower in prostate cancer, and the 
latter was lower in melanoma, while the „stratification with weighting‟ method 
was the best method in both breast and prostate cancer. This indicates that this 
method is relatively more stable than the others (Figure 17). 
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Figure 17: Common genes across different top gene ranking lists of combined studies. 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: the number of common 
genes. The different embedded color symbols indicate the four different methods.  
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3.2.4. Evaluation of the number of common genes between the combined 
melanoma studies and 180 known metastatic melanoma biomarkers  
 
 
The enhanced method was then checked to determine whether it could retrieve 
more gene biomarkers for melanoma than had been identified so far in the 
literature. A PubMed search (query: metastasis, melanoma, biomarkers, last 
accessed March 2013) retrieved 180 metastatic melanoma biomarkers (see 
table s3 in appendix). These 180 genes are defined here as „true biomarkers‟ 
for melanoma, and were compared with the different top gene ranking lists that 
were selected based on the different methods using the 5 melanoma datasets 
(Hoek et al., 2004, Smith et al., 2005, Riker et al., 2008, Scatolini et al., 2010, 
Rose et al., 2011), four of the 5 studies were combined as „training‟ studies at 
each stage of analysis. Similar to the above approach, the 10 genes 
incremental addition approach was applied between 10 and 500 genes. The 
number of common genes was used to measure the effectiveness of the 
method in identifying true biomarkers. The „more common genes‟ outcome 
means that the method was able to identify true melanoma biomarkers (i.e., true 
positives). With results shown in figure 18, it was clearly seen that the „non-
stratification with weight‟ method (red square) revealed the greatest number of 
the 180 metastatic melanoma biomarkers, while the next best method is 
„stratification with weight values‟ (purple cross). 
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Figure 18: Common genes between the top gene ranking lists of combined studies and 
the 180 metastatic melanoma biomarkers 
Horizontal axis: Number of genes between 10 and 500. Vertical axis: the number of 
common genes. The different color symbols indicate the four different methods. The 
data number (e.g., M1234) shows which four datasets were applied as combined 
studies in the ‘leave one out’ study. 
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Summarizing all four above evaluations, it was seen that the „stratification with 
weighting‟ method produced more reliable results than did the other three 
methods. In order to forward validate this viewpoint, a top gene list were derived 
from all 5 datasets of melanoma, and then compared with the known 180 
metastatic melanoma biomarkers (five datasets shown on table 6).  It was found 
that the combined all 5 datasets together could generated the most common 
gene outcome when it compared to the other outcomes of „stratification with 
weighting‟ in Figure 18 (purple cross). The final number of common genes was 
18 (figure 19). However, in figure 18, the highest numbers in each common 
gene outcome by „stratification with weighting method‟ were approximate 14 or 
16. The improved number may provide an evidence for the more microarray 
datasets using in integrated analysis the higher number of reliable true 
biomarker can be identified (Figure 19). 
 
 
 
Figure 19: Common gene numbers between top gene ranking lists of all 5 melanoma 
datasets and 180 metastatic melanoma biomarkers 
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3.2.5. A new 200 gene signature of melanoma derived from the application 
of ‘stratification with weighting’ method 
 
In order to check if „stratification‟ and „weighting‟ are two factors which are able 
to enhance the biomarker discovery, I applied the „stratification with weighting‟ 
method to reanalyze the original 5 microarray melanoma datasets to produce 
the new ranking gene list. Table 18 shows the top 200 genes of the new list.  
 
 
 
Table 18:  The 200 genes with highest ranking position after selection by ‘stratification 
with weighting’ method. Source dataset (Hoek et al., 2004, Smith et al., 2005, Riker et al., 
2008, Scatolini et al., 2010, Rose et al., 2011) 
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3.2.6. Re-analysis of the previous 200 gene significant with the enhanced 
‘stratification with weighting’ gene list  
 
 
The new 200 genes list (table 18) generated by the „stratification with weighting‟ 
method was compared with the old 200 genes list generated by modified 
method GWGS + GWRS (table 11, section 3.1.1), 91% of the genes were 
similar between the 2 lists. Thus, only 18 genes (or 9%) were found that were 
not common between the old and the enhanced lists. These 18 genes are 
displayed with green background on table 18. Interestingly, these 18 genes 
were all located in the lower ranks of the gene list. The genes with yellow 
background were transcription factors (table 18). The 18 genes of the old 200 
gene list (table 19) have not been reported by any microarray or wet-lab studies 
to be associated with melanoma. Of the 18 new genes (see table 18 with green 
background) in the enhanced list, 6 were reported by at least one of the 16 
microarray studies referred to previously (see table 21), and 7 were reported by 
wet-lab studies (table 22). A further four genes (i.e., LUM, HLA-DRB1, CXCL1 
and NGFR) have been validated in both microarray and wet-lab studies and are 
shown with yellow background in table 22. Another worthy of attention was that 
17 of 18 new genes were located in the top 300 genes of previous ranking list, 
however, only 12 of 18 old genes were in the top 300 of new ranking list (Table 
19 and 20). These illustrated that new genes derived from the „stratification with 
weighting‟ method were still in higher positions of old list, but the old genes did 
not have the similar situation in the new list. 
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No. OLD genes
old ranking 
position
new ranking 
position
1 HLA-DRB2 75 279
2 LOC100133484 76 250
3 LOC100133661 77 251
4 LOC100133811 78 252
5 LOC730415 79 253
6 ZNF749 80 254
7 AKR1C2 93 300
8 IGL@ 106 465
9 IGHV4-31 162 651
10 TP63 163 532
11 CYP4B1 169 203
12 KLK11 173 207
13 CHP2 174 907
14 LOC100126583 187 769
15 CYP4F8 188 206
16 SCGB1D2 190 230
17 RORA 191 221
18 LGALS7 192 1259
No. NEW genes
new ranking 
position
old ranking 
position
1 COL1A1 145 247
2 HTN1 171 208
3 ACER1 173 205
4 RDH12 174 206
5 OLFM3 175 207
6 HS6ST2 176 209
7 SPINK6 177 211
8 LCP2 180 230
9 LUM 183 239
10 SPRR2G 184 220
11 CXCL1 189 331
12 HLA-DRB1 190 254
13 XG 191 237
14 KIAA1881 192 240
15 KIAA1199 193 227
16 LOXL3 195 243
17 NGFR 196 222
18 DSCR8 198 245
Table 19: The 18 genes present in the previous 200 gene list that are not 
included on the enhanced gene list 
Table 20: The positions of new 18 genes in previous and enhanced 
200 gene lists 
 
Chapter 3: Results 
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The relative ranking positions of genes in these two gene lists was investigated 
using two comparisons. The first assessed the ranking position of common 
genes of the 2 gene lists, the second assessed the ranking position of the 12 
melanoma significant genes in the new signaling network. The ranking positions 
of 18 common genes (at the enhanced list) that were reported by both 
microarray and wet-lab studies are shown in table 23. Table 24 shows the 
ranking position of 12 proposed biomarkers of melanoma in both gene lists. 
 
Table 23 shows that there was no significant change in gene ranking position for 
7 of the 18 common genes. Indeed there were identical ranking positions for 3 
Genes
KIAA1199 Hoek et al , 2004
NGFR Hoek et al , 2004
LCP2 Hoek et al , 2004 Koh et al , 2009
HLA-DRB1 Hoek et al , 2004 Mandruzzato et al , 2006
LUM Hoek et al, 2004 Haqq et al , 2005 Alonso et al , 2007
CXCL1 Hoek et al , 2004 Haqq et al , 2005 Bogunovic et al , 2009
In 16 Microarray  Studies
Genes
LUM Vuillermoz et al , 2004 Sifaki et al , 2006 Radwanska et al , 2008 Brezillon et al , 2009
COL1A1 Lin et al , 2005
HLA-DRB1 Luongo et al , 2004
CXCL1 Dhawan & Richmond, 2002 Di Cesare et al , 2007 Botton et al , 2011 Sapoznik et al , 2012
NGFR Radfar et al , 2006 Chan & Tahan, 2010
LOXL3 Kirschmann et al , 2002
MMA1 de Wit et al , 2002 de Wit et al , 2005
Studies
Table 21: The new genes validated by 16 independent microarray studies 
Table 22: The new genes validated by independent wet-lab experimental studies 
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genes (DCD, HMGA2, and TFPI2), and 4 genes (MAGEA2, MAGEA3, MIA, and 
ALDH1A3) exhibited a slightly changed ranking position. Interestingly, 11 genes 
(>60% of total genes) were ranked at higher positions in the new list, 
suggesting the positions of meaningful genes were pushed up by „stratification 
with weighting‟ method. 
 
The similar situation was observed with genes of the 12 biomarkers for 
melanoma (Table 24), except that CHP2 did not appear at all in new 200 genes 
list. While nine genes (75%) were ranked higher in the new 200 genes list. three 
genes (EGFR, FGFR2, COL11A1) were ranked slightly lower in the new gene 
list (2 to 4 positions lower). Importantly, of the four wet-lab validated genes (i.e., 
SHC4, CXCL13, PTPRF, and COL11A1), three of them were ranked higher by 
at least 8 positions. Thus, the melanoma network represented in Figure 12 was 
not changed by the substituted of these new 18 genes in the new list. 
 
When combining the results of table 23 and 24, it was clear that these changes 
in ranking positions allowed us to see that the new „stratification with weighting‟ 
method ranked the meaningful pathway genes at higher positions than 
previously. In this sense the new method appears to be more robustly able to 
detect reliable biomarkers of melanoma. 
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Table 23: Ranking position for the 18 substituted genes in the two 200 gene lists 
for melanoma 
Table 24: Ranking position of 12 melanoma biomarker genes in two 200 
gene lists  
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4. DISCUSSION 
This study first of all attempted to develop a new integrated bioinformatics 
approach for the identification of gene biomarkers based on multiple microarray 
data. The main contributions of this study to my original aim are summarized as 
follows: 
1. I developed a new bioinformatics approach by applying ranking of gene 
significance to increase the application range.  
2. I defined a new signature of 200 genes in human melanoma, and 
through the associations with melanoma driver genes, 12 melanoma 
biomarkers were identified. 4 of them were validated by laboratory 
experiments.   
3. I developed a general framework approach to enhance the integrated 
analysis method by adding two factors („stratification‟ and „weighting‟). 
The computational evaluation showed that the framework approach can 
identify a more meaningful signature than other methods.  
 
The following sections describe the main discovery of this study. 
 
4.1. Discovery and validation of a 12-genes biomarker of 
melanoma 
 
 
A review of the literature reveals poor congruence between gene signatures 
generated by different microarray-based melanoma studies (John et al. 2008; 
Bittner et al. 2000; Tímár et al. 2010). Unsurprisingly therefore, microarray-
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based melanoma gene biomarkers have had poor translation to clinical practice, 
and melanoma diagnosis is still based on clinical and histopathological features 
of the tumour (Schramm et al. 2011). To perform a meta-analysis on microarray 
gene expression data, Rhodes et al. (2002) introduced a model for combination 
of differentially-expressed genes based on their p-value in a statistical test 
(Rhodes et al. 2002). However, there are two significant limitations in its 
application to microarray data: (1) many microarray studies can contain small 
numbers of samples, for which the p-value can therefore be problematic, and 
(2) the p-values of a gene across different studies may have large variations. 
Thus, the smallest p-value may determine the outcome of Sp (effective 
significance of p-value). Here a new and universally-applicable method has 
been proposed to overcome some limitations of the Rhodes model. The core 
mathematic model proposed in this study measures firstly the significant gene 
ranking list in an individual dataset by the „genome-wide relative significance‟ 
(GWRS), and then assesses the significant gene ranking list across multiple 
datasets by the „genome-wide global significance‟ (GWGS).  
 
In the GWRS, fold-change was used for this study.  This can  be changed to 
different test methods when datasets are suitable for the using situation. In this 
study, T-test, ANOVA, SAM, fold-change (formulas were showed in section 
1.4.4) were considered as the methods for use in GWRS. After testing in five 
melanoma microarray studies, only fold-change is suitable for the microarray 
datasets situation. The other three methods depend on p-values, and so the 
smaller samples could not generate reliable p-values. However, fold-change 
relies on either fold-change increase or decrease, and because this method 
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does not request the smallest sample numbers it can be used for solving the 
limitation of using small number samples. 
 
A comparison of my GWRS with the Rhodes et al method was conducted by 
applying it to two datasets (GSE3189 and GSE12391) (section 2.3.2). From the 
Sr values and Sp values of the corresponding top 50 genes, it was clear that Sp 
values could be controlled by the smallest p value group, risking  so data 
imbalance can  be easily produced. However, GWRS depends on ranking 
positions of genes and so avoids the imbalance problem and treats the two 
datasets more equally. Another advantage of GWRS is that applying „fold-
change‟ and ranking position instead p-value could avoid the influences of 
sample number limitation. For example the sample number limitation also 
appeared in this study; only two control samples are in someone dataset. Key to 
this situation, „fold-change‟ was applied instead of p-values to show differences 
of gene expressions, and then ranking them to get sr values. Thus, comparing 
to previous p-value-dependent methods, GWGS and GWRS could be applied 
more widely.  
 
The comparison between metastatic melanoma and normal skin was done to 
reveal the significant associated gene expression in melanoma to define the 
biomarker of metastatic melanoma. The effectiveness of this new approach can 
be supported by several lines of evidence and validation.  
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First, a considerable number of novel genes (e.g., GTAG1A/1B/2, GAGE1-
8/12B-J, XAGE1A-E, IL8, IGF2/INS-IGF2, SHC4, LEP, TF, CYP3A5, TP63 and 
GBP5) revealed by our method were not identified as significant genes in the 
set of previous 16 melanoma microarray studies published between 2000-2011 
used in this study, but none the less have still been confirmed as being 
melanoma-associated by independent „wet-lab‟ studies in the literature (table 
11).  
 
Second, the new method identified a core signature of 12 genes (i.e., EGFR, 
FGFR2, FGFR3, IL8, PTPRF, TNC, CXCL13, COL11A1, SHC4, CHP2, 
PPP2R2C and WNT4) that are closely associated with known melanoma driver 
genes. Of note, however, six of these signature genes (i.e., IL8, SHC4, 
COL11A1, CHP2, PPP2R2C and WNT4) were not reported previously by 
microarray-based melanoma studies, although two (i.e. IL8 and SHC4) have 
been identified in independent wet-lab studies (Zhang et al. 2011, Fagiani et al. 
2007 and Pasini et al. 2009). This leaves WNT4, CHP2, PPP2R2C and 
COL11A1 as genes which have not been previously reported to be associated 
with melanoma either via microarray or wet-lab studies. However, Fedida-
Metula recently suggested a relationship between Ca2+ signaling members and 
PP2A and melanoma tumour growth (Fedida-Metula et al. 2012). Moreover 
CHP2 (full name „calcineurin-like EF hand protein‟) is involved in calcium 
signaling, while PPP2R2C is a member of the PP2A family.  
 
Third, the expression of gene encoding the MAPK-associated members (i.e., 
COL11A1, CXCL13, PTPRF, SHC4) of the 12-gene biomarkers have been 
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validated in a comparative analysis of normal melanocytes and melanoma cells 
in vitro and in primary versus metastatic melanoma biopsy tissue in situ in this 
project. All four markers were found to be preferentially associated with 
melanoma, being differentially expressed in primary and metastatic melanoma. 
Strikingly, COL11A1, CXCL13, and PTPRF were not detectable in epidermal 
melanocytes of normal healthy human skin epidermis. SHC4 was expressed at 
only very low levels in normal epidermal melanocytes, as previously shown 
(Fagiani et al, 2007). 
 
The over-expression of COL11A1, CXCL13, PTPRF, and SHC4 in melanoma 
cells in vitro and in situ may reflect the observed over-expression of the 
associated genes in our microarray meta-analysis results. The considerably 
higher level of SHC4 expression in the perikaryon of melanoma cells is of note, 
and concurs with other studies showing restricted expression in melanomas, 
while only weak expression in normal melanocytes and benign nevi (Fagiani et 
al, 2007). There is evidence that SHC4 is highly expressed at the transition from 
radial growth phase to vertical growth phase and metastatic melanomas, 
contemporaneous with the acquisition of melanoma migratory competence and 
invasive potential (Fagiani et al. 2007; Pasini et al. 2009). This protein tyrosine 
phosphatase acts as a signaling molecule to regulate cell growth, differentiation, 
mitotic cycle, and oncogenic transformation (Junta et al. 2008). PTPRF is 
usually expressed in the cell membrane (i.e. is a receptor-type protein tyrosine 
phosphatase) where it interacts with β-catenin. Like β-catenin, it may be 
translocated to the nucleus upon activation. The over-expression of COL11A1, 
CXCL13, PTPRF and SHC4 in our melanoma cell lines and primary and 
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metastatic tissue, and their potential association with MAPK signalling suggests 
these could be biomarkers for melanoma and so potential therapeutic targets. 
Based on the limitation of melanoma tissue samples, only these 4 genes were 
validated. The role of the others in the signature will be the focus of follow-on 
work from this thesis.  
 
The computational evaluation conducted in this project also indicates that this 
new 12-gene biomarker signature achieved excellent diagnostic power in 
distinguishing primary and metastatic melanoma from normal skin. The 
integrated analysis of these five microarray datasets has identified a robust 12-
gene biomarker signature that includes six previously-unreported genes in 
melanoma. Further experimental validation of the role of these 12 signature 
genes in a revised signaling network (Figure 12) may provide new insights into 
the underlying biological mechanisms driving the progression of melanoma. 
Moreover, given that the source „original signatures‟ in this meta-analysis 
involved much larger numbers of genes (e.g., 589, 100, 65, 455 genes per 
signature), the excellent classification accuracy ratio performance achieved by 
our melanoma biomarker signature with just 12 genes is of note. This supports 
the view that our integrated approach extracts more informative genes than do 
the original signatures. From a clinical perspective our 12-gene signature could 
therefore be a more valuable biomarker for melanoma in the clinical setting. 
This will need to be followed up in further studies. 
 
The method developed in this study was focused on gene expression 
association research, and was not directed to detecting gene mutations. It is 
 
Chapter 4: Discussion 
 
158 
 
noted that BRAF, as one of main mutated gene for melanoma, was not shown 
in the list of differential expressed genes. This project focused on gene 
association not the gene mutation. 
Five melanoma microarray datasets were applied in this study, as they all 
contain benign nevi/normal skin and metastatic melanoma samples (including 
cell line and biopsy). Because of the sample limitation, some datasets do not to 
contain normal skin or benign nevi sample. The normal skin and benign nevi 
samples were pooled together and considered as control group. Some 
microarray studies in the literature also investigated the relationship between 
benign nevi/normal skin and metastatic melanoma, e.g., some articles 
determined that significantly-different gene expression occurs between benign 
nevi and metastatic melanoma and so can define diagnosis biomarkers of 
metastatic melanoma (Kashani-Sabet et al., 2009; Smith et al., 2005). Others 
determined that metastasis and survival correlate with genes based on 
comparing combined benign nevi/normal skin with melanoma samples 
(Mandruzzato et al, 2006). 
 
Table 25: The fold-change of 12 genes in five melanoma microarray datasets 
 
Gene GSE4570 GSE4587 GSE7553 GSE12391 GSE22301
1 EGFR -2.80597 -25.6657 -4.75 -1.54833 22.34352
2 FGFR2 3.168142 -1068.81 -6.01 -1.82438 1.90731
3 FGFR3 -1.39801 -232.953 -6.73 -1.55501 17.9909
4 CXCL13 -1.05814 60.14563 18.98 1.435844 2.721906
5 COL11A1 -37.162 4.71954 10.98 2.036713 1.29632
6 WNT4 -36.1569 -39.4524 -5.31 -1.98495 1.103384
7 PTPRF 3.810742 -3.44544 -3.01 -1.87123 32.91988
8 PPP2R2C NA -14.1279 -11.34 -1.20658 NA
9 TNC 191.1111 4.232415 8.74 4.000489 41.61225
10 IL8 -1.74774 130.9839 13.57 7.148044 527.4839
11 CHP2 1.658228 -352.38 -8.34 NA 1.7495
12 SHC4 NA 26.42012 2.24 2.237992 NA
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The table 25 shows the fold change in expression for 12 marker genes between 
benign nevi/normal skin with metastatic melanoma in five individual microarray 
studies (green and yellow show the significant fold each gene). No one 
individual fold value could influence the finial meta-analysis result, no matter 
whether control sample is nevi or normal skin. This demonstrates that 
combining the significance of genes between benign nevi /normal skin with 
metastasis melanoma across multiple studies lead to the identification of gene 
biomarker of metastasis melanoma. 
 
 
4.2. Enhancement for the computational method  
 
 
As the microarray technique becomes increasingly popular, meta-analysis is 
been frequently applied to extract more information. However, meta-analysis 
still faces a critical concern i.e., that not all microarray data are of the same 
quality due to their use of various platforms and experimental set-ups. The 
quality of meta-analyses mainly depends on the quality of each individual 
microarray dataset (Larsson & Sandberg, 2006). Thus, the accuracy and 
reproducibility of microarray datasets have been a subject of some debate 
(Severgnini et al., 2006). 
 
To address this challenge, four meta-analysis methods were assessed in this 
study to investigate the potential impact of some of these intrinsic microarray 
weaknesses. Experimental results revealed that: 
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 (1). The genes selected using the „stratification with weighting‟ method (i.e., 
separating biopsy data from cell line data, and measuring the quality of datasets 
by D value, the ratio of each dataset‟s D value is as weighting of this dataset 
when calculated by GWRS across multiple datasets, see section 2.4.2) always 
achieved the good classification accuracy. This method also yielded the 
greatest number of common genes versus the other methods. 
(2). The second next most effective enhancement method was „non-
stratification with weighting‟ method. This method also can retrieve relatively 
good classification accuracy and a high number of common genes. 
(3). When one compares the results of „stratification‟ and „non-stratification‟ 
methods without weighting, it is clear that the results of „stratification‟ method 
were much better than after „non-stratification‟. 
(4). The new 200 ranked gene list which was detected by the „stratification with 
weighting‟ method was also more meaningful. Although there were only 18 (of 
200) genes that were different compared with the previous list, the new list 
generated by „stratification with weighting‟ method did not lose any meaningful 
genes of the previous gene list, and also added some new validated genes into 
the gene list. The old 18 genes of previous list that did not appear in the new list 
furthermore have never been reported in any melanoma studies. However, 
some genes of newly added 18 genes have been reported in microarray studies 
or wet-lab studies or both melanoma studies. The other advantage of the 
improved method is that the ranking positions of the most meaningful genes 
were increased comparing with the previous positions.  
  
 
Chapter 4: Discussion 
 
161 
 
In conclusion, the GWRS and GWGS methodologies could help deal with  the 
limitation of sample numbers of datasets, and also merging individual datasets 
together to retrieve the higher relevant melanoma signature. However, the 
method is limited by that they did not fully recognize the influence of differences 
in datasets, like different type of platform, type of samples, quality of dataset etc. 
Based on these, the new stratification-based methodology provided a more 
robust set of gene associations in this integrated microarray analysis. In 
addition, combining either „stratification‟ or „non-stratification‟, with „weighting‟ 
i.e., ω, always yielded better results versus the unweighted methodology. This 
means that it is very important to treat microarrays differently according to their 
data quality (the ratio of D value, see section 2.4.2). Both „weighting‟ and 
„stratification‟ are two important factors for enhancing the robustness of meta-
analysis of microarray data. Combining the strengths of GWRS, GWGS, 
„stratification‟ and „weighting‟, a new framework for others in the field to consider 
was proposed, which combines these two useful factors together in an 
integrated analysis of microarray studies (Figure 20). In the new framework, the 
„stratification with weighting‟ method was applied to a combined multi-study 
scenario, and when the gene list was screened by wrapper feature selection 
method with machine learning (figure 20) for getting robust genes. These 
proposed algorithm is defined in Fig.20 below with associated test following. 
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The proposed new framework was applied for integrated analysis of microarray 
datasets. When applied to datasets of one disease, firstly each individual 
dataset should be measured for quality based its D-values, the quality value is 
used for distributing the importance ratios of all datasets. Then the datasets are 
grouped based on one or more different features, like sample type, microarray 
technique, number of genes or samples. After grouping, each individual study of 
Selected studies on one kind of disease with corresponding microarray 
datasets 
GWRS of genes on individual study of each group 
GWGS of genes across multiple studies of each group with ω 
Figure 20: The proposed procedure of microarray meta-analysis to yield robust significant gene 
associations. This consists of two steps for characterizing the genome-wild global significance of 
genes, and an additional step for integrating the gene significance from biopsy and cell line 
samples, followed by a machine learning approach for the searching of robust genes. 
Microarray Datasets are grouped by one or more defined features 
Each individual Meta-Significance of each group (e.g.Sr1, Sr2 …) 
  
Combined-Meta-Significance (Sr) 
 
 
 
 
 
Machine learning (SVM) for greedy search of genes with most 
robustness in classification of control and disease 
Wrapper approach method was applied for the robust signature. 
 
Microarray Datasets are measured the quality by D-value (ω). 
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each group is calculated by GWRS, and combined by GWGS with weighting to 
generate the significant gene list of each group. Applying GWGS again to 
combine the significant gene lists of all groups, allows them to generate a final 
gene list for the disease. Wrapper feature selection with SVM method is then 
applied to detect the disease signature from the final list. The genes are 
inputted based on the in ranking order of the list and using a one-gene 
incremental addition approach. When the most robustness classification 
accuracy ratios are generated, the inputted genes are considered as the robust 
signature of the disease. 
 
In summary, this study suggests that: 
1. The proposed method combining individual studies together is able to 
reduce the false negatives comparing to individual analysis, and increase 
the effectiveness of statistical analysis of microarray datasets. 
2. A proposed new signaling network for melanoma, which involve 12 new 
biomarker genes. 4 of them were validated in this study. 
3. The new method adding stratification and wighting shows to be able to 
suit general applications of integrated analysis of microarray data.  
 
It is, however, noted that this study is limited by two factors: 
1. The number of samples of microarray datasets used in this study were 
small, which might have impact to the discovery of robust biomarkers . 
2. 4 of 12 genes were validated in the biological experiments. Further 
experiments are needed for the validation of the remaining 8 genes.  
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5. CONCLUSION AND FUTURE WORK 
Two significant contributions on the integrated analysis of microarray data were 
made in this thesis.  
First, a new method to address the limitations of Rhodes‟ meta-analysis method 
was proposed. This new method was applied to the integrated analysis of five 
melanoma datasets and generated a new signature of melanoma containing 
200 genes. Based on their interactions with four melanoma driver genes 
(NRAS, BRAF, c-Kit, and MITF), a new signaling network based on pathway 
analysis was created. This new signaling network includes 12 core genes from 
the 200 gene signature (i.e., EGFR, FGFR2, FGFR3, IL8, PTPRF, TNC, 
CXCL13, COL11A1, SHC4, CHP2, PPP2R2C and WNT4). These genes belong 
to three main signaling pathways (MAPK pathway, WNT pathway and Ca2+ 
pathway). Four of the 12 genes (i.e., SHC4, CXCL13, COL11A1, and PTPRF) 
link to the MAPK pathway and have been validated in wet-lab validations. In this 
study, the four genes all showed having strong relationship in biopsy and cell 
with melanoma, the other 8 genes will be focused in future work. 
 
Second, the computational method was enhanced integrating the two factors, 
these factor are „stratification‟ by sample type and „weighting‟ by data quality to 
provide more flexibility in treating microarray data based on the biological nature 
of the samples and on the quality of dataset.  
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Stratification was the improved integrated analysis, and differences between 
each individual dataset in terms of platform, sample types, number of genes or 
probe-sets etc. were considered by this factor.  
 
Weighting, which is the ratio of the D value of one dataset to the sum of D 
values for all datasets, improved the analysis as represented the quality of 
individual microarray datasets. The assessment of microarray dataset quality is 
very important part in combined analysis of multiple microarray datasets, 
because the quality of microarray data influences microarray experimental 
procedure directly, and will bring instability for the next level of the analysis. 
 
The evaluations performed in this thesis clearly showed that the method 
including „stratification‟ and „weighting‟ together produces more robust results in 
biomarker discovery. It is noted that the „stratification with weighting‟ method 
has produced different results than the „non-stratification‟ or „without weighting‟ 
method: 
 
(1) The best accuracy ratios were obtained by „stratification with weighting‟ 
method in Wrapper Feature selection with SVM evaluation. The next best 
method is „Non-stratification with weighting‟. It clearly showed that 
„weighting‟ (the quality of dataset) is as the important factor in combined 
multiple datasets analysis. 
 
(2) When evaluated the number of common genes between top gene lists of 
training datasets and the top gene list of individual testing dataset, the 
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„stratification with weighting‟ method was also the best method. It means 
that whatever the combined multiple datasets were changed, the method 
still can retrieve the same top genes, and these genes were more reliable 
genes in corresponding disease. 
 
(3) When evaluated the number of common genes across different variations of 
combined training studies, the higher number of common genes also 
represented how stable the method and the top genes are.  The 
„stratification with weighting‟ method is still the best method in this 
evaluation. 
 
(4) When applied the top gene lists which generated across multiple melanoma 
microarray datasets by the four methods to compare with 180 known 
metastatic melanoma biomarkers, found that „stratification with weighting‟ 
was the second best method. 
 
(5) Apply the „stratification with weighting‟ method to combine the all five 
original melanoma datasets, and then the generated gene list compared to 
180 metastatic melanoma biomarker, the number of common genes was the 
highest in the comparisons of the other gene lists with the 180 biomarkers. It 
also evidenced that more microarray datasets were integrated in the 
analysis more reliable biomarker can be identified.  
 
(6) The „stratification with weighting‟ method identified 18 new genes when 
compared the new 200 genes with the previous 200 gene list, and brought 
more validation genes into the new 200 gene list. The old 18 genes in 
previous gene list were never reported by any study, however, in the 
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enhanced list, 6 genes were reported by at least one microarray studies, 
and 7 genes were reported by wet-lab studies. Four genes were validated in 
both microarray and wet-lab studies. 
 
(7) The most meaningful genes are ranked at higher positions. There were 18 
common genes between previous and new gene list which were reported by 
both microarray and wet-lab studies. >60% of them (11 genes) presented 
higher positions in new list, and other 7 of them had identical or slightly 
changed ranking positions. 
 
(8) Even though the 200 genes were changed, the network of melanoma was 
not influenced. The 11 of proposed 12 biomarkers based on the previous 
method were still in the top 200 genes list of the „stratification with weighting‟ 
method.  Of them, 9 genes (75%) were increased the positions. And the 
three of four wet-lab validated genes (SHC4, CXCL13, PTPRF, and 
COL11A1) were higher at least 8 positions than previous. 
 
The results demonstrated that the „stratification with weighting‟ method is able to 
increase the detection of true biomarker (true positives) more effectively. 
 
Future work 
 
In the future, the validation of 12 biomarkers of melanoma in wet-lab is in 
process, based on only 4 of them in MAPK pathway were validated by IHC and 
ICC and the limitations of samples, the four genes only were validated in 
normal, primary and metastatic samples, and the sample number was a few, the 
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gene progression have been not done. The next plans about the 12 biomarkers 
are: 
 
(1) Before wet-lab validation, simulation of pathway for the 12 biomarkers would 
be done for computational validation. The method also be applied for the 
enhanced gene list. 
 
(2) Continually validate the 12 biomarkers of melanoma in vitro studies, exam 
the progression of melanoma (normal → benign nevi → primary melanoma 
→ metastatic melanoma) based on one donor ideally, but from mixed donor 
also possible if the number is large. 
 
(3) The significance of the 12 genes based on the differential expression, no 
matter the expression is up or down. Especially for the down-regulated 
genes, the IHC and ICC may not help in validation. Based on that, knock 
down each gene of 12 biomarkers should be important validation. Through 
knock down each of them one by one to analysis whether the gene may 
influence others and how the gene works in the whole network. 
 
 
 
For the new „stratification with weighting‟ method and new proposed approach, 
future works could include the following. 
 
(1) In this study, the datasets were stratified and analyzed based on differences 
in sample types (cell line vs. biopsy). The method still can be evaluated by 
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other types of stratification, for example, based on differences in platforms, 
differences in number of genes or probe-sets etc. And the stratification could 
be improved, like combined multiple stratified factors together, i.e., consider 
the differences of platform and sample types at the same time. The multiple 
factors combination could derive more elaborative classification and could 
improve robustness of microarray outcomes. 
 
(2) The „weighting‟ could be measured by different measurements. In this study, 
the D-value was applied to assess the quality of dataset, and it may be 
beneficial to include instead by other algorithms to represent different quality 
of datasets. 
 
(3) The new 200 gene list will be analyzed more deeply, not only to compare 
with the previous 200 gene lists and the literature based 180 biomarkers. 
They will be analyzed in other ways (like pathway analysis) to indicate 
whether meaningful genes exist in the new list. 
 
(4) ChIP-on-chip analysis should be considered for the biomarkers of melanoma 
in further research, based on this enhanced meta-analysis microarray 
method. ChiP-on-chip is a technique that can detect the interactions of 
proteins and DNA by combining chromatin immunoprecipitation (ChIP) and 
microarray technology (chip).   
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Appendix:  
This appendix includes the literature search I conducted with the terms 
„microarray datasets; and melanoma‟ in PubMed published for the years 2000-
2011. Of these 22 studies, 16 reported data on gene signatures that shared little 
commonality or overlap between studies. 
 
2000 
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, 
M., Simon, R., Yakhini, Z., Den-Dor, A., Sampas, N., Dougherty, E., Wang, E., 
Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., 
Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., 
Sondak, V., Hayward, N., Trent, J. (2000). Molecular classification of cutaneous 
malignant melanoma by gene expression profiling. Nature 406, 536-540. 
Bittner et al. (2000) used 38 samples (7 controls and 31 melanomas) to 
detect gene expressions using an 8,150 cDNA microarray. They identified 19 
melanomas as a major cluster and found the down-regulated genes of the 
major cluster related to cell migration, especially decreased expressions in 
integrin β1, β3 or α1, syndecan 4 and vinculin. Over-expressed genes were 
outside of the major gene cluster and were relevant to fibronectin. 
   
2003: 
Zuidervaart, W., van der Velden, P.A., Hurks, M.H., van Nieuwpoort, F.A., Out-
Luiting, C.J.J., Singh, A.D., Frants, R.R., Jager, M.J., Gruis, N.A. (2003). Gene 
expression profiling identifies tumour markers potentially playing a role in uveal 
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melanoma development. British Journal of Cancer 89, 1914-1919. 
Zuidervaart et al. (2003) detected 15 highly differentially expressed genes 
(>1.5 fold higher) in a microarray comparing 12 human uveal melanoma cell 
lines with 3 uveal melanocyte cultures. Four candidate genes were selected 
as tumour markers to discriminate 19 primary uveal melanoma samples into 
two classes. This may indicate differential uveal melanoma development 
processes. 
 
Dooley, T.P., Curto, E.V., Davis, R.L., Grammatico, P., Robinson, E.S., Wilborn, 
T.W. (2003). DNA microarray and likelihood ratio bioinformatics methods: 
discovery of human melanocyte biomarkers. Pigment Cell Res 16, 245-253. 
Dooley et al. (2003) investigated 25 significant biomarkers of normal 
melanocytes by comparing normal human epidermal melanocytes with one 
primary melanoma cell line (MS7) and one metastatic melanoma cell line 
(SKMel-28). They advised some biomarkers could be potential molecular 
targets for diagnostics and drug discovery in melanoma. 
 
2004: 
Hoek, K., Rimm, D.L., Williams, K.R., Zhao, H., Ariyan, S., Lin, A., Kluger, H.M., 
Berger, A.J., Cheng, E., Trombetta, E.S., Wu, T., Niinobe, M., Yoshikawa, K., 
Hannigan, G.E. (2004). Expression profiling reveals novel pathways in the 
transformation of melanocytes to melanomas. Cancer Res 64, 5270-5282. 
Hoek et al, 2004 detected 589 significantly expressed genes by Affymetrix 
U133A dataset based on a 2.5 fold change in melanoma. Of these, 315 were 
up-regulated and 274 were down-regulated between normal melanocytes 
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and melanoma cells. They reported some novel pathways and expression in 
melanoma cells, like NOTCH pathway activation, altered expression in 
embryonic development and epidermal transition transcriptional regulators, 
activation of cancer antigens, and down-regulated growth suppressors 
including NECDIN.  
 
Mirmahammadsadegh, A., Baer, A., Nambiar, S., Bardenheuer, W., Hengge, 
U.R. (2004). Rapid identification of dysregulated genes in cutaneous malignant 
melanoma metastases using cDNA technology. Cell Tissues Organs 117, 119-
123. 
Mirmohammadsadegh et al, 2004 detected a series of differential gene 
expressions through comparing total RNA of melanoma metastases and 
primary human melanocytes from 10 patients. They selected five genes 
(including GRB10, BAX, BAD, GSTT1, GSR) as examples and suggested 
that the significant genes may be used as targets to provide therapeutic 
guidance.  
 
McDonald, S.L., Edington, H.D., Kirkwood, J.M., Becker, D. (2004). Expression 
analysis of genes identified by molecular profiling of VGP melanomas and MGP 
melanoma-positive lymph nodes. Cancer Biology & Therapy 3, 110-120. 
McDonald et al., 2004 identified 5 known genes (ST13, CST-8, DKC1, 
NESP55, and NP-C2) and 1 unknown gene (16.7 kD) which could play 
important roles in advanced stage melanoma by examining gene expression 
patterns between primary melanoma and melanoma-positive lymph node 
specimens. 
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2005: 
Smith, A.P., Hoek, K., Becker, D. (2005). Whole-genome expression profiling of 
the melanoma progression pathway reveals marked molecular differences 
between nevi/melanoma in situ and advanced-stage melanoma. Cancer Biol 
Ther 4, 1018-1929. 
 
Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, 
B.L., Federman, S., Miller, J.R. 3rd, Allen, R.E., Singer, M.I., Leong, S.P., Ljung, 
B.M., Sagebiel, R.W. (2005). The gene expression signatures of melanoma 
progression. Proc Nati Acad Sci U S A 102, 6092-6097. 
 
      Smith et al, 2005 and Haqq et al. (2005) conducted a comprehensive study 
on different stages of malignant melanoma development based on whole 
genome expression profiles. Smith et al, 2005 investigated the top 50 up-
regulated and 50 down-regulated genes in advanced-stage melanoma in 
order to see the main expression changes between early-stage and 
advanced-stage melanoma.  Haqq et al. (2005) reported 19 gene signatures 
between nevi and metastases. A major finding of the study of Haqq et al. 
(2005) was the identification of two different gene patterns found in 
metastases reflecting those in the vertical or radial growth phase cells of 
primary melanomas.  
 
Okamoto, I., Pirker, C., Bilban, M., Berger, W., Losert, D., Marosi, C., Haas, 
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O.A., Wolff, K., Pehamberger, H. (2005). Seven novel and stable translocations 
associated with oncogenic gene expression in malignant melanoma. Neoplasia 
7, 303-311. 
Okamoto et al, 2005 have identified 20 over-expressed genes which were 
located in tumour-related regions of chromosomes by Affymetrix U133A gene 
chip using five malignant melanoma cell lines. These included AKT1, BMI1, 
CDK6, CTNNB1, E2F1, GPNMB, GPRK7, KBRAS2, LDB2, LIMK1, MAPK1, 
MEL, MP1, MUC18, NRCAM, PBX3, RAB22A, RAB38, SNK and STK4. They 
also indicated that the down-regulated CDK6 expression can dramatically 
reduce the growth of all five cell lines. 
 
2006: 
Winnepenninckx, V., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S.R., 
Avril, M.F., Ortiz Romero, P.L., Robert, T., Balacescu, O., Eggermont, A.M., 
Lenoir, G., Sarasin, A., Tursz, T., van den Oord, J.J., Spatz, A. (2006). Gene 
expression profiling of primary cutaneous melanoma and clinical outcome. J 
Natl Cancer Inst 98, 472-482. 
Winnipennickx et al, 2006 attempted to detect the significantly-expressed 
genes related to the progression and prognosis of melanoma. Based on 
gene expression the patterns in primary tumours differed between patients 
with a 4-year distant metastasis-free survival from those who developed 
metastases within this time. 254 genes associated with metastasis-free 
survival primary melanoma were identified. 
 
Mandruzzato, S., Callegaro, A., Turcatel, G., Francescato, S., Montesco, M.C., 
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Chiarion-Sileni, V., Mocellin, S., Rossi, C.R., Bicciato, S., Wang, E., Marincola, 
F.M., Zanovello, P. (2006). A gene expression signature associated with survival 
in metastatic melanoma. J Transl Med 4, 1-11. 
The study by Mandruzzato et al. (2006) is based on the expression profiles of 
17,500 probes of 43 stage III and IV metastatic melanoma tissues in 38 
patients. 80 probes corresponding to 70 genes (45 and 35 probes relevant to 
longer and shorter survival times respectively) were identified by significance 
analysis of microarrays (SAM). In further analysis, they used a survival 
prediction model to predict 30 relevant survival probes from the 80 probes by 
supervised principal components (SPC) and cross-validation. 
 
2007: 
Alonso, S.R., Tracey, L, Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., 
Linares, J., Serrano, S., Saez-Castillo, A.I., Sanchez, L, Pajares, R., Sanchez-
Aguilera, A., Artiga, M.J., Piris, M.A., Rodriguez-Peralto, J.L. (2007). A high-
throughput study in melanoma identifies epithelial-mesenchymal transition as a 
major determinant of metastasis. Cancer Research 67, 3450-3460. 
The study by Alonso et al. (2007), is based on gene-expression profiles of 34 
vertical growth phase (VGP) melanoma patients (21 developed nodal 
metastatic disease, and all had the minimum follow-up 36 months), and 
identified 243 genes (206 over-expressions and 37 down-expressions). All 
showed comparisons with >2 fold ratio and a false discovery rate is <0.2.  
 
Jaeger, J., Koczan, D., Thiesen, H.J., Ibrahim, S.M., Gross, G., Spang, R., 
Kunz, M. (2007). Gene expression signatures for tumour progression, tumour 
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subtype, and tumour thickness in laser-microdissected melanoma tissue. Clin 
Cancer Res 13, 806-815. 
Jaeger et al. (2007) analyzed the 22,283 probe expression profiles of 41 
primary melanomas and metastatic melanoma using oligonucleotide 
microarrays, 389 probe sets corresponding to 308 genes were identified with 
significant differential expression (Jaeger, 2007). A predictive diagnostic 
model (Support vector machine, SVM) was applied to discriminate these two 
stages of melanoma, and it achieved >85% correct classifications in cross-
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